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ABSTRACT 93	
The body of work in this thesis presents the research and publications under a 94	
general theme of outcome measurement, evidence synthesis and reporting 95	
quality in surgery. The work highlights the author’s own personal contributions 96	
and publications under this theme, and collaborations with colleagues from 97	
Oxford University, Harvard Medical School, Imperial College London and 98	
University College London. This thesis provides an in depth commentary on 99	
evidence-based surgery, with discussion on the challenges of conducting 100	
randomised controlled trials in surgery. Systematic review and meta-analysis 101	
methodology is discussed, exploring the nuances and assumptions of 102	
random/fixed effect models, quality assessment using GRADE and 103	
assessment of risk of bias (RoB) using Cochrane’s ROBINS-I tool. The author 104	
has evaluated reporting quality in surgery, identifying suboptimal compliance 105	
with the CONSORT-NPT checklist. This work formed basis for change of 106	
policy and the requirement for mandatory completion and uploading of a 107	
CONSORT statement by authors when submitting articles to the peer-108	
reviewed journal, International Journal of Surgery (IJS), with significant 109	
improvement in compliance. 110	
 111	
The commentary also reviews plastic & reconstructive breast surgery, and 112	
provides an in-depth discussion on quality of life assessment, COSMIN, 113	
minimal important differences (MID), how to choose a questionnaire and 114	
particular domains in a study, and reporting using CONSORT and SPIRIT-115	
PRO checklists. Health-utility measures for cost-utility analyses are also 116	
discussed. The authors’ systematic reviews and meta-analyses are presented 117	
on clinical outcomes and PROs of DIEP versus implant-based reconstruction; 118	
and on immediate versus delayed reconstruction, in context of radiotherapy 119	
(RT). The former review provides a weak recommendation that DIEP 120	
reconstruction maybe more cost-effective and yield higher PRO scores, with 121	
suitable warnings in light of poor quality and serious risk of bias. The RT 122	
review identified no statistically significant difference in outcomes between 123	
immediate and delayed breast reconstruction (BRR), challenging dogma 124	
where majority of UK BRR are delayed, with significant heterogeneity in 125	
outcome measurement, suboptimal reporting of core outcome set and no 126	
grading of complications. The reviews have demonstrated paucity of high 127	
quality evidence and the need for future high quality studies. The PhD award 128	
will facilitate the author in establishing a research group and to undertake 129	
postdoctoral research. This will include conducting a national stream funded 130	
large prospective cohort study in evaluating immediate versus delayed 131	
autologous BRR, in context of radiotherapy, with robust reporting of BRR core 132	
outcome set and incorporation and measurement of disease-specific PROs 133	
and cost-effectiveness, addressing the limitations highlighted by the reviews. 134	
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1. INTRODUCTION 187	
 188	
1.1 Evidence based Medicine (EBM) 189	
 190	
EBM is defined as the integration of the best available evidence with clinical 191	
expertise and patient preferences for optimal decision-making (Kang, 2016). 192	
Surgical research has come a long way since Richard Horton likened it to 193	
‘comic opera’ in a Lancet commentary (Horton, 1996). There has been rising 194	
interest in surgeons conducting high quality prospective cohort studies and 195	
randomised controlled trials (RCTs). Initiatives such as the implementation of 196	
a nationwide surgical trials programme in the UK have been welcomed 197	
(Khajuria and Agha, 2013). However, surgical research has inherent 198	
challenges including issues related to blinding, inconsistent care provider 199	
expertise, differential learning curves and centre’s volume. Poor reporting of 200	
outcomes is associated with bias in evaluating intervention effectiveness, 201	
culminating in increasing inconsistency between conclusions and results and 202	
precluding reliable critical appraisal and data interpretation by the readers. 203	
Indeed surgeons have much work to do to enhance the quality of the scientific 204	
basis on which their practice is based on, and a major issue to address is the 205	
poor quality reporting of outcomes (Khajuria and Ahmed Agha, 2015). 206	
 207	
Furthermore, it is well established that RCTs in Surgery are challenging to 208	
conduct (McCulloch et al., 2002, Davies et al., 2020). Firstly, there maybe a 209	
lack of clinician equipoise. The state of equipoise is, however, a prerequisite 210	
for conducting RCTs (McCulloch et al., 2002). Lack of funding and 211	
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infrastructure has also been cited as a barrier, and funding bodies may be 212	
influenced by poor quality of previous surgical research. Issues related to 213	
blinding, inconsistent care provider expertise, differential learning curves and 214	
centre’s volume also impact surgical RCTs (Khajuria and Agha, 2013). During 215	
learning curves, errors, adverse events and complications maybe more likely. 216	
Randomising between a familiar and an unfamiliar operation may therefore 217	
introduce bias against the latter. Moreover, the degree of acceptable technical 218	
variation within a surgical procedure needs to be clearly defined a priori. 219	
Imprecise definitions may lead to overlap in treatments with resultant bias. 220	
Blinding is challenging in surgical trials, for both patients and surgeons, 221	
although the outcome assessment can be blinded. ‘Type 3 RCTs’, i.e. those 222	
that compare a surgical and a non-surgical treatment pose difficulties with 223	
regards to equipoise of patients, as adverse events may differ greatly 224	
(Solomon et al., 1994). For example, a surgical procedure is irreversible. 225	
Patients may also perceive benefit for one technique over another; this can 226	
hamper recruitment into surgical trials and/or make randomized allocation of 227	
treatment challenging (Winters et al., 2015).  228	
 229	
Recruitment challenges in surgery and breast reconstruction have been 230	
demonstrated by the QUEST (quality of life after mastectomy and breast 231	
reconstruction) randomization trials (Winters et al., 2015). These were 232	
designed for the primary aim of determining the acceptability of a RCT of 233	
breast reconstruction among patients and clinicians. Those not needing 234	
PMRT were randomised to extended autologous LD or implant-assisted LD 235	
reconstruction (QUEST A). Those needing PMRT were randomized to either 236	
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immediate autologous LD or staged–delayed autologous LD procedures 237	
(QUEST B). However, after 18 months of recruitment, only 17 and 8 patients 238	
respectively were recruited to QUEST A and B, and acceptance rates of 19 239	
and 22% respectively. The trials failed to reach target recruitment in a timely 240	
manner. The challenges to recruitment identified were misperceptions of 241	
clinical equipoise by patients, and patients expressing strong preferences for 242	
breast reconstruction types and timings, despite provision of adequate trial 243	
information (Winters et al., 2015).  244	
 245	
Finally, even when trials meet target recruitment, challenges remain. This was 246	
demonstrated by the BRIOS RCT comparing immediate one-stage ADM-DTI 247	
versus 2-stage IBR (Negenborn et al., 2018). This demonstrated increased 248	
complications in the single stage group, but despite this, no difference in QOL 249	
outcomes, with several potential methodological issues accounting for the 250	
discrepancy (Winters and Khajuria, 2018b). Despite adding to the evidence-251	
base, uncertainty still remains regarding the role of ADM in IBR, with future 252	
studies, such as the iBRA study (Potter et al., 2016), underway to further 253	
inform the debate.  254	
 255	
1.1.1 Systematic Reviews 256	
 257	
Systematic reviews seek to collate evidence using pre-defined eligibility 258	
criteria in order to answer a specific research question. They aim to minimize 259	
bias by using explicit, systematic methods documented a priori in a protocol. 260	
The research question is clearly defined and often the Patient, Intervention, 261	
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Comparator and Outcome (PICO) framework is utilised. The components 262	
include pre-specified eligibility criteria (inclusion/exclusion criteria), a 263	
systematic search strategy, assessment of the methodological quality and risk 264	
of bias in the studies, interpretation and presentation of the results, with or 265	
without a meta-analysis. The PRISMA guidance is followed. 266	
 267	
Conversely, a literature review qualitatively summarises evidence using 268	
informal or subjective methods. It provides a summary and overview of a 269	
topic, as opposed to answering a specific research question. Unlike in a 270	
systematic review, there is no a priori defined eligibility criteria, systematic 271	
search strategy, assessment of methodological quality and risk of bias or any 272	
meta-analysis.  273	
 274	
For meta-analysis, two popular statistical models exist, Random effects and 275	
Fixed effects models. The assumption for the Fixed effects model is that there 276	
is one true effect size that underlies all studies in the analysis; any differences 277	
in observed effects are secondary to sampling error (Borenstein et al., 2010). 278	
Conversely, for the Random effects model, one allows the true effect to differ, 279	
i.e. the effect sizes may vary from study to study. The goal is to estimate the 280	
mean of a distribution of true effect sizes. Since each study provides 281	
information about a different effect size, small studies cannot be discounted 282	
by giving them small weights, nor can large studies be given too much weight 283	
(Schmidt et al., 2009). The width of the confidence intervals (CIs) for a meta-284	
analysis is influenced by the individual study estimates and number of studies 285	
combined. Moreover, for the random effects model, the precision of the 286	
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estimate will decrease with increasing heterogeneity, and the confidence 287	
interval width will widen. As more and larger studies are entered in the meta-288	
analysis, one would expect the confidence intervals to decrease, based on 289	
overall greater sample size. However, if the additional studies increase the 290	
heterogeneity, the confidence interval width may increase. 291	
 292	
1.2 Breast cancer reconstruction 293	
 294	
Breast cancer is the commonest malignancy and the primary cause of cancer-295	
associated mortality in women (Ginsburg et al., 2017, Winters et al., 2017). 296	
Risk factors include: number of relatives affected, menstrual status, advancing 297	
age, family history and presence of bilateral disease (Howell et al., 2014, 298	
Singletary, 2003). Upto 10 percent of cases are attributed to hereditary 299	
malignancy, primarily due to BRCA gene mutations. Presence of BRCA1 300	
confers a 50-85% chance of developing breast malignancy (King et al., 2003). 301	
Another risk factor is length of oestrogen exposure, associated with early 302	
menarche, late menopause and late age at first full-term pregnancy.  303	
 304	
Breast conserving surgery (BCS) with radiotherapy, or mastectomy is 305	
normally offered as management options, with comparable oncological 306	
outcomes (Veronesi et al., 2002, van Maaren et al., 2019). Autologous 307	
abdominal flaps and implant-based procedures are the most frequently 308	
employed breast reconstruction (BRR) approaches in the United Kingdom 309	
(UK) and the United States of America (USA) (Ho et al., 2017). Autologous 310	
BRR involves utilising the patient’s own tissues taken from a different parts of 311	
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the body, utilising excess skin and fat to restore breast volume and excised 312	
skin following mastectomy. Skin and fat are taken with intact blood vessels, 313	
which are anastomosed to blood vessels in the chest, establishing blood flow 314	
and flap survival. Different donor sites can be used, most commonly the 315	
abdomen, compared to thigh or buttocks (O'Halloran et al., 2018). Commonly 316	
used abdominal-based flaps include the Deep Inferior Epigastric Perforator 317	
(DIEP) flap; Transverse Rectus Abdominus Myocutaneous (TRAM) flap and 318	
the Superficial Inferior Epigastric Artery (SIEA) flap (Figure 1). 319	
 320	
 321	
 322	
 323	
 324	
 325	
 326	
 327	
 328	
 329	
 330	
Figure 1. Figure depicting DIEP and TRAM donor sites; DIEP flap does not 331	
contain section of the rectus abdominis muscle (Chovan, 2019) 332	
 333	
Koshima and Soeda first described the DIEP flap in 1989 (Koshima and 334	
Soeda, 1989), with Allen and Treece popularising its use in breast 335	
reconstruction in 1994 (Allen and Treece, 1994). The Deep Inferior Epigastric 336	
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Perforator artery originates from the external iliac artery and advances to the 337	
lateral edge of the rectus muscle, travelling towards the arcuate line on its 338	
deep surface. The flap consists of skin, fat and the perforator vessel only; 339	
hence no muscle is harvested unlike for the TRAM flap. The flap is transferred 340	
to the chest where the DIEP artery is anastomosed to the recipient vessels, 341	
most commonly the internal mammary vessels. Conversely, the TRAM flap is 342	
based on the superior epigastric artery. The DIEP flap has largely superseded 343	
the TRAM flap, since no muscle is harvested in the DIEP flap. This reduces 344	
the risk of complications such as abdominal bulge or hernia. The SIEA flap is 345	
based on the superficial inferior epigastric artery, which is of smaller calibre 346	
than the DIEP and often too small to perfuse the flap. 347	
 348	
The traditional immediate two-stage Implant-based Reconstruction (IBR) 349	
involves placement of a tissue expander in a sub-muscular pocket. This 350	
provides a vascularised tissue layer in between the expander and the 351	
mastectomy flap, protecting against mastectomy flap necrosis. While this is 352	
still the mainstay of treatment, its limitations include lack of lower pole and 353	
infero-lateral breast expansion, increased time for subsequent expansion, 354	
increased pain associated with expansion, and, re-operative pocket 355	
modification at a subsequent date (Hallberg et al., 2018, Smith et al., 2018a). 356	
An acellular dermal matrix (ADM) was introduced to address some of these 357	
limitations.  358	
 359	
ADMs are utilised in immediate Direct-To-Implant (DTI) breast reconstruction,  360	
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as time-efficient and potentially less expensive alternative to tissue expanders 361	
and free flap surgeries (Salzberg, 2006). In the sub-muscular approach, the 362	
ADM is sutured between the inframammary fold and the inferior border of the 363	
surgically released pectoralis major muscle to provide support and coverage 364	
of the implant in the lower pole of the breast. The ADM properties also allow 365	
for incorporation of the allograft to the native skin with minimal fibrosis or 366	
contracture. From an aesthetic standpoint, a meta-analysis by (DeLong et al., 367	
2019) concluded that objective observers consider acellular dermal matrix-368	
assisted expander-to-implant breast reconstructions aesthetically superior to 369	
reconstruction with only muscular coverage, but patients appear to be equally 370	
satisfied with both reconstructive options. The BRIOS trial, comparing one-371	
stage versus two-stage IBR reconstruction, concluded that risks for adverse 372	
outcomes were significantly higher in the one-stage ADM group, with no 373	
differences in quality of life outcomes (Negenborn et al., 2018). 374	
 375	
1.3 Loco-regional post-mastectomy radiotherapy (PMRT)  376	
 377	
Adjuvant loco-regional post-mastectomy radiotherapy of the chest wall and 378	
regional lymph nodes (regional lymph node irradiation, RNI: internal 379	
mammary and supraclavicular) is historically indicated for locally advanced 380	
disease (Yang and Ho, 2013, Macdonald et al., 2011). These indications 381	
expanded based on level-one evidence by the Early Breast Cancer Trialists 382	
Collaborative Group (EBCTCG) (McGale et al., 2014). The EBCTCG meta-383	
analysis showed significantly improved disease-free and overall survival after 384	
PMRT and RNI in intermediate risk women with tumours <50 mm and 1-3 385	
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positive lymph nodes (Marks et al., 2017). Despite these findings, new USA 386	
guidelines (Recht et al., 2017) highlight that the EBCTCG review of 1133 387	
patients was based on historical studies from the 1970s and 1980s without 388	
the benefits of contemporary systemic treatments, showing much lower risks 389	
for all cancer endpoints (Kunkler et al., 2017). The current PMRT 390	
recommendations for this intermediate risk group remains controversial and is 391	
awaiting the results of the SUPREMO (Selective Use of Postoperative 392	
Radiotherapy AftEr MastectOmy) trial, which is the only randomised trial of 393	
chest wall RT in which BRR and toxicity have been prospectively assessed 394	
(Russell et al., 2015, Donker et al., 2014).  395	
 396	
Despite potential oncological advantages, PMRT may have deleterious effects 397	
on breast cosmetic outcomes and may increase surgery complications 398	
following immediate BRR (O'Halloran et al., 2017). Previous studies 399	
evaluating the impact of PMRT on types of immediate BRR showed its 400	
potential feasibility in this setting with lower morbidities compared to implant-401	
based procedures (Bennett et al., 2018, Jagsi et al., 2018, Barry and Kell, 402	
2011, Ho et al., 2017). Surprisingly, the rapid adoption of immediate implant-403	
based reconstruction in about 70% of women compared to 34% of autologous 404	
procedures when PMRT is recommended may be influenced by surgeon and 405	
patient preferences, regardless of current evidence (Jagsi et al., 2018, Potter 406	
et al., 2019, O'Halloran et al., 2017).  The MROC cohort comparing immediate 407	
versus delayed reconstruction evaluated complications requiring re-408	
hospitalization or re-operation; these were designated as “major” 409	
complications (Yoon et al., 2018). Reconstructive failures, defined as 410	
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complications necessitating implant or flap removal, were also recorded. 411	
Controlling for demographic and clinical covariates, delayed reconstruction 412	
was associated with significantly lower odds of any complication and of major 413	
complications, compared with immediate procedures. Delayed autologous 414	
patients were at significantly lower risk of complications compared to 415	
immediate autologous patients, but there was no difference for implant 416	
patients (Yoon et al., 2018). 417	
 418	
However, increasing recommendations for PMRT and growing numbers of 419	
immediate BRR have prompted numerous questions about their optimal 420	
combination (O'Halloran et al., 2018).  The EBCTCG trials omitted patients 421	
with immediate BRR and previous publications have not provided clarity 422	
concerning the choice between immediate and delayed BRR (McGale et al., 423	
2014). Despite this, immediate autologous BRR is commonly recommended 424	
in the setting of PMRT, given the potential long-term benefits on patient’s 425	
QOL and breast cosmetic satisfaction (Santosa et al., 2018, Velikova et al., 426	
2018). Currently, immediate autologous BRR and PMRT recommendations 427	
are highly variable (Momoh et al., 2012, Kelley et al., 2014). The landmark 428	
‘Gap Analysis’ publication in Lancet Oncology by the International Association 429	
of Breast Surgery highlighted this as a key unanswered question in breast 430	
cancer research (Cutress et al., 2018).  431	
 432	
Potter and colleagues conducted a systematic review showing methodological 433	
variations in the definitions of surgery complications, including their disparate 434	
reporting, significantly precluding inter-study comparisons (Potter et al., 2011). 435	
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Complications of autologous breast reconstruction with PMRT include: flap-436	
related fat necrosis, partial/total flap loss, poor wound healing and 437	
fibrosis/contracture that reduces breast volume (Ho et al., 2017). Surgical 438	
complications contribute variably to decreases in patient satisfaction and 439	
impaired cosmetic outcomes (Ho et al., 2017). Potter and colleagues 440	
proposed a standardised BRR core outcomes set through expert consensus 441	
using Delphi methodology (Potter et al., 2015). The range of complications, 442	
including flap-related complications and unplanned surgery, were itemised. 443	
The BRR core outcome set has yet to recommend a standardised 444	
measurement tool for evaluating surgical complications. Currently, surgeons 445	
are recommended to use the Clavien-Dindo classification (CDC) (Dindo et al., 446	
2004). Patient-reported QOL outcomes using validated BRR questionnaires 447	
such as the BREAST-Q and the European Organisation for Research and 448	
Treatment of Cancer (EORTC) (QLQ)-BRECON23 are recommended to 449	
evaluate comparative effectiveness (Pusic et al., 2009, Winters et al., 2010, 450	
Winters and Thomson, 2011, Cano et al., 2012, Klassen et al., 2009, Tevis et 451	
al., 2018, Santosa et al., 2018, Winters et al., 2018).  452	
 453	
1.4 Quality of Life (QOL) 454	
  455	
Health-related quality of life (HRQoL) is a multi-dimensional concept with self-456	
reported domains related to physical, mental, emotional, and social 457	
functioning. It goes beyond direct measures of population health, life 458	
expectancy, and causes of mortality. Patient-Reported Outcomes (PROs) 459	
pertain to measurement of any aspect of a patient’s health status that comes 460	
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directly from the patient. Evaluation of clinical variables such as morbidity and 461	
mortality are necessary but not sufficient for adequate outcome assessment, 462	
as a mastectomy can have a profoundly negative impact on a woman’s 463	
physical, psychological and sexual wellbeing (Dean et al., 1983, Eltahir et al., 464	
2013, Winters et al., 2014, Cserni et al., 2018, Cohen et al., 2016, Chen et al., 465	
2010, Erdmann-Sager et al., 2018, Pusic et al., 2009, Klassen et al., 2009, 466	
Winters et al., 2010, Cano et al., 2012, Pusic et al., 2012, Cano et al., 2014, 467	
Efficace et al., 2015, Macadam et al., 2016, Dikmans et al., 2019). For many 468	
procedures, the more discriminating outcome is the patient’s own perception 469	
of the surgical result and impact on quality of life.  470	
 471	
QOL measurement is pertinent in comparative effectiveness research (CER). 472	
Here, two active forms of treatment are compared or usual care in comparison 473	
with usual care with an additional intervention element. Capturing the patient-474	
own perception is essential in a prospective clinical CER to examine real-475	
world outcomes related to treatment modalities. Patient-reported outcome 476	
measures (PROMs) are standardised questionnaires that measure QOL 477	
(Cano et al., 2009). The BREAST-Q and European Organisation for Research 478	
and Treatment of Cancer (EORTC) Breast Cancer-Specific Quality of Life 479	
Questionnaire (QLQ-BRECON23) are two psychometrically robust, validated 480	
disease-specific PROMs to evaluate QoL for breast reconstruction (Pusic et 481	
al., 2009, Winters et al., 2018). PROMs for assessing HRQoL in patients with 482	
breast cancer comprise the 30-item EORTC QLQ-C30 (Aaronson et al., 1993) 483	
and the disease-specific QLQ-BR23 (Sprangers et al., 1996). For breast 484	
reconstruction, patient-reported QOL outcomes using these validated BRR 485	
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questionnaires are integral to comparative effectiveness studies (Pusic et al., 486	
2009, Winters et al., 2010, Winters and Thomson, 2011, Cano et al., 2012, 487	
Klassen et al., 2009, Tevis et al., 2018, Santosa et al., 2018). Their 488	
development and validation includes three phases (Pusic et al., 2009): 1) 489	
Phase I: Item Generation and Conceptual Framework Formation - generates 490	
a pool of items to ensure all important areas are considered for inclusion in 491	
the final scale; encompasses literature review, patient interviews 492	
(predominant component), and expert opinion. Item pool is then pre-tested on 493	
small sample of patients – to check ambiguities; confirm appropriateness, and 494	
determine acceptability and completion time; 2) Phase II: Item Reduction - 495	
field testing using larger patient sample – to revise or eliminate items; and 3) 496	
Phase III: Psychometric evaluation using Rasch measurement methods and 497	
analyses to guide scale construction. Reliability, validity, and responsiveness 498	
are confirmed.  499	
 500	
The COSMIN (COnsensus-based Standards for the selection of health 501	
Measurement INstruments) initiative has aimed to improve the selection of 502	
outcome measurement instruments by developing tools for selecting the most 503	
appropriate instrument. Selecting unsuitable/poor quality outcome 504	
measurement instruments may generate bias, lead to waste of resources and 505	
be potentially unethical as patients contribute little to knowledge but still suffer 506	
from the burden/risks of the study. 507	
 508	
When selecting an instrument, the outcome should be clearly defined. With 509	
respect to HRQoL, it should be clarified which subdomains are relevant for the 510	
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target population. The COSMIN initiative has developed several tools to help 511	
researchers choose the most appropriate initiative. These include: 1) 512	
COSMIN taxonomy and definitions of measurement properties, clustered 513	
within three domains, i.e. validity [construct, content and criterion validity], 514	
reliability [internal consistency, reliability, measurement error] and 515	
responsiveness; 2) COSMIN checklist to evaluate the methodological quality 516	
of studies on measurement properties; 3) Search filter for finding studies on 517	
measurement properties; 4) Protocol for systematic reviews of outcome 518	
measurement instruments; 5) Database of systematic reviews of outcome 519	
measurement instruments; and 6) Guideline for selecting outcome 520	
measurement instruments for outcomes included in a Core Outcome Set.   521	
 522	
A domain refers to the distinct area of experience that a given questionnaire is 523	
designed to explore. As per the SPIRIT-PRO extension, PRO measures 524	
maybe multidimensional (e.g. HRQOL) or unidimensional (e.g. specific 525	
symptom such as pain). Defining the key objectives and hypothesis a priori 526	
will encourage the key PRO domains to include in the study, reducing the risk 527	
of multiple statistical testing, a Type I error and selective reporting of PROs 528	
based on statistically significant results (Calvert et al., 2018). The BREAST-Q 529	
breast reconstruction module has satisfaction domains (e.g. satisfaction with 530	
back and abdomen). When evaluating patients undergoing abdominal-based 531	
flaps, the ‘satisfaction with abdomen’ domain is pertinent. Conversely, if 532	
evaluating the Latissimus Dorsi (LD) flap, the ‘satisfaction with back’ is more 533	
pertinent. The chosen domains should be described in the study protocol a 534	
priori.       535	
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Health utility measures include the EQ-5D instruments, with the 5-level EQ-5D 536	
version (EQ-5D-5L) introduced by the EuroQol Group in 2009 to improve the 537	
instrument’s sensitivity (EuroQol, 2019). It consists of five dimensions: 538	
mobility, self-care, usual activities, pain/discomfort and anxiety/depression. 539	
Each dimension has 5 levels, from “no problems” through to “extreme 540	
problems”. The patient indicates his/her health state by choosing the most 541	
appropriate statement in each of the five dimensions. This decision results in 542	
a 1-digit number that identifies the level selected for that dimension (EuroQol, 543	
2020). The digits for the five dimensions can be combined into a 5-digit 544	
number that describes the patient’s health state. This summary index score is 545	
based on societal preference weights for the health state, with the weights 546	
referred to as ‘utilities’; these are often used to compute QALYs for economic 547	
analyses (EuroQol, 2019). Health state index scores generally range from 548	
less than 0 to 1 (the value of full health), with higher scores indicating higher 549	
health utility.  550	
 551	
The EORTC has developed the QLU-C10D, a multi-attribute utility instrument 552	
derived from the cancer-specific quality of life questionnaire, EORTC QLQ-553	
C30 (King et al., 2016). U.K.-specific utility weights have been defined 554	
(Norman et al., 2019) and will enable cost-utility analysis (CUA) for economic 555	
evaluation of new oncology therapies and technologies in the UK, where cost 556	
and resource allocation are fundamental. Nevertheless, there is a growing 557	
view that measurement of health alone (for example through QALYs) in 558	
economic evaluation is often insufficient (Ryan et al., 2006). This is especially 559	
the case where there are significant spillover effects of intervention, for 560	
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example impacts on carers or family. Moreover, QALYs typically measure 561	
one’s health status, but do not measure what people are capable of doing, as 562	
a sense of broader wellbeing.  To address this, (Flynn et al., 2015) proposed 563	
the use of an alternate cost utility index, the Investigating Choice Experiments 564	
Capability Measure for Adults (ICECAP-A), which has 5 attributes, each of 565	
which are scored between 1 to 4 ranging from full capability to no capability.  566	
These include: 1) Stability (being able to feel settled and secure) 2) 567	
Attachment (being able to have love, friendship and support) 3) Autonomy 568	
(being able to be independent) 4) Achievement (being able to achieve and 569	
progress) and 5) Enjoyment (being able to have enjoyment and pleasure). 570	
 571	
An important concept when interpreting QOL outcomes is the minimally 572	
important difference (MID). MID is defined as the smallest change in a HRQoL 573	
domain, which is perceived as ‘important’ by the patient and clinician, which 574	
may indicate a change in management (Cocks et al., 2012, King, 1996, Cano 575	
et al., 2014). Small differences in QOL scores maybe statistically significant, 576	
without clinical relevance. MID estimates can also facilitate clinical trial design 577	
by informing the choice of sample size and specifying clinical trial endpoints. 578	
MIDs are determined by anchor-based methods, which express a change in 579	
HRQoL scores within specific domains of a patient and/or physician-derived 580	
rating, and distribution-based methods, that utilise statistical distribution of 581	
HRQoL scores (e.g. standard deviation), often considered as providing 582	
supportive evidence to anchor-based methods (Musoro et al., 2019).  For the 583	
reconstruction module of the BREAST-Q, a minimal important difference 584	
score of 4 points has been proposed to be clinically useful when assessing an 585	
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individual patient’s outcome for the different domains (i.e. breast satisfaction; 586	
psychosocial wellbeing; physical wellbeing and sexual wellbeing), based on 587	
analysis of prospectively collected data from 3052 Mastectomy 588	
Reconstruction Outcomes Consortium (MROC) patients (Voineskos et al., 589	
2020).  590	
 591	
Longitudinal analysis of HRQOL is pertinent, as HRQOL maybe incorporated 592	
by oncology trials as a major endpoint, in order to evaluate the clinical benefit 593	
of new therapeutic strategies. Methods used to analyse longitudinal HRQOL 594	
include: 1) general linear mixed model (GLMM) 2) Item Response Theory 595	
(IRT) models and 3) time-to-event models such as the time-to-HRQoL score 596	
deterioration (TTD). One challenge associated with longitudinal assessment 597	
of HRQOL is the potential occurrence of a response shift (RS) effect. This is 598	
defined as “a change in the meaning of one’s self-evaluation of a target 599	
construct”. This maybe due to change in patients’ internal standards of 600	
measurement (i.e. scale recalibration); change in values (i.e. the domains 601	
making up the target construct) or redefinition of the target construct 602	
(reconceptualization). TTD has been recommended as the optimal method to 603	
analyse longitudinal HRQOL, as it takes into account the occurrence of the 604	
RS recalibration component by choosing different reference scores to qualify 605	
the deterioration and it is reported using hazard ratios (HR), a format familiar 606	
to clinicians. Anota et al. demonstrated that definition of TTD can influence 607	
change in HRQOL results, precluding inter-study results comparison. In the 608	
breast cancer study, the choice of the reference score impacted on the 609	
median TTD. When the best previous score was used as the reference, 610	
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instead of the baseline score, the median TTD of cognitive functioning 611	
decreased while that of the breast and arm symptoms increased. The TTD 612	
approach has the advantage of taking recalibration into account without 613	
additional questionnaires, by using changing scores as a reference.  614	
 615	
To facilitate transparent and better reporting of QOL outcomes, a number of 616	
tools have been designed. The CONSORT-PRO statement was designed to 617	
promote transparent reporting of RCTs where PROs are primary or important 618	
secondary outcomes (Calvert et al., 2013). The statement was based on the 619	
methodological framework for guideline development proposed by the 620	
EQUATOR Network (Moher et al., 2010), with the initial work led by ISOCOL. 621	
The development process involved a systematic review of existing guidelines, 622	
survey of key stakeholders, with final dissemination to ISOCOL members. 623	
Subsequently, the final CONSORT PRO guidance was released. For trial 624	
protocols, the SPIRIT PRO guidance has been published (Calvert et al., 625	
2018). Whilst guidance exists to facilitate transparent reporting, it is important 626	
that PRO findings are obtained from robust methodological practices and are 627	
analysed consistently. To address this, the Setting International Standards in 628	
Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data 629	
(SISAQOL) Consortium has published consensus recommendations for PRO 630	
analysis in cancer RCTs (Coens et al., 2020).  631	
 632	
For implant-based reconstruction, there is growing evidence that PMRT 633	
increases the rate of serious adverse events, with a reduction in patient 634	
satisfaction, quality of life (QoL) and objective cosmetic outcomes (Ricci et al., 635	
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2017, Cordeiro et al., 2014, Pu et al., 2018). Conversely, for autologous flap 636	
reconstruction, the evidence is more equivocal and the optimal sequence of 637	
reconstruction and PMRT is unclear (Rogers and Allen, 2002, Chatterjee et 638	
al., 2009, Cooke et al., 2017, Taghizadeh et al., 2015, O'Connell et al., 639	
2018a). Overall, the dogma is that patients who are expected to require 640	
PMRT are advised to undergo delayed autologous breast reconstruction or 641	
‘delayed-immediate’ reconstruction, which utilises a temporising implant, 642	
facilitating preservation of native breast skin and a chest wall mound whilst 643	
the patient awaits a planned exchange to autologous reconstruction 644	
(Kronowitz et al., 2004). However, the patient must live without a breast for 645	
substantial time and this may culminate in psychosocial morbidity associated 646	
with mastectomy alone (Wilkins et al., 2000). Moreover, there is perceived 647	
evidence to suggest potential satisfactory outcomes, comparable complication 648	
rates and PROs, after immediate autologous breast reconstruction with 649	
adjuvant radiotherapy (Chatterjee et al., 2009, Taghizadeh et al., 2015, Cooke 650	
et al., 2017). Furthermore, some protagonists have reported higher baseline 651	
QoL scores before intended immediate breast reconstruction with adjuvant 652	
radiotherapy compared to intended delayed reconstruction (Billig et al., 2017).   653	
 654	
Subsequent parts of the thesis will focus on key papers published by the 655	
author on the aforementioned theme. 656	
 657	
1.5 Aim 658	
The aim of the author’s work was to evaluate outcome measurement and 659	
reporting quality in surgery, with a focus on plastic & reconstructive breast 660	
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surgery and autologous reconstruction with or without radiotherapy. The 661	
author has also assessed the quality of evidence, reporting of clinical 662	
complications as well as patient-reported complications, and evaluated 663	
compliance of RCTs against the CONSORT checklist for Non-664	
Pharmacological Treatments (NPT).  665	
 666	
 667	
 668	
 669	
 670	
 671	
 672	
 673	
 674	
 675	
 676	
 677	
 678	
 679	
 680	
 681	
 682	
 683	
 684	
 685	
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2. Report Quality of Surgical Randomised Controlled Trials (RCTs) 686	
 687	
RCTs represent the gold standard in evaluating intervention effectiveness and 688	
are classified as Level Ib by the Oxford Centre for Evidence Based Medicine. 689	
However, poor reporting can inhibit adequate critical appraisal by readers and 690	
lead to inconsistencies between results and conclusions. Adequate and 691	
accurate reporting is fundamental to facilitate critical appraisal and 692	
interpretation of the data by the readers. 693	
 694	
The Consolidated Standards of Reporting Trials (CONSORT) statement was 695	
developed to provide a set of standards for transparent reporting of RCTs. 696	
Surgical RCTs have inherent challenges, with issues related to blinding, 697	
inconsistent care provider expertise and centres’ volume all having an impact 698	
on the outcomes. The 2008 CONSORT extension for non-pharmacological 699	
treatment interventions (CONSORT NPT) (Boutron et al., 2008) is an 700	
extension on the 2001 CONSORT checklist, and takes into account the 701	
aforementioned challenges inherent to surgical RCTs. 702	
 703	
The author conducted a systematic review and meta-analysis evaluating the 704	
compliance of RCTs in Surgery against the CONSORT NPT statement (Yao 705	
et al., 2014) [Appendix 1,2,10]. The aim of the project was to answer a 706	
specific research question, i.e. “in the Ophthalmic Surgery literature, is the 707	
reporting quality of RCTs against the CONSORT NPT statement optimal.” A 708	
systematic review methodology was deemed most optimal to evaluate all the 709	
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literature published in the field, within a defined period, with pre-defined 710	
inclusion and exclusion criteria.   711	
 712	
The mean CONSORT score of the 65 RCTs was 8.9 out of 23 (39%, range 713	
3.0–14.7, SD 2.49). The poorest-reported items were: title and abstract; 714	
details of how adherence with protocol was assessed; and, interpretation of 715	
results [Figure 2; Appendix 1]. No paper adequately reported all items in the 716	
CONSORT checklist. There was no correlation between CONSORT score 717	
versus the impact factor (Spearman rho = 0.14, P = 0.29, Cohen’s d = 3.297), 718	
or the number of authors (Spearman rho = 0.01, P = 0.93, Cohen’s d = 1.533). 719	
There was no statistically significant difference between the scores of single- 720	
and multi-centre trials. 721	
 722	
This work [Appendix 1,2,10] has been cited multiple times. The poor reporting 723	
compliance identified corroborated the poor compliance in a number of other 724	
surgical specialties (Camm et al., 2015). The work formed basis for change of 725	
policy and the requirement for mandatory completion and uploading of a 726	
CONSORT statement by authors when submitting articles to the peer-727	
reviewed journal, International Journal of Surgery (IJS), with significant 728	
improvement in compliance (Agha et al., 2016). 729	
 730	
The strengths of the review include the fact that subjectivity was minimised in 731	
by predefining the scoring strategy among the reviewers. The item was only 732	
scored if all elements were reported, on the basis that CONSORT items 733	
represent absolutely fundamental information; ‘the minimum criteria,' that 734	
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should be reported in a RCT. Furthermore, all items on the checklist were 735	
given equal weighting. Whilst this may not reflect their relative importance, it 736	
was nonetheless an objective approach to analyse deficits, patterns, as well 737	
as overall compliance. Two independent authors performed the scoring to 738	
reduce bias. 739	
 740	
There were several limitations. The period studied was restricted to 2011, so 741	
did not allow analysis of temporal trends in the CONSORT score. Many items 742	
contain multiple elements. Whether reviewers score items in regard to the 743	
multiple elements is a potential area of subjectivity, although this was 744	
minimised by the aforementioned strategy. No correlation was identified 745	
between CONSORT score and surrogate markers of papers quality; this 746	
maybe attributed to inclusion of inadequately powered studies. Finally, the 747	
search was restricted to the English language, with the potential of missing 748	
articles for inclusion.   749	
 750	
Given many journals have now made uploading a reporting guidance checklist 751	
as a mandatory part of article submission, future work should analyse 752	
temporal trends in compliance and reporting quality. Reviews should be 753	
prospectively registered, with comprehensive search of the databases, 754	
without language restriction.     755	
 756	
I was involved in the conception, design, design of search strategy, database 757	
searching, data extraction, statistics, interpretation, drafting and critical review 758	
of manuscript.  759	
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3. Clinical outcomes, Patient-Reported Outcomes (PROs) and Cost of 760	
Deep Inferior Epigastric Perforator (DIEP) flap versus Implant-based 761	
Breast Reconstruction 762	
 763	
Two of the commonest reconstructive modalities include autologous 764	
reconstruction using the deep inferior epigastric perforator (DIEP) flap and 765	
implant-based reconstruction (IBR). The treatment choice is determined by a 766	
number of patient and surgeon factors. Nevertheless, many plastic surgery 767	
units worldwide consider autologous reconstruction superior, replacing “like 768	
with like” (Sisco et al., 2012).  There is growing evidence to suggest that 769	
autologous BRR may culminate in superior clinical and PROs (Matros et al., 770	
2015, Santosa et al., 2018, Lagares-Borrego et al., 2016, Tonseth et al., 771	
2008, Atherton et al., 2011). IBR is associated with complications, including 772	
infection, migration, exposure/extrusion, rupture, patient dissatisfaction due to 773	
edge visibility/implant animation and reduced/absent nipple sensation.  774	
Capsular contracture can result in pain, asymmetry, increased palpability and 775	
need for implant removal (Agha et al., 2015). Allergan’s 10-year cumulative 776	
risk study found that 24.6% of patients who underwent IBR developed 777	
capsular contracture (Spear and Murphy, 2014). Conversely, DIEP flap is 778	
widely considered the “gold standard” for postmastectomy BRR. 779	
 780	
The known surgical complications for DIEP and IBR are detailed below. The 781	
rates of complications are derived from the data from the Mastectomy 782	
Reconstruction Outcome Consortium (MROC) cohort (Wilkins et al., 2018). 783	
    784	
	 30	
Breast 
Complication 
Implant 
(DTI 
and TE) 
(%) 
Pedicled 
TRAM 
(%) 
Free 
TRAM 
(%) 
DIEP 
(%) 
LD 
(%) 
 
 
 
Haematoma 3.5 3.6 4.1 6.0 4.1 
Wound 
dehiscence 
1.6 1.2 1.0 3.6 1.4 
Wound 
infection 
10.0 6.0 4.1 3.8 8.2 
Mastectomy 
skin flap 
necrosis 
6.6 6.0 6.2 7.7 5.5 
Seroma 2.9 2.4 0.0 0.8 2.7 
Capsular 
contracture 
0.8 - - - 1.4 
Implant 
malposition 
0.5 - - - 1.4 
Implant 
leakage, 
rupture, 
and/or 
deflation 
1.1 - - - 0.0 
Acute partial 
flap necrosis 
- 11.9 5.2 2.5 1.4 
Total flap loss - 1.2 2.1 1.4 0.0 
Fat necrosis - 7.1 5.2 9.0 0.0 
Seroma - 0.0 2.1 5.2 19.2 
Abdominal 
wall bulge, 
laxity or 
hernia 
- 4.8 3.1 1.6 0.0 
 785	
From a cost standpoint, some authors have argued that DIEP reconstruction 786	
is more cost-effective, resulting in lower overall complications and superior 787	
PROs, compared with IBR (Matros et al., 2015, Atherton et al., 2011, 788	
Lagares-Borrego et al., 2016). Whilst some North American and European 789	
centres have published cost-analyses on DIEP and IBR, the data are sparse, 790	
especially from public and free universal health care system settings. 791	
 792	
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The author conducted and published a meta-analysis evaluating clinical 793	
outcomes, Patient-Reported Outcomes (PROs) and Cost of DIEP flap versus 794	
Implant-based Breast Reconstruction (Khajuria et al., 2019) [Appendix 3-5, 795	
11]. The aim of the project was to answer a specific research question, i.e. in 796	
patients aged 18 or over with breast malignancy undergoing mastectomy and 797	
breast reconstruction, does DIEP reconstruction lead to superior clinical, 798	
patient-reported outcomes and cost compared with Implant-based 799	
reconstruction. A systematic review methodology was deemed the most 800	
optimal to answer the research question, as there had been a number of 801	
studies published in the literature evaluating DIEP and IBR, and the SR was 802	
performed to obtain overall summary measures for outcomes, to help facilitate 803	
informed consent and the shared decision making process with the patient. 804	
 805	
 Robust Cochrane methodology was followed and comprehensive screening 806	
of 6381 articles was undertaken. Cochrane’s Review Manager 5.3 software 807	
was used to perform the meta-analysis. Odds ratios [95% confidence intervals 808	
(CI)] were used to evaluate dichotomous outcomes (surgical complications). 809	
Standard mean differences (95% CI) were used for continuous outcomes 810	
between treatment groups.  Heterogeneity between studies was assessed in 811	
Review Manager 5.3 (Liu et al., 2013) using the Higgins and Thompson’s I2 812	
statistic.(Higgins and Thompson, 2002) Levels of heterogeneity were defined 813	
as: low (I2 <50%), moderate (I2 50% - 80%), and high (I2 >80%). A random-814	
effects model was used for cohorts with heterogeneity (I2>50%) (DerSimonian 815	
and Laird, 2015). As heterogeneity was generally moderate or high, and 816	
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outcome measures differed between studies, these were combined using the 817	
DerSimian and Laird random-effects model. 818	
 819	
Out of 6,381 articles screened, 16 were included [unilateral 782 DIEPs, 376 820	
implants; mean age 49 years, follow-up (months): DIEP 29.9; IBR 35.5]. Mean 821	
flap loss and fat necrosis rates were 3.97% (SD 4.90) and 9.67% (SD 17.0), 822	
respectively. There was no difference in mean length of stay (MD 0.63 823	
[confidence interval (CI) −9.17 to 10.43]; P =0.90) [Figure 5; Appendix 4]. The 824	
number of reoperations for complications was significantly lower in DIEP 825	
versus IBR [MD −0.29 (CI −0.48 to −0.09); P <0.01] [Figure 6; Appendix 5]. 826	
The mean difference (MD) is the difference in means of the intervention and 827	
control groups, whereas the standardised mean difference (SMD) is the MD 828	
divided by the standard deviation (SD), from either or both groups (Faraone, 829	
2008). MD was employed as the studies included in the meta-analysis used 830	
the same, continuous outcome and unit of measure. Conversely, a SMD 831	
would be used when studies assess the same outcome but measure it in 832	
different ways, e.g. measuring a clinical outcome where studies have used 833	
different psychometric scales (Paramanandam and Roberts, 2014). It would 834	
be necessary to standardise to a uniform scale before they can be combined. 835	
The SMD is also easier to interpret compared to MD, as SMD can be 836	
interpreted using Cohen’s guidelines, where SMD of 0.2, 0.5 and 0.8 equates 837	
to a small, medium and large effect respectively (Cohen, 1988). It can also be 838	
easily converted to a number needed to treat (NNT) (da Costa et al., 2012); 839	
NNTs are more intuitive and easier to interpret for clinicians. 840	
 841	
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There were no randomized controlled trials. Study quality was low with high 842	
risk of bias. One study reported $11,941/Quality-adjusted Life Year 843	
incremental cost effectiveness ratio for DIEP, with higher breast Quality-844	
adjusted Life Year (DIEP 19.5; IBR 17.7) using Breast Questionnaire; Two 845	
comparative studies evaluating PROs favoured DIEP. Three studies 846	
evaluating cost, favoured DIEP. 847	
 848	
Study quality was assessed using the Grading of Recommendations 849	
Assessment, Development and Evaluation (GRADE) tool (Atkins et al., 2004). 850	
The quality of evidence was applied to each outcome. An overall GRADE 851	
quality rating was then applied to the body of evidence across outcomes. Key 852	
elements were considered: study design; study quality pertaining to study 853	
methods/execution, consistency (i.e. how similar are the estimates of effect 854	
across studies); directness (extent to which patient population, interventions 855	
and outcome measures are similar to those of interest); and precision (width 856	
of the confidence intervals) (Atkins et al., 2004). The highest quality rating is 857	
for randomized trial evidence.  This is downgraded to moderate, low, or very 858	
low quality evidence, based on: limitations in design and implementation of 859	
studies, suggesting high likelihood of bias; unexplained 860	
heterogeneity/inconsistency in results; and imprecision of results (wide 861	
confidence intervals).  862	
 863	
The Risk of Bias in Nonrandomized Studies of Interventions (ROBINS-I) tool 864	
was utilised to assess risk of bias (RoB). It covers 7 domains from which bias 865	
may be introduced, with “signalling questions” facilitating judgments about 866	
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RoB for each outcome. The judgments within each domain were carried 867	
forward for an overall RoB judgment across bias domains. For the breast 868	
reconstruction reviews, the domains responsible for moderate/serious risk of 869	
bias, included: 1) bias due to presence of confounders between groups, which 870	
were unaccounted for. Majority of the studies also did not define the patient 871	
baseline characteristics, while some studies, due to their retrospective nature, 872	
were not able to report patient characteristics, as the data were unavailable. 873	
No data were available on the level of care provider expertise and centre’s 874	
volume; 2) bias in the selection of participants into the study, with all studies 875	
being non-randomised studies of the effects of interventions (NRSIs); 3) bias 876	
due to deviations from intended interventions, with lack of pre-published 877	
protocols or information on how adherence to protocol was assessed; 4) 878	
missing data, insufficient follow-up and attrition bias; and 5) bias in outcome 879	
measurement – heterogeneity, with outcomes not defined a priori or graded, 880	
lack of blinding with ascertainment and response biases. 881	
 882	
In this systematic review, the mean total flap loss rate was 3.97%. This is 883	
greater than the 1.4% rate from the MROC cohort (Wilkins et al., 2018). The 884	
mean fat necrosis rate in this systematic review was 9.67%; this is similar to 885	
the 9.0% rate in the MROC cohort (Wilkins et al., 2018). The capsular 886	
contracture rate reported in the systematic review was 3.33%, greater than 887	
0.8% reported in the MROC cohort. The differences maybe explained by the 888	
small sample sizes and significant heterogeneity in outcome reporting in the 889	
studies included in the systematic review. Majority of the studies did not 890	
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define the complications a priori, precluding adequate interpretation of the 891	
results.      892	
 893	
This was the first published systematic review and meta-analysis in available 894	
literature to evaluate clinical outcomes, PROs, and cost of DIEP versus IBR. It 895	
was published in a peer-reviewed journal (Khajuria et al., 2019) [Appendix 896	
11]. One of the most pertinent findings from this review was the poor reporting 897	
of outcomes in the Plastic & Breast Reconstructive Surgery literature. Clinical 898	
complications are poorly reported as percentages without standardised 899	
reporting using classifications such as Clavien-Dindo (Dindo et al., 2004) and 900	
complication-specific classifications, e.g. Baker’s classification (for capsular 901	
contracture) or flap necrosis classification (Lie et al., 2013). Reporting 902	
complications as percentages is suboptimal, as there is no stratification 903	
according to management (nonoperative/conservative or operative 904	
management) (Khajuria and Mosahebi, 2019, Khajuria and Farhadi, 2020). 905	
 906	
 907	
Moreover, there was inconsistency and heterogeneity in clinical outcome 908	
reporting. Only 8/14 (57.1%) studies evaluating DIEP reported flap loss rates. 909	
Only 3/6 (50.0%) studies evaluating IBR reported implant-specific 910	
complications, including capsular contracture. Only 1 of these studies 911	
classified capsular contracture according to the Baker’s classification. Since 912	
classification/grades help guide management strategies, inaccurate 913	
classification, and grading of these complications, risks biased comparisons of 914	
clinical outcomes between studies, rendering it difficult to interpret the study 915	
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findings. This corroborates the results from the systematic review by (Potter et 916	
al., 2011), on reporting quality of BRR clinical outcomes, that identified poor 917	
reporting quality and need for a core outcome set to facilitate outcome 918	
assessment in effectiveness studies. Furthermore, no studies reported 919	
outcomes using the validated CDC.  920	
 921	
Out of 6 IBR studies, 3 reported implant-specific complications; 2 out of 6 922	
studies did not categorize type of IBR and reported as “implant 923	
reconstruction”. Three out of 6 studies reported EP reconstruction, and 1 924	
reported DTI. Due to the scarcity of IBR data, further subgroup analysis was 925	
not possible. Future studies should clearly specify the type of reconstruction – 926	
DTI/EP; subpectoral or prepectoral and whether acellular dermal matrix was 927	
utilized. Adequate reporting as part of a core outcome set will facilitate inter-928	
study comparisons and meta-analyses. 929	
 930	
Out of 16 studies, only 2 comparative studies (12.5%) reported PROs. A 931	
major paradigm shift is needed to incorporate PROs in all studies evaluating 932	
BRR, as also supported by the recent publication of the “Gap analysis” in 933	
BRR (Cutress et al., 2018). Evaluating clinical outcomes without PROs is a 934	
major drawback in evaluating outcomes in BRR, as the reconstruction must 935	
satisfy the patient with regard to physical, psychological, and sexual well-936	
being (Pusic et al., 2009). Disregard of these domains renders outcome 937	
assessment incomplete and suboptimal. Two comparative studies that 938	
evaluated PROs in our review favored DIEP reconstruction. Matros et al. 939	
utilized a robust, validated, disease-specific questionnaire, BREAST-Q. 940	
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BREAST-Q scores were reported as consistently higher for DIEP compared 941	
with IBR in postoperative years 1–8, with a higher breast Quality-adjusted Life 942	
Year for DIEP. Conversely, Tønseth et al. used generic PRO tools, SF-36, 943	
which revealed no difference in QoL between DIEP and IBR, and Visual 944	
Analog Scale, with superior cosmetic outcome with DIEP. The study also 945	
used a non-validated study-specific questionnaire that demonstrated higher 946	
breast satisfaction, improved social relationship, and body image satisfaction 947	
for DIEP. The results from the author’s review corroborated results from 948	
(Santosa et al., 2018) who evaluated PROs for 2,013 patients (523 949	
autologous reconstructions; 1,490 IBR) from the MROC cohort, pre and 2 950	
years post BRR, using the BREAST-Q. 951	
The 4 domains evaluated were as follows: satisfaction with breasts, 952	
psychosocial well-being, physical well-being, and sexual well-being. At 2 953	
years, patients who underwent autologous reconstruction had higher breast 954	
satisfaction, higher psychosocial well-being, and sexual well-being than did 955	
those who underwent IBR (Santosa et al., 2018). Lack of a significant 956	
difference in QoL between DIEP and IBR reported by Tønseth et al in the 957	
author’s study may be due to the small sample size in the study (n = 50) and 958	
use of a nonspecific, generic QoL tool, SF-36, which may not be sensitive 959	
enough to measure changes as a result of BRR intervention or to capture all 960	
aspects of outcome specific to breast surgery. Moreover, as purported by the 961	
author, QoL domains should be defined a priori, facilitating estimations of 962	
potential effect size (Winters and Khajuria, 2018b). Three comparative studies 963	
evaluated cost, all favoring DIEP (Matros et al., 2015, Atherton et al., 2011, 964	
Lagares-Borrego et al., 2016). Two studies were conducted in a universal 965	
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health care system (UK and Spain) and 1 was conducted in a health 966	
insurance-based model (USA), making direct comparisons on cost difficult. 967	
This is exacerbated by only 1 study performing robust cost effectiveness 968	
analysis, calculating an ICER of $11,491 for DIEP (Matros et al., 2015). An 969	
ICER is the additional cost for DIEP to obtain 1 year of perfect breast-related 970	
QoL compared with IBR; a threshold of $50,000–$100,000 for a year in 971	
perfect overall health has been deemed as acceptable for the adoption of new 972	
technologies or techniques in developed countries (Laupacis et al., 1992). 973	
Heterogeneity in cost-evaluation methods and reporting prevented the 974	
calculation of an overall cost-effectiveness summary measure in the author’s 975	
systematic review. 976	
 977	
Adequate reporting of core outcome measures is required to minimize 978	
reporting bias and facilitate evidence synthesis. Prospective, multicentre, 979	
cohort studies using robust PROMs tools, evaluating cost-effectiveness and 980	
contributing to national/international registries, will facilitate national-level 981	
policy and shared decision-making. 982	
 983	
In the DIEP versus IBR review, I was involved in the conception, design, 984	
PROSPERO registration, design of search strategy, database searching, data 985	
extraction, performing all the analysis, interpretation of the data, drafting and 986	
critical review of the manuscript.  987	
 988	
 989	
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4. Clinical outcomes and PROs of Immediate versus Delayed autologous 991	
breast reconstruction, in context of adjuvant and neoadjuvant 992	
Radiotherapy (RT) 993	
 994	
The author conducted and published a meta-analysis to evaluate the quality 995	
and strengths of the evidence regarding surgical complications in autologous 996	
abdominal flaps in the context of RT receipt and timing (Khajuria et al., 2020) 997	
[Appendix 6-9, 12]. The aim of the project was to answer a specific research 998	
question, i.e. in patients aged 18 or over with breast malignancy undergoing 999	
mastectomy and breast reconstruction, does immediate reconstruction yield 1000	
superior clinical and patient-reported outcomes compared with delayed 1001	
reconstruction. A systematic review methodology was deemed the most 1002	
optimal to answer the research question, as there had been a number of 1003	
studies published in the literature evaluating immediate and delayed 1004	
reconstruction, and the SR was performed to obtain overall summary 1005	
measures for outcomes, to help facilitate informed consent and the shared 1006	
decision making process with the patient. The recent Breast Cancer 1007	
Campaign gap analysis publication in Lancet Oncology identified this a key 1008	
clinical and translational research gap in breast cancer research (Cutress et 1009	
al., 2018), with radiotherapy timing being a contentious issue.  1010	
 1011	
The UK National Flap Registry (UKNFP) Report 2019 identified that the 1012	
majority of breast reconstructions were, in fact, delayed reconstructions 1013	
(49.0%), compared with immediate reconstructions (45.2%). There is inter-1014	
unit and regional variation in terms of timing of radiotherapy and breast 1015	
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reconstruction, which is a contentious issue, as also highlighted in the ‘Gap 1016	
Analysis’ publication. So, the current question in the field is that in patients 1017	
with breast cancer undergoing mastectomy, who need radiotherapy, should 1018	
the flap be irradiated or should the reconstruction be delayed, with evaluation 1019	
of clinical and quality of life outcomes. 1020	
 1021	
Radiotherapy timing evaluated commonly used adjuvant and less commonly 1022	
pre-operative RT (Neo RT), administered prior to skin-sparing mastectomy 1023	
and immediate breast reconstruction (Zinzindohoue et al., 2016). QOL studies 1024	
were evaluated for their methodological rigour. This was the first meta-1025	
analysis published in available literature to compare clinical and patient-1026	
reported outcomes for abdominal-based breast reconstructions in the context 1027	
of adjuvant, neoadjuvant and no RT groups (Khajuria et al., 2020) [Appendix 1028	
12].  1029	
 1030	
Robust Cochrane methodology was employed. In this review, if CDC grades 1031	
were not defined, the complications reported by the included studies were 1032	
retrospectively graded by two independent authors according to CDC; any 1033	
discrepancies were discussed and agreed by the senior author. Cochrane’s 1034	
Review Manager 5.3 software was used to perform the meta-analysis. Odds 1035	
ratios [95% confidence intervals (CI)] were used to evaluate dichotomous 1036	
outcomes (surgical complications). Standard mean differences (95% CI) were 1037	
used for continuous outcomes between treatment groups.  Heterogeneity 1038	
between studies was assessed in Review Manager 5.3 (Liu et al., 2013) using 1039	
the Higgins and Thompson’s I2 statistic (Higgins and Thompson, 2002). 1040	
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Levels of heterogeneity were defined as: low (I2 <50%), moderate (I2 50% - 1041	
80%), and high (I2 >80%). A random-effects model was used for cohorts with 1042	
heterogeneity (I2>50%) (DerSimonian and Laird, 2015). As heterogeneity was 1043	
generally moderate or high, and outcome measures differed between studies, 1044	
these were combined using the DerSimian and Laird random-effects model.   1045	
 1046	
No eligible studies prospectively graded surgical complications according to 1047	
an accepted classification such as CDC [fat necrosis; partial or total flap loss; 1048	
infection and wound complications (dehiscence, delayed wound healing)]. 1049	
One study graded partial flap loss using a novel flap necrosis classification 1050	
system (Modarressi et al., 2017), adapted from Kwok et al (Lie et al., 2013). 1051	
Only 30.30% (30/99) of all surgical complications reported across the 12 1052	
included studies were defined a priori and none were classified as per CDC. 1053	
 1054	
Meta-analyses comparing adjuvant versus no RT showed no inter-study 1055	
differences in rates of: overall complications; CDC grade 3; CDC grade 2; 1056	
surgical complications; fat necrosis; unplanned emergency re-operations for 1057	
complications or infection [Figure 8, Appendix 7]. There were no total flap 1058	
losses. Likewise, comparing neoadjuvant versus no RT showed no 1059	
differences in overall complications, CDC grade 3, fat necrosis or total flap 1060	
loss rates. Rates of partial flap loss were higher in the Neo RT versus no RT 1061	
groups [Figure 9, Appendix 8].  1062	
 1063	
Data were also pooled to provide an overall summary measure of combined 1064	
RT (adjuvant and neoadjuvant) compared to no RT. The merit of this 1065	
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approach was discussed with a senior clinical oncologist and the rationale 1066	
was to explore the impacts of radiotherapy in general and as an expanded 1067	
patient group, that is potentially hypothesis-generating. This showed 1068	
significantly higher overall complications in the combined RT groups 1069	
compared with no RT, with no inter-study differences in: CDC grade 3; grade 1070	
2 complications; rates of fat necrosis or emergency re-operations for 1071	
complications [Figure 10; Appendix 9]. Rates of partial flap loss were also 1072	
higher in the combined RT compared to no RT, with no differences in rates of 1073	
total flap loss, infection or wound complications. 1074	
 1075	
There was limited reporting of patient-reported QOL outcomes. Study designs 1076	
comprised two prospective studies (Cooke et al., 2017, Billig et al., 2017) and 1077	
one retrospective study (O'Connell et al., 2018a), limited by small patient 1078	
numbers and short follow-up for the adjuvant groups. There was no 1079	
standardized evaluation of cosmetic outcomes, precluding meta-analyses. 1080	
Studies lacked robust methodology and quality and were based on 1081	
independent panel assessments of medical photographs, with more recent 1082	
use of Vectra XT 3-D (O'Connell et al., 2018b). 1083	
 1084	
There were no significant intergroup differences in surgical complications 1085	
following PMRT or Neo RT versus no RT. Reported meta-analyses of surgical 1086	
complications in pooled RT groups (PMRT and neo-adjuvant) in this review 1087	
however showed significantly higher rates of overall complications and partial 1088	
flap loss following RT compared to no RT groups. Combined analyses of RT 1089	
patients reflect the value of adequately large patient groups, where cohorts of 1090	
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at least 1000 women are recommended for the studies to be adequately 1091	
powered to detect significant differences. It illustrates that a larger sample 1092	
size with more events serves as the proof of principle that the individual 1093	
studies are underpowered to detect statistical differences based on fewer 1094	
event rates. 1095	
 1096	
Current evidence for irradiating autologous abdominal flaps remains indirect 1097	
and largely of poor quality within only two moderate quality studies out of 1098	
twelve in this report. Future cohort studies should be designed and powered 1099	
akin to quasi randomised trials and take advantage of newly evolving study 1100	
designs including multiple cohort randomised controlled trials or trials within 1101	
cohorts (Young-Afat et al., 2017). These designs permit collection of big data 1102	
within registry or cohort platforms and allow multiple synchronous randomised 1103	
trials to be conducted in a cost-effective manner (Young-Afat et al., 2017). 1104	
 1105	
In the radiotherapy review, I was involved in the conception, design, 1106	
PROSPERO registration, design of search strategy, database searching, data 1107	
extraction, performing all the analysis, interpretation of the data, drafting and 1108	
critical review of the manuscript.  1109	
 1110	
 1111	
 1112	
 1113	
 1114	
 1115	
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5. The impact of mobile technology on teamwork and communication in 1116	
surgical and medical settings 1117	
 1118	
A PRISMA-compliant systematic review was conducted to evaluate the impact 1119	
of mobile technology on teamwork and communication in surgical and medical 1120	
settings (Martin et al., 2019). I was involved in the conception, design, 1121	
development of search strategy, screening of articles, data extraction, 1122	
analysis and drafting. The review highlights the potential benefits of mobile 1123	
technology, which is ubiquitous among healthcare professionals. However, 1124	
the paucity of high-quality evidence for its effectiveness and other common 1125	
barriers limit widespread uptake.  1126	
 1127	
The aim of the review was to assess the quality and breadth of evidence for 1128	
the impact of mobile technologies on communication and teamwork within 1129	
surgical and medical hospital settings. The systematic review methodology 1130	
was deemed most appropriate to carry out a robust assessment of the 1131	
evidence-base on which to base recommendations and identify areas for 1132	
future research. The review was prospectively registered on PROSPERO 1133	
(CRD42017064128) and conducted in accordance with the PRISMA 1134	
Statement.  1135	
 1136	
A robust search strategy was developed and comprehensive search was 1137	
undertaken of MEDLINE, PsycINFO, EMBASE, CINAHL Plus, HMIC, the 1138	
Cochrane Library, and National Institute of Health Research Health 1139	
Technology Assessment Database. Mobile technology was defined as hand-1140	
	 45	
held devices (mobiles, smartphones, tablets, or bespoke mobile devices) that 1141	
facilitate 2-way communication or data transfer and which directly impact 1142	
patient care. Screening of the articles was conducted independently be me 1143	
(AK) and another author, and Cohen’s kappa was calculated to determine 1144	
inter-rater reliability. Data on the study design, population, intervention, 1145	
comparators, setting and quantitative and qualitative outcomes were 1146	
extracted. The outcomes included: 1) workflow, efficiency and quality of 1147	
communication; 2) accessibility and inter-team relationships and 3) 1148	
professionals’ views of mobile technology. In addition to the National Institutes 1149	
of Health Quality Assessment Tools, the mobile health (mHealth) evidence 1150	
reporting and assessment (mERA) checklist was used to assess quality and 1151	
risk of bias (Agarwal et al., 2016). The mERA is a reporting guideline for 1152	
mHealth, similar to CONSORT (Schulz et al., 2010) and PRISMA (Liberati et 1153	
al., 2009).  1154	
 1155	
Out of 8072 articles screened, 38 were included in the final analysis. The data 1156	
demonstrated that overall there is a lack of high-quality evidence evaluating 1157	
the impact of mobile technologies on communication and teamwork in hospital 1158	
settings. Fourteen studies reported quantitative outcomes, all but 2 using 1159	
questionnaires, and 7 used content analysis of mobile phone data. Two 1160	
studies used direct observational data. One assessed time taken to complete 1161	
handover while the other assessed the speed and latency of communication. 1162	
Two further studies reported qualitative outcomes, with one using semi-1163	
structured interviews and focus groups and the other using an exploratory 1164	
case study approach. Finally, a mixed-methods approach was adopted by 6 1165	
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studies, with all including content analysis of messages sent or received; 4 1166	
included additional structured interviews, 2 included questionnaires, and 2 1167	
included more direct observation. Meta-analysis was not performed due to 1168	
heterogeneity in study designs and outcomes. Instead, a narrative synthesis 1169	
was conducted. Broadly speaking, the studies reported that introduction of 1170	
mobile devices led to enhanced workflow, efficiency, and communication 1171	
quality. They also reported improvement in clinical handover, faster response 1172	
times to clinical messages, and facilitation in easy delivery of non-urgent 1173	
information while also supporting the triage, prioritization, and timeliness of 1174	
communication. Moreover, mobile devices improved accessibility, inter-1175	
professional interactions, and senior decision maker involvement in clinical 1176	
care. The technology was valued by healthcare staff for being more 1177	
convenient and was preferred to existing modes of communication such as 1178	
traditional pagers/bleeps. Nevertheless, few studies reported that doctors felt 1179	
frequently interrupted by low-value and unnecessary information, often 1180	
inappropriate given the content and context. Other issues identified with 1181	
mobile devices included cost, lack of institutional integration and support, poor 1182	
battery life, reliability, small screen size and potential risk to security and 1183	
confidentiality of patient information.  1184	
 1185	
The strengths of the review include the fact that this is the first systematic 1186	
review in available literature to evaluate the quality and breadth of evidence 1187	
on the impact of mobile technology on teamwork and communication in 1188	
surgical and medical hospital settings. The protocol was prospectively 1189	
registered, and the review was conducted in accordance with PRISMA 1190	
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guidance. Robust methodology was implemented, with comprehensive 1191	
database searching, independent screening of articles, assessment of 1192	
methodological quality and reporting quality. Due to the heterogeneity in study 1193	
designs and outcome measures, a meta-analysis was not performed, and 1194	
instead a narrative synthesis was performed. The conclusion has been put in 1195	
context, in light of the quality of the evidence.  1196	
 1197	
The limitations of the review include the paucity of high quality evidence. The 1198	
reporting of studies as measured by the mERA checklist was also suboptimal, 1199	
with a mean score of 6.1 of 16 (range, 3-11), and no study was fully 1200	
compliant. The poorest reported items were: Item 6 (usability/content testing); 1201	
Item 11 (limitations for delivery at scale); Item 12 (contextual adaptability) and 1202	
Item 13 (replicability) [detailed descriptions of the items are documented by 1203	
(Agarwal et al., 2016)]. Most of the studies were single-centre studies and 1204	
examined small populations in restricted environments that do not truly 1205	
represent complex real-world settings, limiting generalizability. It is difficult to 1206	
draw clear conclusions due to methodological inadequacies including the lack 1207	
of prospective randomization or assessment of matched comparator groups, 1208	
the limited number of participants and truncated study lengths, and, due to 1209	
significant variability in methodologies and outcomes employed, an inability to 1210	
effectively pool results from multiple studies. Twenty-six studies included 1211	
questionnaire-based data collection, yet only 6 discussed validity testing of 1212	
the questionnaires used. While some of these methodological flaws may be 1213	
attributed to the inherent difficulty of assessing such interventions in complex 1214	
surgical and medical hospital settings, few studies clearly set out to try and 1215	
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overcome these challenges in a meaningful way. Of the 22 interventional 1216	
studies reviewed, only 2 had any form or randomization or prospective 1217	
assessment of matched comparator groups, and in the remainder only 5 1218	
made reference to pre-intervention baseline data against which the mobile 1219	
intervention was compared.   1220	
 1221	
In summary, an evidence-based approach to the development, deployment 1222	
and evaluation of new mobile communication devices is needed. Future, 1223	
prospective randomized studies are required with a priori defined outcomes to 1224	
evaluate comparative effectiveness. Studies should have larger sample sizes 1225	
to ensure they are adequately powered. In addition, for questionnaire-based 1226	
data, tools used must be validated. Studies should be adequately reported in 1227	
line with the mERA checklist, and journal editors and key stakeholders should 1228	
consider incorporating reporting guidelines into their ‘instructions to authors’, 1229	
i.e. making mERA checklist submission as a mandatory part of manuscript 1230	
submission. Mandatory requirement to complete reporting checklists has been 1231	
shown to enhance compliance in other areas of surgery (Agha et al., 2016).    1232	
 1233	
  1234	
 1235	
 1236	
 1237	
 1238	
 1239	
 1240	
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6.  Discussion  1241	
 1242	
The author has a large body of published work in high impact journals in 1243	
evidence synthesis, outcome measurement and reporting quality in surgery, 1244	
with a focus in Plastic & Reconstructive Surgery, forming the basis of an 1245	
application for a PhD by Publication at the University of Portsmouth (Khajuria 1246	
and Agha, 2013, Khajuria and Ahmed Agha, 2015, Khajuria and Mosahebi, 1247	
2019, Khajuria et al., 2019, Khajuria et al., 2017a, Smith et al., 2018b, Winters 1248	
and Khajuria, 2018a, Yao et al., 2014, Khajuria et al., 2018).  1249	
The author has also been supervising students, with resultant publications 1250	
(Ishak et al., 2019, Reddy et al., 2020, Mantelakis and Khajuria, 2020) 1251	
[Appendix 16-17]. The PhD award will further facilitate the author in 1252	
establishing a research group and to undertake postdoctoral research. This 1253	
will include conducting a national stream funded large prospective cohort 1254	
study (IDEAL framework Stage 2b)/RCT (IDEAL framework Stage 3) 1255	
(McCulloch et al., 2009) in evaluating immediate versus delayed autologous 1256	
breast reconstruction, in context of radiotherapy, with robust reporting of 1257	
breast reconstruction core outcome set (Potter et al., 2015) and incorporation 1258	
and measurement of disease-specific PROs and cost-effectiveness. The first 1259	
step will include conducting a national clinician survey to establish if clinical 1260	
equipoise (McCulloch et al., 2002) truly exists and a national patient survey to 1261	
understand patient preferences and willingness to be recruited and/or 1262	
randomised. The next step would be to set up a multicentre prospective 1263	
cohort study (IDEAL framework stage 2B) or RCT (IDEAL framework stage 3) 1264	
with follow-up of at least 1 year. Steering committee will consist of plastic and 1265	
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breast surgeons, patient advocates and oncologists, in collaboration with the 1266	
Royal College of Surgeons (RCS)- affiliated UK Reconstructive Surgery Trials 1267	
Network (RSTN) and the Association of Breast Surgery (ABS)-affiliated iBRA 1268	
Net. Core outcome sets, with complications as per Clavien Dindo 1269	
classification (Dindo et al., 2004) and PROs using BREAST-Q and EORTC 1270	
QLQ-BRECON23 will be reported. This cohort may allow a novel RCT trial 1271	
design called Trials within Cohorts (TWiCs) (Young-Afat et al., 2017) to be 1272	
established, facilitating recruitment, with a priori quality of life domains 1273	
(Winters and Khajuria, 2018). Moreover, ICERs (Matros et al., 2015) will be 1274	
calculated, to determine a breast QALY, i.e. the increased cost for obtaining 1 1275	
year of perfect breast health related quality of life between two groups. 1276	
 1277	
The collaborative model, employed by bodies such as RSTN and the iBRA 1278	
Net, has facilitated rapid, multicentre data collection with resultant high impact 1279	
publications (Potter et al., 2019). Surgical research in the future will likely rely 1280	
on these models to cultivate collaboration. This will encourage multicentre 1281	
studies that will enhance power of the studies as well as their generalizability, 1282	
whilst ensuring the rigorous evaluation of novel surgical techniques, products 1283	
and implants within the field of oncoplastic breast surgery to optimise the 1284	
interval validity.  1285	
 1286	
 1287	
 1288	
 1289	
 1290	
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6.1 Strengths of this work 1291	
 1292	
The author has addressed fundamental questions in the overarching theme of 1293	
evidence-based healthcare as well as focussing on plastic and reconstructive 1294	
breast surgery, with key research questions. All original articles published by 1295	
the author are the first in available literature in their respective themes. The 1296	
work was planned meticulously by the author as well as through 1297	
collaborations with a multidisciplinary group of plastic surgeons, breast 1298	
surgeons, clinical oncologists, methodologists who have experience in 1299	
systematic reviews and reporting quality (Khajuria and Agha, 2013, Khajuria 1300	
and Ahmed Agha, 2015, Khajuria et al., 2017b, Khajuria et al., 2017a, Winters 1301	
and Khajuria, 2018a, Winters et al., 2010, McCulloch et al., 2009, Smith et al., 1302	
2018b, Martin et al., 2019, Mantelakis and Khajuria, 2020, Venkatesh et al., 1303	
2020). The review protocols were registered a priori on PROSPERO with pre-1304	
defined patient population, intervention, comparator and outcomes. The 1305	
reviews were PRISMA-compliant and Cochrane methodology was followed. 1306	
For the radiotherapy review, complications were graded retrospectively by two 1307	
independent authors, as per the Clavien-Dindo classification. A random 1308	
effects model was utilised, along with robust methods to assess the quality 1309	
and risk of bias.    1310	
 1311	
6.2 Limitations 1312	
 1313	
The studies are limited by the quantity and quality of the available evidence.  1314	
No Level-I evidence was included in the results of the breast reconstruction 1315	
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studies, which were based on primarily low-quality studies. No reporting 1316	
guidelines were used for observational studies (STROBE checklist) (von Elm 1317	
et al., 2007) or for case series (PROCESS statement) (Agha et al., 2018). For 1318	
observational studies, key elements that were poorly reported included: the 1319	
eligibility criteria; the sources and methods of selection of participants; clearly 1320	
defined outcomes; participant characteristics; potential confounders; effect 1321	
modifiers; explanation of how sample size was calculated; statistical methods 1322	
used to adjust for confounding; explanation on how missing data and any loss 1323	
to follow-up was addressed; and comment of limitations and external validity. 1324	
It was particularly challenging to retrospectively grade surgical interventions 1325	
using CDC in the radiotherapy meta-analysis; in three studies, reported 1326	
complications were not amenable to retrospective grading, compromising the 1327	
interpretability and reliability of the results. Only 30.3% of all surgery 1328	
complications reported (30/99) across the 12 included studies in the 1329	
radiotherapy review were defined a priori, with potential for selective outcome 1330	
reporting. Panel assessments of cosmetic outcome also potentiate risk of 1331	
observer bias.  1332	
 1333	
In the DIEP versus IBR review (Khajuria et al., 2019), there is imprecision with 1334	
wide confidence intervals and high heterogeneity, when evaluating length of 1335	
stay. Whilst the published paper states there is no effect, this should be 1336	
interpreted with caution in light of the wide confidence intervals and the 1337	
imprecision of the estimate, which may preclude any meaningful interpretation 1338	
of the summary effect, apart from highlighting the need for further research 1339	
with higher quality studies, larger sample sizes and low heterogeneity and 1340	
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lower variability in outcome measurement.  The same conclusion may be 1341	
drawn for the number of reoperations for complications. Whilst the paper 1342	
states a lower mean number of reoperations for complications for DIEP 1343	
reconstruction, the estimate is imprecise, with wide confidence intervals, 1344	
necessitating further research with higher quality studies.  1345	
 1346	
The radiotherapy review (Khajuria et al., 2020) further highlights the issues 1347	
related to interpreting summary effect measures, based on imprecision of the 1348	
individual study estimates, and wide confidence intervals. In addition, none of 1349	
the studies considered were RCTs, so the evidence relates to association, 1350	
rather than causality. Whilst the forest plots comparing adjuvant RT versus no 1351	
RT and well as neoadjuvant RT versus no RT, state no differences in overall 1352	
complications, examining combined RT versus no RT showed greater overall 1353	
complications in RT group. The greater overall sample size gave greater 1354	
precision and narrower confidence intervals; but the evidence remained very 1355	
weak.   1356	
 1357	
The best available evidence was used (RCTs if available, or prospective 1358	
cohort studies).  When these were not available, poorer quality evidence was 1359	
used, with suitable warnings. It is well established that conducting a meta-1360	
analysis does not overcome limitations in the design and execution of the 1361	
primary studies. Combining studies of poor quality with those more rigorously 1362	
conducted may yield a false sense of precision of the true effect and in some 1363	
cases may be misleading. Indeed concerns have been raised regarding 1364	
interpreting meta-analyses in Plastic Surgery, given majority of included 1365	
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primary studies are of poor quality, with heterogeneity within and between 1366	
primary studies (McGuire et al., 2019). For the DIEP versus IBR review 1367	
(Khajuria et al., 2019), in the protocol, the use of sensitivity analysis was 1368	
purported, with exclusion of poor quality studies to determine the impact on 1369	
the effect summary. However, due to the paucity of studies (e.g. only two 1370	
studies reported comparative data on length of stay and number of 1371	
reoperations for complications), this approach was not possible. It may be 1372	
argued that given the heterogeneity and poor quality of the studies, a 1373	
narrative synthesis should have been performed for all outcomes, not just for 1374	
PROs and cost, and that a meta-analysis should not have been performed.  1375	
 1376	
For the radiotherapy review, there were 4 moderate quality studies, with the 1377	
remaining studies of poor quality. Out of the 4 moderate quality studies, 3 did 1378	
not have a control group, so were not included in the meta-analysis. Similarly, 1379	
it may be argued that a narrative synthesis, as opposed to meta-analysis, 1380	
would be the more suitable, in light of the poor quality and serious risk of bias, 1381	
for studies included in the review.  Meta-analysis using published means and 1382	
percentages does not permit the adjustments that are possible with individual 1383	
patient data.  There is no way of adjusting the results.  In the absence of 1384	
randomised controlled trials, only associations can be shown; not cause and 1385	
effect. Nevertheless, it is important to provide the best available evidence 1386	
even when that evidence is very poor.  The absence of high quality of 1387	
evidence can be used for directing future research.”                      1388	
 1389	
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Generic PRO tools used in the studies in the reviews may not be sensitive 1390	
enough to pick up clinically meaningful differences. There is also no evidence 1391	
contrasting the psychometric robustness of the disease-specific BREAST-Q 1392	
versus EORTC QLQ-BRECON23 questionnaires. As previously purported by 1393	
the author in Lancet Oncology, further validation work of the BREAST-Q 1394	
scales may be required, since in the large, multi-centre BRIOS trial evaluating 1395	
one-stage ADM-implant versus 2-stage BRR found no correlation between 1396	
complications and PRO scores, which was somewhat surprising (Winters and 1397	
Khajuria, 2018a). Finally, the external validity of the reviews may be 1398	
compromised, as majority of the included studies are single-centre studies, 1399	
primarily from middle-high income countries, implicating the results may not 1400	
be generalizable to practice and outcomes in low-income countries.  1401	
 1402	
6.3 Future work 1403	
 1404	
After the PhD award, the author will build on the work in this report as a post-1405	
doctoral research fellow, with the aim to address the aforementioned 1406	
limitations and set up and lead a multi-centre IDEAL-2b/ IDEAL 3 study 1407	
(McCulloch et al., 2009) to establish the optimal sequence of RT in 1408	
abdominal-based autologous breast reconstruction. The IDEAL framework 1409	
describes an evidence-based and step-wise approach towards conducting a 1410	
RCT. Specific 2b features (prospective cohort) will include establishment of 1411	
prospective databases, relevant outcome measures and learning curve 1412	
evaluation using the cumulative sum (CUSUM) method (Maguire et al., 2013).  1413	
First stage will involve conducting a national clinician survey to establish if 1414	
	 56	
clinical equipoise (McCulloch et al., 2002) truly exists and to ascertain the 1415	
feasibility and willingness of surgeons to recruit. Patient and public (PPI) 1416	
engagement will help to understand patient preferences and willingness to be 1417	
recruited and/or randomized. Core outcome sets, with a priori defined 1418	
complications as per CDC (Dindo et al., 2004) and PROs using BREAST-Q 1419	
and EORTC QLQ-BRECON23 will be reported. Moreover, Incremental Cost 1420	
Effectiveness Ratios (ICERs) (Matros et al., 2015) will be calculated, to 1421	
determine a breast Quality Adjusted Life Year (QALY), i.e. the increased cost 1422	
for obtaining 1 year of perfect breast health-related quality of life between 1423	
immediate and delayed groups. The results will be reported using established 1424	
tools e.g. STROBE/CONSORT, with focus on the individual components both 1425	
at design stage and at reporting stage. To improve the systematic reviews, I 1426	
would ensure that if there were significant heterogeneity, wide confidence 1427	
intervals and moderate-serious risk of bias, that a narrative synthesis is 1428	
performed as opposed to a meta-analysis.  The RoB issues, as previously 1429	
discussed, could be addressed in future observational studies. Studies should 1430	
use the best possible methods of adjusting for confounding, for example 1431	
individual patient data meta-analysis and propensity score matching (Austin, 1432	
2011). Confounding can be controlled at the design stage, by restriction (i.e. 1433	
using inclusion and exclusion criteria) or matching (where confounders are 1434	
allocated equally in the different arms of the study); at the analysis stage, 1435	
standardisation may be employed, where confounders such as BMI can be 1436	
adjusted for or via statistical adjustment using multivariate regression.  1437	
Methods to quantify selection bias have been proposed, including the ‘relative 1438	
odds ratio’, which is the ratio of the odds among participants to the 1439	
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corresponding estimate in the source population (Nohr and Liew, 2018). If 1440	
both populations have the same ORs, ROR is 1, indicating no bias; a ROR >1 1441	
indicates overestimation and a ROR <1 indicates underestimation. 1442	
Prospective, longitudinal studies with sufficient follow-ups are needed. 1443	
Protocols should be published and outcomes should be defined a priori. 1444	
Outcome assessment should be blinded. Outcomes should be adequately 1445	
reported using classifications such as CDC and the core outcome set. 1446	
 1447	
With regards to neoadjuvant RT, the Royal Marsden and Imperial College 1448	
Healthcare NHS Trusts are conducting the Primary Radiotherapy And DIEP 1449	
flAp Reconstruction Trial (PRADA) trial, investigating the feasibility of using 1450	
neoadjuvant radiotherapy prior to mastectomy and reconstruction (Trust, 1451	
2016). The investigators set out to formally evaluate the safety of reversing 1452	
the order of mastectomy plus immediate DIEP flap reconstruction and 1453	
adjuvant radiotherapy in a phase II study, with a view to a subsequent 1454	
randomised controlled trial testing local control, complication rates and quality 1455	
of life outcomes, including patient satisfaction (BREAST-Q reconstruction 1456	
module) as well as volume and symmetry using 3D-surface imaging. The trial 1457	
results will further facilitate the informed consent process and contribute to 1458	
development of national, evidence-based guidance in breast reconstruction. 1459	
Other ongoing studies include the DBCG RT Recon Trial, a multicentre RCT, 1460	
evaluating delayed-immediate versus delayed breast reconstruction, with 1461	
estimated completion date in November 2023 (DBCG, 2018). Delayed-immediate 1462	
reconstruction includes reconstruction with silicone implant or expander covered 1463	
by pectoral muscle and mesh or matrix. Conversely, Delayed reconstruction 1464	
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includes autologous or implant-based (one- or two-stage, +/- acellular dermal 1465	
matrix (ADM)) and is performed 6-12 months after completion of chemotherapy 1466	
and PMRT. Whilst immediate reconstruction may be the preferred choice for 1467	
many surgeons and patients, the MROC cohort demonstrated no difference in 1468	
patient satisfaction or in psychological, sexual, or physical well-being. Thus, the 1469	
DBCG RT Recon Trial may also provide valuable insights into the optimal timing 1470	
of breast reconstruction and RT, especially in the context of UK breast 1471	
reconstruction where majority of the breast reconstructions performed in the 1472	
UKNFR were delayed. 1473	
 1474	
Data from registries (such as the UKNFR) and high-quality cohort studies 1475	
(e.g. MROC) will identify trends in practice and form basis for identifying novel 1476	
research questions and hypotheses. Systematic reviews and meta-analyses 1477	
will also be important to determine overall effect estimates, on the pre-1478	
requisite that good quality studies and data are available to meta-analyse. 1479	
With regards to funding for a cohort study, funding streams will include 1480	
national bodies, such as BAPRAS, ABS and RCS. Several grants are 1481	
available, and an additional benefit and feature of the collaborative model has 1482	
been the need for limited funding to conduct the studies.  1483	
 1484	
 1485	
 1486	
 1487	
 1488	
 1489	
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7. Conclusion 1490	
 1491	
The thesis evaluates the reporting quality and outcome reporting in surgery, 1492	
with a focus on plastic and reconstructive breast surgery. The DIEP vs. IBR 1493	
systematic review provides a weak recommendation that DIEP reconstruction 1494	
maybe more cost-effective and yield higher PRO scores, with the major 1495	
limitation and caveat that the results are based on poor quality studies with 1496	
serious risk of bias. The results however, do corroborate the results from the 1497	
MROC cohort, the most robust cohort in the BRR literature, which was 1498	
excluded from the systematic review, as it did not fulfil the inclusion criteria. 1499	
The key finding is the presence of significant heterogeneity in outcome 1500	
measurement, suboptimal reporting of core outcome set and no grading of 1501	
complications, with no inference that can be derived about clinical 1502	
management in the breast reconstruction literature. The review has identified 1503	
that there is insufficient high quality evidence and we need future studies to 1504	
be more robust and of higher quality. It has provided key insights on areas to 1505	
focus and improve in future studies to enhance the evidence-base of breast 1506	
reconstruction.  1507	
 1508	
The radiotherapy review identified no statistically significant difference in 1509	
outcomes between immediate versus delayed breast reconstruction in context 1510	
of radiotherapy, based, once again, on poor quality evidence. The result 1511	
contributes to the knowledge and challenges the current dogma in the UK 1512	
where majority of the patients who need radiotherapy, undergo delayed 1513	
reconstruction, as opposed to immediate reconstruction (as per the UK 1514	
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National Flap Registry Data). The review has also demonstrated the paucity 1515	
of high quality evidence and the need for future high quality studies. 1516	
 1517	
Majority of the individual studies are non-randomised, with small sizes, 1518	
inadequate follow-ups, single-centre and retrospective. Reporting guidelines 1519	
are available but not being adhered to. CONSORT and SPIRIT PRO 1520	
guidelines exist for trial reporting and protocol reporting respectively, but 1521	
majority of the studies are observational studies and currently no STROBE 1522	
PRO extension exists. These insights from the reviews highlight the need for 1523	
future multicentre, prospective studies with sufficient follow-ups, with 1524	
adequate outcome measurement and reporting.  1525	
 1526	
There is a perennial need to enhance reporting quality of clinical 1527	
complications as per core outcome set, using robust tools/classification 1528	
systems such as CDC. Complications reported as percentages without 1529	
standardised reporting using classifications such as CDC and complication-1530	
specific classifications, e.g. Baker’s classification (for capsular contracture), 1531	
should be avoided, as there is no stratification according to management 1532	
(nonoperative/conservative or operative management) (Khajuria and 1533	
Mosahebi, 2019). Mandatory inclusion of adequate reporting in papers 1534	
enforced by journals will facilitate improved reporting, evidence 1535	
synthesis/meta-analysis and enhanced interpretability of research findings.    1536	
 1537	
 1538	
 1539	
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Abstract
Purpose Randomised controlled trials (RCTs)
represent a gold standard for evaluating
therapeutic interventions. However, poor
reporting clarity can prevent readers from
assessing potential bias that can arise from a
lack of methodological rigour. The
Consolidated Standards of Reporting Trials
statement for non-pharmacological
interventions 2008 (CONSORT NPT) was
developed to aid reporting. RCTs in
ophthalmic surgery pose particular challenges
in study design and implementation. We aim
to provide the first assessment of the
compliance of RCTs in ophthalmic surgery to
the CONSORT NPT statement.
Method In August 2012, the Medline
database was searched for RCTs in
ophthalmic surgery reported between 1
January 2011 and 31 December 2011. Results
were searched by two authors and relevant
papers selected. Papers were scored against
the 23-item CONSORT NPT checklist and
compared against surrogate markers of paper
quality. The CONSORT score was also
compared between different RCT designs.
Results In all, 186 papers were retrieved.
Sixty-five RCTs, involving 5803 patients, met
the inclusion criteria. The mean CONSORT
score was 8.9 out of 23 (39%, range 3.0–14.7,
SD 2.49). The least reported items related to
the title and abstract (1.6%), reporting
intervention adherence (3.1%), and
interpretation of results (4.7%). No significant
correlation was found between CONSORT
score and journal impact factor (R¼ 0.14,
P¼ 0.29), number of authors (R¼ 0.01,
P¼ 0.93), or whether the RCT used paired-
eye, one-eye, or two-eye designs in their
randomisation (P¼ 0.97).
Conclusions The reporting of RCTs in
ophthalmic surgery is suboptimal. Further
work is needed by trial groups, funding
agencies, authors, and journals to improve
reporting clarity.
Eye advance online publication, 12 September
2014; doi:10.1038/eye.2014.206
Introduction
The randomised controlled trial (RCT) is a
cornerstone of medical research and evidence-
based medicine. RCTs are widely regarded as
the ‘criterion standard’ for evaluating the
effectiveness of an intervention. They are
classed in the Levels of Evidence as level 1b by
the Oxford Centre for Evidence-based
Medicine.1 However, poorly reported RCTs are
associated with bias in estimating the
effectiveness of interventions,2,3 and
inconsistencies between the conclusions and
results.4 Adequate and accurate reporting is
vital to facilitate critical appraisal and
interpretation of the data by the readers.
The Consolidated Standards of Reporting
Trials (CONSORT) statement was developed to
provide a minimum set of standards for
transparent reporting of RCTs. The original
CONSORT statement, published in 1996,5 has
since been revised in 2001,6,7 and updated most
recently in 2010.8 Additionally, an extension to
the statement was developed to address specific
issues surrounding the reporting of RCTs
evaluating surgical interventions.9 The 2008
CONSORT extension for non-pharmacological
treatment interventions (CONSORT NPT) is an
extension on the 2001 CONSORT checklist that
incorporates additional issues relating to
masking difficulty, intervention complexity, and
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inconsistent care providers’ expertise that commonly
affect surgical RCTs.10,11
RCTs in ophthalmology represent further challenges
for researchers;12 for example, each patient has the
potential to contribute two data points. Studies in
ophthalmology may require alternative designs and
hence alternative methods of analysis to accommodate
this.13,14 Previously, reporting of RCT abstracts in
ophthalmology has been suboptimal.15 A review of 24
ophthalmology RCTs published in 1999 found that only
an average of 33.4 out of 57 descriptors were adequately
reported to the standard described in the 1996 CONSORT
statement.16 We are unaware of previous assessments
regarding the compliance of RCTs in ophthalmic surgery
to the CONSORT NPT, and could find no reference in a
computerised search of the PubMed database.
The primary objective of this study was to assess the
compliance of recent RCTs in ophthalmic surgery to the
2008 CONSORT NPT extension of the CONSORT 2001
statement. The secondary objectives included identifying
any associations between CONSORT NPT compliance and
surrogate markers of article quality, including ISI 2011
impact factor of the publishing journal, number of
authors, number of patients in the trial, and whether the
study was a single- or multi-centre study. The association
between CONSORT score and different designs in
randomisation of ophthalmology RCTs was also analysed.
Materials and methods
Search method
The Medline database was searched during August 2012
for RCTs from the period 1 January 2011 to 31 December
2011 for the Medical Subject Headings ‘Ophthalmic
Surgical Procedures’ NOT ‘Pharmacology’, with the
‘explode’ function activated. Limitations were set for
English language and trials on human subjects. Results
were then manually searched independently by two
authors (ACY and AK) for RCTs that satisfied the inclusion
criteria. The RCTs were identified by reviewing the titles
and abstracts of the results. Where there was insufficient
information in the title and abstract for determining
inclusion, the full article was obtained and reviewed. The
two authors then resolved any conflicts in article selection
by consensus. Where differences remained, a third author
(CFC) was consulted to make the final decision. After the
final selection was confirmed, all full articles were
obtained. The search protocol is summarised in the
PRISMA (Preferred Reporting for Systematic Reviews
and Meta-Analyses) flow diagram (Figure 1).
Studies were only included if they were randomised,
parallel-group RCTs in humans, involving a surgical
procedure as at least one intervention arm. Excluded
were studies involving purely pharmacological
interventions, cost-effectiveness or economic analyses,
interim analyses, short communications, simulation
studies, and studies involving only cadaveric eyes.
Scoring
The papers were then scored independently by two
authors (ACY and AK) against the 23 items on the 2008
CONSORT NPT extension of the 2001 CONSORT
checklist. Each item was given an equal weighting,
scoring 1 each, for a total of 23. Articles were scored 1 for
an item if all information detailed in the respective item
was reported, an approach reflective of the latest
CONSORT 2010 guidelines.8 Otherwise the item was
scored 0. Two items were subdivided in the CONSORT
NPT statement: item 4 included three parts (4A, 4B, and
4C), and item 11 had two parts (11A, 11B). For these items
each had its parts scored independently, with each worth
a third and one-half, respectively. The resulting mark out
of 23 was termed the ‘CONSORT score’. After initial
scoring, any discrepancies in scores between the two
authors were settled by consensus. If agreement could
not be reached, the third author (CFC) was consulted for
the final decision.
Secondary analyses
The relationship between the CONSORT score and several
surrogate markers of article quality were also analysed (all
prespecified). These included the number of authors;17,18
number of patients; ISI 2011 impact factor of publishing
journal;19 and whether the study was a single or multi-
centre study. The relationship between the CONSORT score
and different designs in randomisation of ophthalmology
RCTs, as defined by Lee et al,12 was analysed: paired-eye
design, one-eye design, and two-eye design.
Statistical analyses
Inter-rater reliability was assessed using the Cohen’s
kappa score calculation. Spearman Rank correlation
coefficient was used to assess the relationship between
CONSORT score and surrogate markers of article quality.
The Mann–Whitney U test was used to measure inter-
group differences between single- and multi-centre trials.
The Kruskal–Wallis test was used to analyse the
CONSORT scores between different study designs:
paired-eye, one-eye, and two-eye designs. Differences in
CONSORT score between same-group, different-group,
and mixed two-eye designs were also analysed using
the Kruskal–Wallis test. All statistical analyses were
carried out using SPSS (version 22.0; SPSS Inc., Chicago,
IL, USA).
Reporting quality of parallel randomised controlled trials
AC Yao et al
2
Eye
Results
In all, 186 articles were retrieved from the search of the
Medline database (Figure 1). Of these, 69 articles were
selected. Following review of the full articles, four
articles were excluded: two for not being RCTs, and two
for being unrelated to ophthalmology. The remaining 65
RCTs, involving 5803 patients, met the inclusion criteria.
Inter-observer concordance for article selection had a
kappa score of 0.91. In total 1495 items were scored.
Following the initial round of scoring, the authors’ scores
were disputed on 50 items (2.8%). All 50 disputed items
were resolved following discussion. The kappa score for
the initial round of scoring was 0.94.
The mean CONSORT score of the 65 RCTs was 8.9 out
of 23 (39%, range 3.0–14.7, SD 2.49). The compliance for
individual items is shown in Table 1 and Figure 2. The
poorest-reported items were item 1: title and abstract
(one paper, 1.6%), item 4c: details of how adherence with
protocol was assessed (two papers, 3.1%), and item 20:
interpretation of results (three papers, 4.7%). No paper
adequately reported all items in the CONSORT checklist.
Six journals’ impact factors were not listed in
ThompsonReuters’ Journal Citation Reports,19 which
included 7 of the 65 RCTs. For the 58 remaining papers,
there was no correlation between CONSORT score and
the impact factor (Spearman rho¼ 0.14, P¼ 0.29, Cohen’s
d¼ 3.297), Figure 3. There was no correlation between
CONSORT score and the number of authors (Spearman
rho¼ 0.01, P¼ 0.93, Cohen’s d¼ 1.533). There was no
statistically significant difference between the scores of
single- and multi-centre trials (P¼ 0.58, Cohen’s
d¼ 0.226), or between paired-eye, one-eye, or two-eye
RCT designs (P¼ 0.98, partial Z2¼ 0.001). In addition,
there was no statistical difference in CONSORT score
between same-group, different-group, and mixed two-
eye RCT designs (P¼ 0.97, partial Z2¼ 0.005).
Discussion
RCT adherence to the CONSORT NPT checklist varied
considerably. The CONSORT score ranged widely from 3
to 14.7 out of 23 items in this study. Several items integral
to trial reporting, such as the background, rationale,
objectives, and hypotheses, were well reported. Notably,
adherence was over 95% to item 2: background, item 5:
specifying objectives/hypotheses, and item 22: general
interpretation of results in the context of current
evidence. Despite this, the mean score was only 8.9 out of
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Figure 1 PRISMA flow diagram of article selection for scoring.
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23 items (39%) on the CONSORT NPT. No RCTs obtained
a full score.
Suboptimal compliance of RCT reporting to CONSORT
is also found across many other surgical specialties
including urological surgery,20 general surgery,21
neurosurgery,22 orthopaedic surgery,23 plastic surgery,24
and vascular surgery,20 as well as medical specialties
such as cardiology.25 The deficiencies identified in
previous studies include particularly poor reporting of
randomisation implementation, masking status, and
healthcare providers.26,27 Similar deficiencies in reporting
quality were found in our study. A review of 164 RCTs by
Agha et al20 in six surgical specialties reported an average
CONSORT score of only 11.2 out of the 22 items (51%)
using the 2001 CONSORT statement. In our study, the
same statement was used with the additional CONSORT
NPT extension. The slightly lower CONSORT scores in
our study is likely accounted for by the additional criteria
within the extension.
The compliance to individual items was similarly
varied. Inter-item variability appears globally consistent
across other specialties.20–25,28 In our study, over 90% of
RCTs adequately reported scientific background and
explaining rationale (item 2), reporting objectives or
hypotheses (item 5), and interpreting results in the
context of current evidence (item 22). This might be
considered unsurprising, as these items represent the
better recognised and readily achievable standards in the
reporting of RCTs. High levels of reporting to item 2,20,25
item 5,21,24,25 and item 2220,25 have also been reported in
other specialties. Despite this, 15 of the 23 items were
reported in less than 50% of the RCTs. Of these items,
nine items were reported in less than 25% of the RCTs.
Similar findings have been found in a wide range of
surgical specialties.20–24,28 Although most RCTs reported
at least one aspect described by the item, a common
reason for failure to score on an item was a failure to
report all aspects highlighted by that item.
Table 1 Adherence of RCTs to individual items of the CONSORT NPT checklist
Item Descriptor Adherence (number of articles (%))
Title and abstract
1 Title and abstract 1 (1.6)
Introduction
2 Scientific background 63 (98.4)
Methods
3 Participant’s eligibility, settings and locations 34 (53.1)
4a Intervention details 53 (82.8)
4b Intervention standardisation 46 (71.9)
4c Assessment or enhancement of protocol adherence 2 (3.1)
5 Objectives and hypotheses 62 (96.9)
6 Primary and secondary outcome measures 24 (37.5)
7 Sample size, interim analyses, stopping rules 7 (10.9)
8 Random allocation sequence generation 28 (43.8)
9 Allocation concealment 13 (20.3)
10 Implementing allocation sequence 6 (9.4)
11a Blinding (masking) status 18 (28.1)
11b Method of blinding 6 (9.4)
12 Statistical methods 32 (50.0)
Results
13 Participant flow 9 (14.1)
New item Details of treatment as they were implemented 11 (17.2)
14 Recruitment and follow-up dates 33 (51.6)
15 Baseline demographic and clinical characteristics 16 (25.0)
16 Numbers analysed 6 (9.4)
17 Outcomes and estimation 4 (6.3)
18 Ancillary analyses 31 (48.4)
19 Adverse events 37 (57.8)
Discussion
20 Interpretation of results taking into account potential bias 3 (4.7)
21 Generalisability 8 (12.5)
22 General interpretation in the context of current evidence 61 (95.3)
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The least reported item was related to the title and
abstract (item 1). This was adequately reported in only 1
RCT (1.6%). Previous studies have shown this item to be
well reported in other specialties.20,22,24 However, these
studies assess compliance against the CONSORT 2001
statement. In our study, RCTs generally mentioned
‘randomisation’ in the abstract or title fulfilling one
aspect of the item. However, RCTs often failed to describe
additional aspects of items as defined by the CONSORT
NPT extension: the experimental treatment, care
provider, centres involved, and masking status. Our
pre-determined scoring strategy required all aspects of
the item to be described to award the score, reflective of
the CONSORT 2010 guidelines.8 Indeed, these findings
are consistent with Camm et al25 assessing reporting of
items to the CONSORT 2010 statement. Sufficiently
detailed abstracts are essential as the readers often base
their assessment of trials on the abstract information.
The value of complete abstract reporting is highlighted
by the CONSORT Extension for Abstracts checklist.29
Despite the publication of the checklist, Knobloch and
Vogt30 identified a mean compliance of only 9.46 out of
the 17 items in the abstract extension checklist in 39
abstracts from the Annals of Surgery. Similarly, Berwanger
et al31 reviewed 227 abstracts from the NEJM, JAMA,
BMJ, and The Lancet, finding that only 21 abstracts (9.3%)
specified masking status.
There was no correlation between CONSORT score
and surrogate markers of article quality. This is perhaps
an unsurprising reflection that the CONSORT statement
is more an assessment tool for the quality of RCT
reporting rather than an assessment tool for the quality of
RCT design itself. Neither the higher number of authors
nor the higher journal impact factor was associated with
improved CONSORT compliance, contrary to the
popular belief that such markers help identify superior
Figure 2 Adherence (%) of RCTs to individual items of the CONSORT extension for the NPT checklist. Overall, the mean adherence to
any given item, including those subdivided, was 36.9%. Adherence ranged from 1 RCT (1.6%), in item 1, to 64 RCTs (98.4%), in item 2.
(New...¼New Item).
Figure 3 Histogram illustrating the distribution of RCTs obtaining particular CONSORT NPT scores.
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articles.17,18 Indeed, the evidence for association between
surrogate markers of quality and CONSORT score is
inconsistent. Camm et al25 highlighted a significant
association between impact factor and CONSORT 2010
score in RCTs concerning anti-arrhythmic agents.
Balasubramanian et al21 found that CONSORT score was
significantly associated with higher author number,
multi-centre studies, and impact factor in general
surgery. However, Agha et al20 reported no significant
difference between CONSORT score and the same
surrogate markers. Additionally, previous studies have
also shown no link between higher impact factor and
improved trial methodology.32 Rigorous adoption of
CONSORT by journals, however, has been shown to
correlate with improved reporting quality.33–37
Fulfilment of the CONSORT checklist items was
suboptimal across different types of RCT design. There
was no significant difference in CONSORT score between
single- and multi-centre trials (P¼ 0.16). In addition,
there was no significant difference (P¼ 0.46) in trials
randomising two eyes to the same group, different
group, or a combination of same group and different
group (mixed). This indicates that the need for
improvement in reporting quality is not confined to
specific types of study, but is applicable globally.
Healthcare providers face particular challenges in
conducting surgical RCTs compared to pharmaceutical
trials.12,38–41 Notable difficulties include achieving and
implementing masking, addressing varying expertise
levels of care providers, and varying patient volumes of
centres. Furthermore, inadequate funding and difficulty
in securing consent may contribute to the lack of
sufficient patient numbers, leading to low sample size
and inadequate study power.42,43 These factors may
affect the accuracy in evaluating the effectiveness of
interventions.44 The CONSORT NPT extension provides
a specific checklist to highlight the standards of reporting
of these factors, which are not necessarily relevant to
pharmaceutical trials.
Accurate and complete reporting of RCTs in
ophthalmic surgery is especially important due to the
potential added level of complexity of study design.
The presence of two potential data points (ie two eyes)
may lead to considerable heterogeneity in design,
randomisation method, and statistical analysis.12,45
Although there is a need to accurately inform readers
of alternative statistical methodology, statistical
consideration with respect to study design is often
under-reported in many RCTs in ophthalmology.12
In our study, 32 of the 64 RCTs (50%) adequately
satisfied item 12 (regarding statistical methods). Poor
reporting quality can prevent readers from assessing the
potential bias that can arise from a lack of
methodological rigour.46
Inadequate adherence to the CONSORT NPT may
arise from failure at any of the four stages of the
awareness-to-adherence model of compliance to
guidelines (awareness, agreement, adoption, and
adherence) defined by Pathman et al.47 Given the
heterogeneity of study designs in ophthalmic surgery,
authors may be reluctant to consider using a checklist
tool that was not developed for such a design. In
addition, the adoption of the CONSORT statement and
its extensions into journals’ ‘Instructions to Authors’ has
been suboptimal.48–51 Despite a 73% increase since 2003,
Hopewell et al49 found that only 62 of 165 (38%) high-
impact journals mentioned the CONSORT statement in
their ‘Instructions to Authors.’ Although 50 of 57
responding editors (88%) stated that their journal
recommended CONSORT, only 35 of 56 respondents
(62%) stated that this was a requirement. Endorsement of
the CONSORT extensions was noted to be especially
lacking. The possibility should be considered that other
factors such as journal word counts may encourage
authors to include CONSORT items only selectively.
There are various limitations to this study. The search
was restricted to articles in the English language and
from the Medline database. The period studied was
restricted to 2011, preventing any analysis of the
temporal trends in CONSORT score. The number of RCTs
including in this period was relatively small, limiting the
power to examine the relationship between CONSORT
scores and surrogate markers of RCT quality. Some
CONSORT items may be included in associated RCT
protocols in the public domain that were not analysed.
Pragmatic difficulties arise in the scoring of RCT
compliance to the CONSORT NPT. Many items contain
multiple elements. Whether reviewers score items in
regard to the multiple elements is a potential area of
subjectivity. Subjectivity was minimised in this study by
predefining the scoring strategy among the reviewers.
The item was only scored if all elements were reported.
This is on the basis that CONSORT items represent
absolutely fundamental information; ‘the minimum
criteria,’ that should be reported in a RCT.8 Furthermore,
all items on the checklist were given equal weighting to
minimise subjectivity. Although this may not reflect their
relative importance, it is nonetheless an objective
approach to analyse deficits, patterns, as well as overall
compliance.
The 2008 CONSORT NPT extension will benefit from
updating to be brought in line with the CONSORT 2010
checklist. Key updates would include addition of the
three new items regarding trial registration, availability
of the trial protocol, and the declaration of funding.
General changes might focus on reducing obfuscation by
alterations in wording: replacing, simplifying, or
removing misused words or phrases. In addition, greater
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specificity and subdivisions of items would help to
address the additional requirements for NPTs.
There is a need to improve the quality of reporting of
RCTs in ophthalmic surgery. The adoption of CONSORT
by journals is associated with improved reporting
quality,33–37,52 and therefore we recommend journals are
explicit towards authors regarding CONSORT before
submission and peer review. Editors, peer reviewers,
authors, and developers of reporting guidelines will
benefit from working closely with groups such as the
Enhancing the Quality and Transparency of Health
Research Network to support development and
dissemination of reporting guidelines.53 Further
development of the CONSORT Statement may help to
improve compatibility to RCTs with alternative
methodologies including within-person randomised trials,
common in ophthalmic surgery. Future extensions to the
CONSORT Statement will hopefully start to address this.27
Conclusion
In conclusion, our findings suggest that the 2008
CONSORT NPT guidelines are not being met in 2011. It is
recommended that the authors, funding agencies, peer-
reviewers, and journal-editors in ophthalmology
collaborate to enhance the integration of CONSORT into
the RCT publication process. Evolution and further
extension of CONSORT will hopefully help to
incorporate studies with alternative methodologies such
as are seen in ophthalmology.
Summary
What was known before
K Despite the importance in the levels of evidence,
randomised controlled trials (RCTs) in many surgical
specialties are often inadequately reported.
K Previous studies have suggested similar inadequacies as
applying to RCTs in ophthalmic surgery, in the reporting
of abstracts.
What this study adds
K This study formally analysed the reporting quality of
RCTs in ophthalmic surgery by assessing compliance to
the 2008 CONSORT extension for Non-Pharmacological
Treatment interventions (CONSORT NPT) guidelines.
K Overall, there was suboptimal compliance of RCTs in
ophthalmic surgery in 2011 to the 2008 CONSORT NPT
guidelines.
K Similar levels of RCT reporting quality were found in
ophthalmic surgery compared with other surgical
specialties.
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INTRODUCTION
Breast cancer is the most common malignancy and the 
principal cause of cancer-related mortality in women.1,2 
Breast-conserving surgery or mastectomy is normally 
offered as management strategies.3 However, mastectomy 
has been associated with a profoundly negative impact on 
a woman’s physical, psychological, and sexual well-being.4 
Assessment of quality of life (QoL) and patient-reported 
outcomes (PROs) is thus especially pertinent in breast 
reconstruction (BRR) surgery, and morbidity and mortal-
ity are necessary but not sufficient for adequate outcome 
Breast
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Introduction: Comparative data on clinical outcomes and cost of deep inferior epi-
gastric perforator (DIEP) and implant-based reconstruction (IBR) are limited. We 
conducted a Preferred Reporting Items for Systematic Review and Meta-analysis-
compliant systematic review and meta-analysis to compare clinical, patient-reported 
outcomes (PROs) and cost.
Methods: The protocol was published a priori on PROSPERO (CRD42017072557). 
EMBASE, MEDLINE, Google Scholar, Cochrane Controlled Register of Trials, 
Science Citation Index, and ClinicalTrials.gov were searched from January 1994 
to August 2018. Two independent reviewers evaluated the articles for inclusion. 
Study quality was assessed using Grading of Recommendations Assessment, 
Development, and Evaluation, and risk of bias (RoB) was assessed using Cochrane’s 
RoB in Nonrandomized Studies of Interventions tool.
Results: Out of 6,381 articles screened, 16 were included [unilateral 782 DIEPs, 
376 implants; mean age 49 years, follow-up (months): DIEP 29.9; IBR 35.5]. Mean 
flap loss and fat necrosis rates were 3.97% (SD 4.90) and 9.67% (SD 17.0), respec-
tively. There was no difference in mean length of stay {standard mean difference 
0.63 [confidence interval (CI) −9.17 to 10.43]; P =0.90}. The number of reopera-
tions for complications was significantly lower in DIEP versus IBR [SMD −0.29 (CI 
−0.48 to −0.09); P < 0.01]. There were no randomized controlled trials. Study qual-
ity was low with high RoB. One study reported $11,941/Quality-adjusted Life Year 
incremental cost-effectiveness ratio for DIEP, with higher breast Quality-adjusted 
Life Year (DIEP 19.5; IBR 17.7) using Breast Questionnaire; 3 studies evaluated 
cost, favoring DIEP. Two comparative studies evaluating PROs favored DIEP.
Conclusions: DIEP reconstruction maybe more cost-effective and yield superior 
PROs. However, poor-quality, bias-ridden studies limit the findings. Adequate 
reporting of core outcome measures is required to minimize reporting bias and 
facilitate evidence synthesis. Prospective, multicenter, cohort studies using robust 
patient-reported outcome measures (PROMs) tools, evaluating cost-effectiveness 
and contributing to national/international registries, will facilitate national-level 
policy and shared decision-making. (Plast Reconstr Surg Glob Open 2019;7:e2486; doi: 
10.1097/GOX.0000000000002486; Published online 29 October 2019.)
A Meta-analysis of Clinical, Patient-Reported 
Outcomes and Cost of DIEP versus Implant-based 
Breast Reconstruction
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assessment.5–17 The reconstruction must satisfy the patient 
with regard to physical, psychological, and sexual well-
being. The exponential rise in QoL and PRO research 
highlights their importance.12,18 Development and valida-
tion of psychometrically robust, validated disease-specific 
PRO tools such as the Breast Questionnaire (BREAST-Q) 
and the European Organization for Research and 
Treatment of Cancer (EORTC) Breast Cancer-specific 
Quality of Life Questionnaire-23 further exemplify this. 
Their development and validation have been described 
previously.9,18–21
Patient demands for BRR have significantly increased 
over the last 2 decades with the doubling of postmastec-
tomy BRR rates from 13% to 26% between 1998 and 2007.22 
This is not only due to advances in oncological manage-
ment but also due to the clearly demonstrable functional 
and psychological benefits.23–26 Two of the commonest 
reconstructive modalities include autologous reconstruc-
tion using the deep inferior epigastric perforator (DIEP) 
flap and implant-based reconstruction (IBR).27 The treat-
ment choice is determined by patient factors (individual 
preference, body image) and surgeon factors (resource 
availability and experience).28 Nevertheless, many plastic 
surgery units worldwide regard autologous reconstruc-
tion, compared with IBR, as the superior modality, replac-
ing “like with like.”22 There is emerging evidence that 
autologous abdominal-based flap BRR may yield superior 
clinical and PROs.15,27,29–31
IBR is associated with complications, including 
implant rupture, infection, migration, exposure/extru-
sion, patient dissatisfaction with edge visibility/implant 
animation and reduced/absent sensation at the nipple.32 
Capsular contracture can culminate in pain, increased 
palpability, asymmetry, and implant removal require-
ment.33 Allergan’s 10-year cumulative risk study found 
that 24.6% of patients who underwent IBR developed 
capsular contracture.34 Conversely, DIEP flap is widely 
considered the “gold standard” for postmastectomy BRR. 
It has largely superseded the traditional transverse rectus 
abdominus myocutaneous (TRAM) flap, by preserving 
the rectus abdominis muscle continuity and integrity, 
limiting donor site complications such as abdominal 
bulge/hernia.35
From an economic standpoint, some protagonists have 
argued that DIEP reconstruction is more cost-effective, 
yielding fewer overall complications and superior PROs, 
compared with IBR.15,27,30 Although some European and 
North American centers have published cost-analyses on 
DIEP and IBR, the data are sparse with relative scarcity 
of data from public and free universal health care system 
settings.
We systematically evaluated the quality of evidence 
and analyzed cost, clinical outcomes, and PROs of 
unilateral DIEP versus IBR in context of breast malig-
nancy. The aim was to help evaluate which technique 
is superior in terms of clinical outcomes, PROs, and 
cost and thus inform worldwide clinical practice and 
facilitate informed consent and patient–clinician-shared 
decision-making.
METHODS
Our protocol was registered and published a 
priori on the National Institute of Health Research 
Prospective Register of Systematic Reviews PROSPERO 
(CRD42017072557) and Systematic Reviews peer-reviewed 
journal.35-37 In the section below, we have detailed the 
search strategy used, the identification and selection of 
studies, and the design with inclusion/exclusion criteria. 
We have subsequently described the risk of bias (RoB) and 
quality assessment, outcomes, data extraction, collection 
and management, and the statistical methods utilized.
Search Strategies
We conducted a comprehensive search of the 
MEDLINE (OVID SP), EMBASE (OVID SP), Google 
Scholar, Cochrane Controlled Register of Trials, Science 
Citation Index databases, and ClinicalTrials.gov from 
January 1994 up to August 2018 to identify studies rel-
evant to the review. A combination of Medical Subject 
Headings terms, free text, and Boolean logical operators 
were used to construct the search strategy, in consultation 
with a literature search expert. Explode function was uti-
lized to capture narrower terms. No language restrictions 
were applied. The reference list of all included articles 
was also screened for relevance. A sample search strategy, 
for EMBASE (OVID SP), is shown below; a similar search 
strategy was adapted for the other databases:
1. exp Breast Neoplasms/OR ((breast adj6 cancer*) or 
(breast adj6 neoplasm*) or (breast adj6 carcinoma*) 
or (breast adj6 tumour*) or (breast adj6 tumor*) or 
(breast* adj4 reconstruct*))
2. exp deep inferior epigastric perforator flap/ OR DIEP 
flap* OR DIEAP flap* OR ((Deep and inferior and epi-
gastric and perforator) adj2 flap*) OR Deep and infe-
rior and epigastric and perforator and flap*)
3. exp breast implant/ OR breast adj3 implant* OR exp 
silicone prosthesis/147 – [(1) AND (2)] OR [(1) AND 
(3)]; publication date: January 1994 to August 2018
Identification and Selection of Studies
Studies were extracted following database searching 
and were populated into an Endnote X8 library (Clarivate 
Analytics, USA). Using prespecified screening criteria, the 
screening was carried out in 2 stages, by 2 independent 
reviewers.
Stage 1: Title and abstract screening carried out by 2 
researchers independently (MP, MG). Any discrepancies 
were resolved by consensus. If any doubts remained, the 
article proceeded to full-text review.
Stage 2: The full texts of the studies included in stage 
1 were downloaded and screened for eligibility by 2 
researchers independently (MP, MG). Discrepancies were 
resolved by consensus. If this was not possible, the senior 
author (AM) was consulted for the final determination for 
inclusion/exclusion of the article.
Study Design
All primary human studies evaluating clinical out-
comes, PROs, or cost for unilateral DIEP flap BRR or 
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IBR in context of breast malignancy were included. The 
intervention included unilateral DIEP BRR, and the com-
parator was IBR. The inclusion and exclusion criteria are 
highlighted below.
Inclusion Criteria
1. Studies involving adult patients aged ≥18 years old
2. Studies involving unilateral autologous DIEP flap BRR 
or IBR in context of breast malignancy
3. Clinical studies [randomized controlled trials (RCTs), 
prospective and retrospective cohort studies and case 
series with 10 or more patients]
Exclusion Criteria
Duplicates, case reports, conference abstracts, simula-
tion studies, review articles, clinical studies in nonhuman 
subjects, patients with segmental or partial mastectomy, 
technical operative repair descriptions with no outcome 
measures, BRR unrelated to cancer, and autologous flap 
techniques other than DIEP were excluded. Studies of 
patients receiving adjuvant postmastectomy radiotherapy 
(PMRT) were also excluded, as adjuvant PMRT is associ-
ated with serious adverse events and reduced QoL in IBR, 
although the evidence is more equivocal for autologous 
reconstruction, and thus would introduce bias and pre-
clude outcome analysis when comparing IBR and DIEP. 
Our group is currently conducting a separate system-
atic review and meta-analysis to investigate outcomes for 
immediate versus delayed autologous reconstruction in 
context of PMRT (PROSPERO CRD42017077945).38
RoB and Quality Assessment
For nonrandomized comparative studies, the RoB in 
Nonrandomized Studies of Interventions (ROBINS-I) by 
the Cochrane collaboration was used.39 ROBINS-I covers 7 
domains from which bias may be introduced, with “signal-
ing questions” facilitating judgments about RoB. These 
domains include: (1) bias due to confounding; (2) bias in 
the selection of participants into the study; (3) bias in the 
classification of interventions; (4) bias due to deviations 
from intended interventions; (5) bias due to missing data; 
(6) bias in the measurement of outcomes; and (7) bias in the 
selection of the reported result. The judgments within each 
domain were carried forward for an overall RoB judgment 
across bias domains.39 To assess individual study methodolog-
ical quality, the Grading of Recommendations, Assessment, 
Development and Evaluation approach40 was utilized.
Outcomes
The primary outcomes were as follows:
1. Clinical (complications: fat necrosis, partial/total flap 
loss, infection, number of reoperation procedures 
for complications and implant-specific complications, 
including capsular contracture, implant rupture, dis-
placement, deflation and scarring), with grades of com-
plications where reported
2. PRO measures (generic and disease-specific PROMs 
tools, eg, BREAST-Q and EORTC-QLQ-BR23)
3. Cost-analyses
Data Extraction, Collection, and Management
A standardized extraction form was used to extract 
data from the full-text articles by 2 independent authors 
(MP, MG). Any discrepancy was resolved by consensus or 
with referral to the senior author (AM). The following 
data were extracted:
 • first author; year of publication; study design; partici-
pant demographics (sex, age, BMI and comorbidity, 
where reported); study setting; length of follow-up;
 • primary outcomes, as above.
Statistical Methods
Using Review Manager 5.3,41 provided by the Cochrane 
Collaboration, an assessment of heterogeneity was per-
formed. The Higgins and Thompson’s I2 statistic was used 
to quantify statistical heterogeneity.42 The DerSimonian 
and Laird random-effects model, which is well established 
for evaluating heterogeneous cohorts, was employed.43 
Odds ratios (ORs) with 95% confidence interval (CI) were 
used to determine dichotomous outcomes (complica-
tions). Continuous outcomes were evaluated by standard-
ized mean differences with 95% CI.
RESULTS
A total of 6,381 records were identified. Out of those, 
16 fulfilled the inclusion criteria and were considered for 
quantitative synthesis.15,27,30,31,44–55 The Preferred Reporting 
Items for Systematic Review and Meta-analysis diagram 
(Fig.  1) depicts how studies were included and the rea-
sons for exclusion. The 16 studies included 782 unilateral 
DIEPs and 376 implants; mean age 49 years, mean follow-
up (months): DIEP 29.9; IBR 35.5. There were 6 pro-
spective cohort studies,27,31,44,47,50,52 8 retrospective cohort 
studies,15,30,45,48,51,53–55 2 case series,46,49 and no RCTs. There 
was 1 multicenter study15; the remaining 15 were single-
center studies. The overall quality of the studies using the 
Grading of Recommendations, Assessment, Development 
and Evaluation criteria was low, with serious RoB using 
the ROBINS-I tool. Tables 1 and 2 summarize the baseline 
characteristics and results (clinical, PROs, and cost).
Clinical Outcomes
Two studies provided comparative data on mean 
length of stay (days),27,30 with no difference between DIEP 
and IBR [SMD 0.63 (CI −9.17 to 10.43); P  =  0.90] and 
significant statistical heterogeneity (I2  =  98%) (Fig.  2). 
Moreover, combining data from single-arm studies (7 
 studies),44,45,49,50,52,53,55 further revealed no difference in 
mean length of stay in days [DIEP (8.32; SD 2.05) versus 
IBR (9.80; SD 8.20), P = 0.89]. Two studies provided com-
parative data on the mean number of reoperations for 
complications,27,30 with a statistically significant lower num-
ber for DIEP versus IBR [SMD −0.29 (CI −0.48 to −0.09), 
P < 0.01] with I2 = 0%. The combined data from single-
arm studies (7 studies)44,51–53,55 showed lower mean num-
ber of revision procedures for DIEP (0.22; SD 0.27) versus 
IBR (0.50; SD 0.68), but without statistical significance 
(P = 0.65). There was no statistically significant difference 
in mean infection rates between DIEP (5 studies)27,44,49,54,55 
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[1.67% (SD 2.29)] and IBR (2 studies)27,52 [5.40% (SD 
2.92)], P  =  0.38. Three studies27,46,52 reported mean 
implant-specific complication rates of 11.1% (SD 9.98); 1 
classified capsular contracture grades as per the Baker’s 
classification, with 1/30 (3.33%) grade IV contracture.52 
Out of all 6 IBR studies, 2 studies did not specify whether 
direct to implant (DTI) or expander–prosthesis (EP) 
reconstruction was employed.15,30 One reported DTI,52 and 
3 reported EP reconstruction.27,31,46 Mean flap loss and fat 
necrosis rates, reported by 9 studies, were 3.97% (SD 4.90) 
and 9.67% (SD 17.0), respectively.27,31,44,47,49,51,53–55 No stud-
ies were reported as per the Clavien–Dindo classification 
(CDC).56 Other than capsular contracture being graded 
as per the Baker’s classification by 1 study,52 none of the 
other complications were graded.
QoL
Two comparative studies evaluated QoL.15,31 Tønseth et 
al31 evaluated 29 patients with DIEP BRR and 21 patients 
with IBR. They utilized a generic PRO tool, Short-Form 
36 (SF-36), which showed no difference in QoL, a non-
validated study-specific questionnaire that showed higher 
breast satisfaction (P < 0.001), improved social relationship 
(P = 0.02) and body image satisfaction (P = 0.01) for DIEP, 
and a nonvalidated Visual Analog Scale, with superior cos-
metic outcome with DIEP (Table  2). Matros et al15 pro-
spectively evaluated 103 patients with DIEP BRR and 172 
patients with IBR and utilized the BREAST-Q. BREAST-Q 
scores were consistently higher for DIEP compared with 
implants in postoperative years 1–8, with a higher breast 
Quality-adjusted Life Year for DIEP (19.5) versus IBR (17.7).
Cost
Three comparative studies evaluated cost.15,27,30 Matros 
et al (USA) calculated an incremental cost-effectiveness 
ratio (ICER) of $11,491 for DIEP, ie, the additional cost of 
DIEP BRR to obtain 1 year of perfect breast-related QoL 
compared with IBR. Lagares-Borrego et al, 2015 (Spain) 
reported no difference in overall cost between DIEP BRR 
(€18,857.77) versus IBR (€20,502.08); P = 0.89. However, 
when considering surgical complications, cost of DIEP 
(€2,859.90) was significantly lower than IBR (€5,837.9), P 
< 0.001. Cost of DIEP was also lower owing to length of 
hospital stay (P < 0.001), consultations (P < 0.001), and 
materials and tests used (P < 0.001), but higher owing to 
duration of procedure (P < 0.001). Atherton et al esti-
mated cost at 3 years: DIEP £10,910 versus IBR £8,034. No 
statistics were performed; however, the authors reported 
that the cost “difference is small and patient will still 
require more revisions (with IBR), and if followed up 
enough will lose this small financial benefit”; the cost dif-
ference maybe “justified by the increased patient satisfac-
tion and cosmetic outcome (with DIEP).”
DISCUSSION
To our knowledge, this is the first systematic review 
and meta-analysis in available literature to evaluate clini-
cal outcomes, PROs, and cost of DIEP versus IBR. Overall 
study quality is low with serious RoB, weakly supporting 
DIEP as a more cost-effective strategy that confers higher 
QoL compared with IBR. Factors limiting the quality of 
evidence include study designs, absence/heterogeneous 
reporting of clinical outcomes, study exclusion due to 
combined reporting of different flaps, and no breakdown 
of outcomes between unilateral and bilateral reconstruc-
tion. Majority of the studies have small sample sizes, were 
conducted in a retrospective manner with potentially 
biased patient recall after variable and delayed lengths of 
time post surgery, and failed to achieve adequate follow-
up periods. Complications such as capsular contracture 
may occur well beyond this time frame. Fifteen or sixteen 
studies were single-center studies, negatively impacting 
generalizability.
Our systematic review demonstrates the inconsistency 
and heterogeneity in clinical outcome reporting, which 
presents a limitation. Only 8/14 (57.1%) studies evalu-
ating DIEP reported flap loss rates. Likewise, only 3/6 
(50.0%) studies evaluating IBR reported implant-specific 
complications, including capsular contracture. Only 1 of 
these studies classified capsular contracture according to 
the Baker’s classification.57 Because classification/grades 
help inform management strategies, inaccurate classifica-
tion, and grading of these complications, risks biased com-
parisons of clinical outcomes between studies, rendering 
it difficult to interpret the study findings. This corrobo-
rates the results from the systematic review by Potter et 
al,58 on reporting quality of BRR clinical outcomes, that 
identified poor reporting quality and need for a core out-
come set to facilitate outcome assessment in effectiveness 
studies. Furthermore, no studies reported outcomes using 
the validated CDC.56 Moreover, no studies reported grade 
of fat necrosis.
Standardization of outcome reporting, with uptake of 
validated tools such as CDC and incorporation into jour-
nal submission guidelines by editors, may promote higher 
quality, standardized reporting and facilitate homogeneity 
and meta-analysis.
Out of 6 IBR studies, 3 reported implant-specific com-
plications; 2 out of 6 studies did not categorize type of IBR 
and reported as “implant reconstruction”. Three out of 6 
Fig. 1. Forest plot for 2 comparative studies, evaluating mean length of stay (days).
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studies reported EP reconstruction, and 1 reported DTI. 
Due to the scarcity of IBR data, further subgroup analysis 
was not possible. Future studies should clearly specify the 
type of reconstruction – DTI/EP; subpectoral or prepec-
toral and whether acellular dermal matrix was utilized. 
Adequate reporting as part of a core outcome set will facil-
itate inter-study comparisons and meta-analyses.
The Mastectomy Reconstruction Outcomes 
Consortium (MROC) is a large, multicenter prospective 
cohort study involving 9 academic and 2 private practices 
in the United States and Canada with high volumes of 
BRR.59 This did not meet our systematic review’s inclusion 
criteria, due to combined data reporting of unilateral and 
bilateral reconstructions, as well as reporting of clinical 
outcomes with combined results from a range of autolo-
gous reconstruction techniques, including DIEP, TRAM, 
free TRAM, and latissimus dorsi (LD) and superficial 
inferior epigastric perforator flaps. Nevertheless, it is per-
tinent to discuss the results from this cohort.
Bennett et al8 prospectively evaluated 2,343 patients 
undergoing postmastectomy autologous reconstruction 
(706), using DIEP, pedicled TRAM, free TRAM, superfi-
cial inferior epigastric perforator, latissimus dorsi or IBR 
(1,637), with comparison of 2-year complication rates. The 
authors found that DIEP had lower failure rates compared 
with IBR (1.3% versus 7.1%, P < 0.001) and lower odds of 
developing infection (OR 0.45; CI: 0.25–0.29; P = 0.006). 
This corroborates with the findings from our systematic 
review with lower rates of infection and revision proce-
dures in DIEP compared with IBR. However, Bennett et al8 
reported higher odds of developing any complication with 
DIEP (OR 1.97; CI 1.41–2.76; P < 0.001), including reop-
erative complications (OR 2.76; CI 1.87–4.07; P < 0.001). 
This in part could be explained by outcomes following 
Fig. 2. Forest plot for 2 comparative studies, evaluating mean number of reoperations for complications.
Table 2. Comparative Studies Evaluating PROs for DIEP versus IBR Reconstruction
Reference Study, 
Location, Design
No. Pts 
(DIEP)
No. Pts 
(IBR)
Mean F/u (mo) with  
SD Where Reported PROs
Matros et al,15 USA, 
cohort* 103 172 NA
BREAST-Q scores consistently higher for DIEP, 1–8 y 
postoperatively†
Breast QALY: 19.5 cw 17.7†
Tønseth et al,31 Norway, 
Cohort‡
29 21 30±12 cw 33.6±12 SF-36 scores:
Physical functioning 85.0 cw 89.0 (NS); role physical 77.5 cw 78.7 
(NS); bodily pain 72.9 cw 74.6 (NS); general health 78.0 cw 
80.4 (NS); vitality 60.0 cw 63.8 (NS); social functioning 87.3 
cw 90.0 (NS); role emotional 75.6 cw 69.8 (NS); mental health 
79.6 cw 77.2 (NS)
Study-specific questionnaire scores:
Satisfied with appearance of breast:
Yes: 24 cw 5; neither yes/no: 3 cw 8; no: 2 cw 8§ (P < 0.0005)
Social relationship:
Improved: 5 cw 0; unchanged: 24 cw 20; worse: o cw 1¶ (P = 
0.02)
Sad about body image:
Yes: 3 cw 5; neither yes/no: 1 cw 6; no: 25 cw 10¶ (P = 0.01)
Study-specific questions concerning self image (NS), social and 
intimate relationship (NS), general health (NS), and general 
satisfaction (NS)
Visual Analog Scale:
Breast shape: 7.9±2.2 cw 5.1±2.5§ (P < 0.0005)
Breast symmetry: 7.6±2.1 cw 6.0±2.9¶ (P = 0.023)
Breast volume: 7.7±2.1 cw 5.4±2.7§ (P = 0.006)
Breast position: 8.8±1.3 cw 6.8±2.6§ (P = 0.003)
Breast consistency: 5.6±2.9 cw 3.8±3.0§ (P = 0.008)
*Retrospective.
†Statistical significance not reported.
‡Prospective.
§Statistically significant (P < 0.01).
¶Statistically significant (P < 0.05).
Cw, compared with (assessing the RoB); QALY, Quality-Adjusted Life Year; NA, not available; NS, no significance.
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adjuvant radiotherapy. Although the detrimental effect of 
PMRT on IBR is well established, the effect on autologous 
reconstruction is more equivocal. This is being evaluated 
in a separate systematic review and meta-analysis by our 
group (PROSPERO CRD42017077945).38 Moreover, con-
founders such as the level-of-care provider expertise, non-
standardized operative technique, differences in centers’ 
volume, and learning curves may further bias the results 
and their interpretability. Indeed, another MROC study 
evaluating hospital variations in clinical complications 
and PROs at 2 years post autologous BRR or IBR dem-
onstrated that complications varied widely between hospi-
tals.10 It also highlighted the limitations of extrapolating 
single-institution level data and the challenges of evaluat-
ing hospital-based outcomes in BRR patients.
In our systematic review, out of 16 studies, only 2 com-
parative studies (12.5%)15,31 reported PROs. A major para-
digm shift is needed to incorporate PROs in all studies 
evaluating BRR, as also supported by the recent publica-
tion of the “Gap analysis” in BRR.12 Evaluating clinical 
outcomes without PROs is a major drawback in evaluating 
outcomes in BRR, as the reconstruction must satisfy the 
patient with regard to physical, psychological, and sexual 
well-being.59 Disregard of these domains renders outcome 
assessment incomplete and suboptimal.
Two comparative studies that evaluated PROs in our 
review favored DIEP reconstruction. Matros et al15 uti-
lized a robust, validated, disease-specific questionnaire, 
BREAST-Q. BREAST-Q scores were reported as consis-
tently higher for DIEP compared with IBR in postopera-
tive years 1–8, with a higher breast Quality-adjusted Life 
Year for DIEP. Conversely, Tønseth et al31 used generic 
PRO tools, SF-36, which revealed no difference in QoL 
between DIEP and IBR, and Visual Analog Scale, with 
superior cosmetic outcome with DIEP. The study also used 
a nonvalidated study-specific questionnaire that demon-
strated higher breast satisfaction, improved social rela-
tionship, and body image satisfaction for DIEP.
The results from our review corroborate results from 
Santosa et al29 who evaluated PROs for 2,013 patients (523 
autologous reconstructions; 1,490 IBR) from the MROC 
cohort, pre and 2 years post BRR, using the BREAST-Q. 
The 4 domains evaluated were as follows: satisfaction with 
breasts, psychosocial well-being, physical well-being, and 
sexual well-being. At 2 years, patients who underwent 
autologous reconstruction had higher breast satisfaction, 
higher psychosocial well-being, and sexual well-being than 
did those who underwent IBR.29 Lack of a significant differ-
ence in QoL between DIEP and IBR reported by Tønseth 
et al in our review may be due to the small sample size in 
the study (n = 50) and use of a nonspecific, generic QoL 
tool, SF-36, which may not be sensitive enough to measure 
changes as a result of BRR intervention or to capture all 
aspects of outcome specific to breast surgery.18 Moreover, as 
purported by our group, QoL domains should be defined 
a priori, facilitating estimations of potential effect size.17
Three comparative studies evaluated cost, all favor-
ing DIEP.15,27,30 Two studies were conducted in a uni-
versal health care system (UK and Spain)27,30 and 1 was 
conducted in a health insurance-based model (USA),15 
making direct comparisons on cost difficult. This is exac-
erbated by only 1 study performing robust cost-effective-
ness analysis, calculating an ICER of $11,491 for DIEP.15 
An ICER is the additional cost for DIEP to obtain 1 year of 
perfect breast-related QoL compared with IBR; a thresh-
old of $50,000–$100,000 for a year in perfect overall 
health has been deemed as acceptable for the adoption of 
new technologies or techniques in developed countries.60 
Heterogeneity in cost-evaluation methods and reporting 
prevented the calculation of an overall cost-effectiveness 
summary measure in our systematic review.
CONCLUSIONS
Limitations in study design and outcome reporting 
preclude firm consensus on best recommendations for 
postmastectomy BRR. However, the evidence supports 
a weak recommendation for DIEP reconstruction being 
more cost-effective and yielding higher QoL compared 
with IBR. There is a pressing need for level I and II data, 
in the form of RCTs and prospective, multicenter, longitu-
dinal cohort studies, with long-term follow-up. These must 
incorporate validated, disease-specific PRO tools such as 
BREAST-Q. Evaluation of a priori core outcome set and 
cost-effectiveness is required for national guidelines, 
optimizing informed consent and facilitating clinician–
patient-shared decision-making.
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Background: Effects of postmastectomy radiotherapy (PMRT) on autologous breast reconstruction
(BRR) are controversial regarding surgical complications, cosmetic appearance and quality of life (QOL).
This systematic review evaluated these outcomes after abdominal free flap reconstruction in patients
undergoing postoperative adjuvant radiotherapy (PMRT), preoperative radiotherapy (neoadjuvant radio-
therapy) and no radiotherapy, aiming to establish evidence-based optimal timings for radiotherapy and
BRR to guide contemporary management.
Methods: The study was registered on PROSPERO (CRD42017077945). Embase, MEDLINE, Google
Scholar, CENTRAL, Science Citation Index and ClinicalTrials.gov were searched (January 2000 to August
2018). Study quality and risk of bias were assessed using GRADE and Cochrane’s ROBINS-I respectively.
Results: Some 12 studies were identified, involving 1756 patients (350 PMRT, 683 no radiotherapy and
723 neoadjuvant radiotherapy), with a mean follow-up of 27⋅1 (range 12⋅0–54⋅0) months for those having
PMRT, 16⋅8 (1⋅0–50⋅3) months for neoadjuvant radiotherapy, and 18⋅3 (1⋅0–48⋅7) months for no radio-
therapy. Three prospective and nine retrospective cohorts were included. There were no randomized
studies. Five comparative radiotherapy studies evaluated PMRT and four assessed neoadjuvant radio-
therapy. Studies were of low quality, with moderate to serious risk of bias. Severe complications were
similar between the groups: PMRT versus no radiotherapy (92 versus 141 patients respectively; odds ratio
(OR) 2⋅35, 95 per cent c.i. 0⋅63 to 8⋅81, P = 0⋅200); neoadjuvant radiotherapy versus no radiotherapy (180
versus 392 patients; OR 1⋅24, 0⋅76 to 2⋅04, P =0⋅390); and combined PMRT plus neoadjuvant radiother-
apy versus no radiotherapy (272 versus 453 patients; OR 1⋅38, 0⋅83 to 2⋅32, P =0⋅220). QOL and cosmetic
studies used inconsistent methodologies.
Conclusion: Evidence is conflicting and study quality was poor, limiting recommendations for the timing
of autologous BRR and radiotherapy. The impact of PMRT and neoadjuvant radiotherapy appeared to be
similar.
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Introduction
Breast cancer is the commonest malignancy and lead-
ing cause of cancer-related mortality in women1,2.
Breast-conserving surgery (BCS) with radiotherapy or
mastectomy are recommended treatments, with compara-
ble oncological outcomes3,4. Autologous abdominal-based
© 2019 The Authors. BJS Open published by John Wiley & Sons Ltd on behalf of BJS Society Ltd BJS Open 2020; 4: 182–196
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free flap and implant-based procedures are the approaches
used most frequently in immediate breast reconstruction
(BRR)5. Autologous BRR has the inherent advantage of
using the patient’s own tissues, taken from a different part
of the body where there is excess fat and skin, to restore
breast volume and appearance after mastectomy. Various
donor sites can be used, most commonly the abdomen6.
Adjuvant locoregional postmastectomy radiotherapy
(PMRT) of the chest wall, and potentially of the regional
lymph nodes, has been indicated historically for locally
advanced disease7,8. These indications increased following
the Early Breast Cancer Trialists’ Collaborative Group9
meta-analyses, which showed significantly improved
disease-free and overall survival after PMRT and regional
node irradiation in women at intermediate risk (tumour
size 50 mm or less and 1–3 positive lymph nodes)10. Newly
proposed US guidelines11 emphasize the need to consider
the lower recurrence rates associated with contemporary
practice and the benefits of systemic therapy12. Current
recommendations for PMRT in the intermediate-risk
group remain controversial, pending the results of the
SUPREMO (Selective Use of Postoperative Radiotherapy
aftEr MastectOmy) trial, evaluating chest wall and/or
axillary radiotherapy13,14.
Adjuvant radiotherapy (PMRT) may have deleterious
effects on breast cosmetic outcomes, quality of life (QOL)
and surgical complications after immediate BRR15. Pre-
vious studies evaluating the impact of PMRT on types
of immediate BRR showed its potential feasibility in this
setting, with lower morbidity rates compared with those
of implant-based procedures5,16–18. Surprisingly, the rapid
adoption of immediate implant-based reconstruction in
about 70 per cent of women, compared with 34 per cent of
autologous procedures when PMRT is recommended, may
be influenced by surgeon and patient preferences, regard-
less of current evidence15,17,19.
Increasing recommendations for PMRT and immediate
BRR have prompted a need to consider their optimal
sequence. Previous systematic reviews have not provided
clarity concerning the choice between immediate and
delayed BRR9. Despite this, immediate autologous BRR
is commonly recommended in the setting of PMRT,
given the potential long-term benefits on patients’ QOL
and breast cosmetic satisfaction20,21. Currently, imme-
diate autologous BRR and PMRT recommendations
are variable22,23. A systematic review24 in 2011 showed
methodological variations in the definitions of surgical
complications, precluding interstudy comparisons.
Complications of autologous breast reconstruction with
PMRT include: poor wound-healing, flap-related fat
necrosis, fibrosis and contracture, which reduce breast
volume5. Surgical complications contribute variably to
decreased patient satisfaction and impaired cosmetic
outcomes5. A standardized core set of outcomes for BRR
has been proposed25 involving a range of complications,
including flap-related complications and the need for
further unplanned surgery. The BRR core outcome set
has yet to recommend a standardized measurement tool
for evaluating surgical complications. Most surgeons
use the Clavien–Dindo classification (CDC)26. Patient-
reported QOL outcomes using validated BRR question-
naires, such as the BREAST-Q and the European
Organisation for Research and Treatment of Cancer
(EORTC) Quality-of-Life Questionnaire (QLQ)-
BRECON23, are recommended to evaluate comparative
effectiveness20,27–32.
This systematic review aimed to evaluate the quality
and strengths of the current evidence regarding surgical
complications in autologous abdominal flaps in the con-
text of the receipt and timing of radiotherapy related to
PMRT5,6 and, less commonly, neoadjuvant radiotherapy,
generally administered before skin-sparing mastectomy
and immediate breast reconstruction33, including assess-
ment of QOL34.
Methods
The protocol was registered and published on the
Prospective Register of Systematic Reviews PROS-
PERO (CRD42017077945)35. The authors adhered to the
PRISMA statement36.
Search strategies
A comprehensive search of the MEDLINE (Ovid SP),
Embase (Ovid SP), Google Scholar, Cochrane Controlled
Register of Trials (CENTRAL), Science citation index
databases and ClinicalTrials.gov (January 2000 to August
2018) was conducted, identifying the relevant studies.
Combinations of Medical Subject Headings (MeSH) terms
and free text were used, including Boolean logical opera-
tors for the search strategy. References of included articles
were also screened for their relevance. The example of an
Embase (Ovid SP) search strategy was adopted for other
databases (Appendix S1, supporting information).
Identification and selection of studies
Database-related searches were entered into an
EndNote™ X8 library (Clarivate Analytics, Philadel-
phia, Pennsylvania, USA). Study screening was performed
independently in two stages by two investigators using
prespecified screening criteria.
© 2019 The Authors. www.bjsopen.com BJS Open 2020; 4: 182–196
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In stage 1, two authors independently screened titles and
abstracts. Discrepancies were resolved by consensus with
the senior author. Remaining doubts regarding an article
resulted in a review of the complete publication.
In stage 2, full-text studies from stage 1 were screened
independently for their eligibility by two reviewers.
Discrepancies were resolved by consensus with a third
reviewer. Authors of eligible studies were contacted (via
e-mail) to reconcile any methodological issues or to pro-
vide more detailed information on data for individual types
of autologous flap.
Study design
All primary human studies evaluating surgical complica-
tions for autologous free flap (microvascular) abdominal
BRR in breast cancer and types of radiotherapy (PMRT,
neoadjuvant and no radiotherapy) were included. Out-
comes also included patient-reported QOL and cosmetic
assessments. Radiotherapy groups were compared with a
control or no radiotherapy group in comparative studies,
compatible with immediate and delayed BRR. Commonly
performed autologous abdominal flaps included: deep infe-
rior epigastric perforator (DIEP), transverse rectus abdo-
minis myocutaneous (TRAM) and the superficial inferior
epigastric artery perforator (SIEA)6.
Inclusion criteria
Inclusion criteria were: women aged at least 18 years with
a diagnosis of invasive breast cancer (TNM categories:
T0–3, N1–3, Mx, M0), undergoing immediate or delayed
abdominal autologous BRR using free flaps (DIEP, TRAM
or SIEA) who received adjuvant radiotherapy (PMRT),
neoadjuvant radiotherapy or no radiotherapy.
Clinical studies that involved at least 50 patients were
included (RCTs, prospective and retrospective comparative
observational studies, and case series).
Exclusion criteria
Review articles, conference abstracts, simulation stud-
ies and clinical studies in non-human subjects were
not included, along with studies involving patients who
received segmental or partial mastectomy, technical
descriptions of operative repair with no outcome mea-
sures, BRR unrelated to breast cancer, implant-based
reconstructions and other non-abdominal autologous flaps.
Risk of bias and quality of studies
Cochrane’s ROBINS-I (Risk Of Bias In Non-randomised
Studies – of Interventions) tool was used for comparative
studies37. This comprises seven domains from which the
risk of bias may be ascertained to produce an overall
risk-of-bias score37. The Grading of Recommendations,
Assessment, Development, and Evaluations (GRADE)
tool38 was used to evaluate the methodological quality of
individual studies.
Study outcomes
Primary outcomes were surgical complications includ-
ing: Clavien–Dindo classification (CDC) grades II and
III26; partial flap loss; total flap loss; fat necrosis (CDC
grades, when reported)39; number(s) of unplanned reop-
erations for surgical complications (excluding cosmetic
revisions); and number(s) of total complications. A surgical
complication was defined as an adverse, postoperative,
surgery-related event that required additional treatment16.
If CDC grades were not defined, the complications
reported by the included studies were graded retrospec-
tively according to the CDC by two independent authors;
any discrepancy was discussed and agreed with the senior
author.
Secondary outcomes were assessed using patient-
reported QOL-validated questionnaires (COnsensus-based
Standards for the Selection of health Measurement
INstruments (COSMIN)40,41, Breast Questionnaire
(BREAST-Q), the EORTC Quality-of-Life Question-
naire (QLQ) – Breast Cancer 2342, the Quality-of-Life
Cancer Generic Questionnaire (QLQ-C30)43, the Numer-
ical Pain Rating Scale (NPRS)44,45, the Patient-Reported
Outcomes Measurement Information System – Profile 29
(PROMIS-29)46, the McGill Pain Questionnaire (MPQ)47,
the Generalized Anxiety Disorder Scale (GAD-7)48 and
the Patient Health Questionnaire (PHQ-9)49), as well as
assessment of cosmetic outcomes using independent panel
or self assessments of medical photographs, and surface
imaging using the Vectra® XT three-dimensional system50
(Canfield Scientific, Parsippany, New Jersey, USA).
Data extraction, collection and management
Two authors independently extracted data from full-text
articles using a standard data form. Any discrepancies were
resolved by consensus with a third reviewer. Reporting
authors of original articles were contacted on up to two
occasions relating to missing data or where additional
information was required.
Data extraction included: first author, year of publication,
study design, study setting, number of centres, duration of
follow-up, study population and participant demographics
(mean age, BMI, smoking, co-morbidities).
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Fig. 1 PRISMA diagram for the review
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Surgical complications were recorded using CDC:
grades II–III26. Two authors reviewed eligible studies and
classified each complication according to the CDC26 if
unreported.
QOL and cosmetic outcomes were listed.
Statistical analysis
When two or more studies reported outcome data, these
were pooled using Review Manager 5.3 software (The
Cochrane Collaboration, The Nordic Cochrane Centre,
Copenhagen, Denmark). Odds ratios with 95 per cent con-
fidence intervals were used to evaluate dichotomous out-
comes (surgical complications). Standard mean differences
(with 95 per cent c.i.) were used for continuous outcomes
between treatment groups. Rates of each complication (fat
necrosis, partial and total flap loss, infection and wound
complications (dehiscence and delayed wound healing))
were compared for PMRT (versus no radiotherapy) and
neoadjuvant radiotherapy (versus no radiotherapy). Data
were also pooled to provide an overall summary measure
of combined radiotherapy (adjuvant and neoadjuvant) com-
pared with no radiotherapy.
Heterogeneity between studies51 was assessed in
Review Manager 5.3 using the Higgins and Thompson
I2 statistic52. Levels of heterogeneity were defined as:
low (I2 less than 50 per cent), moderate (I2 = 50–80 per
cent) and high (I2 above 80 per cent). A random-effects
model was used for cohorts with heterogeneity (I2 above
50 per cent)53. As heterogeneity was generally moderate
or high, and outcome measures differed between studies,
these were combined using the DerSimonian and Laird
random-effects model. Results of meta-analyses are shown
as forest plots. A sensitivity analysis was performed where
possible, to evaluate whether outcomes differed when
restricting the analysis exclusively to high-quality studies.
Clinically meaningful differences in QOL items/
questions or domain scores may vary depending on
response shift, that is a change in the meaning of QOL
scores over time54. This is relevant in longitudinal studies
and may influence clinical significance, defined as greater
than 5-point score differences for EORTC QLQ-C30
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Table 1 Study summaries: comparative adjuvant or neoadjuvant radiotherapy in autologous breast reconstruction, and
non-comparative studies (adjuvant radiotherapy or neoadjuvant radiotherapy only)
Reference Years Country
No. of
centres Type of BRR flap
Overall follow-up
(months)
Group differences
in baseline
characteristics¶ RT dose and regimen
Baumann
et al.69‡
2005–2009 USA 1 msTRAM; DIEP;
SIEA
11* n.a. Total 60 Gy; missing
details
Billig
et al.62§
2012–2017 USA and
Canada
11 TRAM; DIEP; SIEA 24 Adjuvant RT: more
non-Hispanic patients
(P=0⋅001), bilateral
BRR (P=0⋅002),
DIEP/SIEA (P<0⋅001),
adjuvant
chemotherapy
(P<0⋅001); less TRAM
(P<0⋅001)#
Total 50⋅4 Gy over
4 weeks, daily (28
fractions of 1⋅8 Gy)
Chatterjee
et al.59§
1995–2005 UK 1 DIEP 42 (12–120)† Adjuvant RT: more IDC
(P=0⋅02), LVI
(P=0⋅044), positive
axillary LN (P<0⋅001)
Total 45 Gy over
4 weeks (20
fractions)
Cooke
et al.60§
2012–2015 Canada 1 DIEP; SIEA 12 Adjuvant RT: higher TNM
staging, positive LN,
more chemotherapy (P
values not provided)
Total 50/50⋅4 Gy over
4 weeks, daily (25
fractions of 2 Gy/28
fractions of 1⋅8 Gy)
Huang
et al.63‡
1997–2001 Taiwan 1 TRAM 40 (24–74)† n.a. Total 50 Gy; missing
details
Levine
et al.67‡
1999–2011 USA 1 msTRAM; DIEP;
SIEA
22⋅7* n.a. Missing details
Modarressi
et al.64‡
2007–2013 Switzerland 1 DIEP 1 n.a. Missing details
Mull et al.65‡ 2003–2014 USA 1 msTRAM;
TRAM; DIEP
1 Neoadjuvant RT: more
chemotherapy
(P<0⋅01), higher TNM
staging (P<0⋅01); less
hypertension/CAD
(P=0⋅03)
Missing details
O’Connell
et al.58‡
2009–2014 UK 1 DIEP 44⋅3 (i.q.r.
31⋅1–56⋅4)†
Adjuvant and
neoadjuvant RT: more
chemotherapy and
endocrine therapy as
less DCIS/less
advanced invasive
disease (P values not
provided)
Total 40 Gy over
3 weeks (15
fractions)
Peeters
et al.66‡
1997–2003 Belgium 2 DIEP ≥12 n.a. Total 50 Gy; missing
details
Rogers and
Allen61‡
1994–1999 USA 1 DIEP 18⋅7* n.a. Total 50⋅5 Gy over
6⋅5 weeks (missing
details)
Temple
et al.68‡
1990–2001 USA 1 TRAM ≥12 n.a. Total 58 Gy; missing
details
Values are *mean and †median (range), unless indicated otherwise. ‡Retrospective study; §prospective study. ¶Radiotherapy (RT) versus no RT, except
#group difference values are for adjuvant RT versus neoadjuvant RT. BRR, breast reconstruction; (ms)TRAM, (muscle-sparing) transverse rectus abdominis
myocutaneous; DIEP, deep inferior epigastric artery perforator; SIEA, superficial inferior epigastric artery perforator; IDC, invasive ductal carcinoma; LVI,
lymphovascular invasion; LN, lymph node; n.a., not applicable/available; CAD, coronary artery disease; DCIS, ductal carcinoma in situ.
and QLQ-BR2342,43,54. Clinically meaningful differences
are currently being evaluated using a number of methods
such as qualitative interviews and using predefined clinical
anchors55. Clinically meaningful differences in QOL
should be differentiated from statistical significance55.
BREAST-Q findings have been compared with large
population-derived normative data, facilitating clinically
meaningful interpretation of data56,57.
© 2019 The Authors. www.bjsopen.com BJS Open 2020; 4: 182–196
BJS Open published by John Wiley & Sons Ltd on behalf of BJS Society Ltd
Breast reconstruction in patients receiving adjuvant, neoadjuvant or no radiotherapy 187
Table 2 Surgical complications: immediate autologous breast reconstruction and adjuvant radiotherapy including non-comparative
studies (adjuvant radiotherapy only)
No. of patients Follow-up (months)
Total no. of
complications
No. of reoperations
for complications
Reference GRADE ROBINS-I
Adjuvant
RT
No adjuvant
RT
Adjuvant
RT
No adjuvant
RT
Adjuvant
RT
No adjuvant
RT
Adjuvant
RT
No adjuvant
RT
Chatterjee et al.59 Low Serious 22 46 54* 36* n.a. n.a. n.a. n.a.
Cooke et al.60 Moderate Moderate 64 61 12 12 20 16 6 1
O’Connell et al.58 Low Serious 28 80 27⋅5* 48⋅7* 11 20 4 8
Peeters et al.66 Low Serious 16 109 ≥12 ≥12 n.a. n.a. n.a. n.a.
Rogers and
Allen61
Low Serious 30 30 19⋅9 17⋅4 65 41 32 26
Billig et al.62 Moderate Moderate 108 n.a. 24 n.a. 81 n.a. 5 n.a.
Huang et al.63 Low Serious 82 n.a. 40* n.a. 131 n.a. 5 n.a.
*Values are median. GRADE, Grading of Recommendation, Assessment, Development, and Evaluation (tool for grading the quality of evidence);
ROBINS-I, Risk Of Bias In Non-randomised Studies – of Interventions (tool for assessing risk of bias); RT, radiotherapy; n.a., not applicable/available.
Table 3 Clavien–Dindo classification of surgical complications: immediate autologous breast reconstruction and adjuvant
radiotherapy including non-comparative studies (adjuvant radiotherapy only)
Adjuvant RT versus no adjuvant RT
Clavien-Dindo complication
grade†
Reference
Total flap
loss
Partial flap
loss* Fat necrosis*
Wound dehiscence
and delayed
wound healing* II IIIa IIIb
Chatterjee et al.59 n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Cooke et al.60 0 versus 0 9 versus 6 2 versus 1 3 versus 5 2 versus 4 n.a. 6 versus 1
O’Connell et al.58 0 versus 0 0 versus 0 1 versus 2 4 versus 9 3 versus 3 3 versus 3 1 versus 5
Peeters et al.66 n.a. n.a. 6 versus 36 n.a. n.a. n.a. n.a.
Rogers and
Allen61
n.a. n.a. 7 versus 0‡ 11 versus 8 5 versus 7 7 versus 0 25 versus 26
Billig et al.62 0 versus n.a. n.a. 4 versus n.a. 17 versus n.a. 8 versus n.a. n.a. 5 versus n.a.
Huang et al.63 0 versus n.a. n.a. 7 versus n.a. n.a. 82 versus
n.a.
5 versus n.a. n.a.
*Complication grades were not always defined or classified. †Grade II, complications requiring pharmacological treatment with drugs other than those
allowed for grade I complications (drugs other than antiemetics, antipyretics, analgesics, diuretics and electrolytes); grade IIIa, complications requiring
surgical intervention not under general anaesthesia; grade IIIb, complications requiring surgical intervention under general anaesthesia. RT, radiotherapy;
n.a. not applicable/available. ‡P < 0⋅050.
Results
A total of 697 studies were identified. Of these, 12
studies58–69 (including 1756 patients) evaluated adjuvant
radiotherapy (350 patients), neoadjuvant radiotherapy
(723) and no radiotherapy (683) (Fig. 1). There were
three prospective study designs59,60,62 and nine that
were retrospective58,61,63–69, but no RCTs. There were
two multicentre (1 prospective62 and 1 retrospective66)
and ten single-centre studies (2 prospective59,60 and
8 retrospective58,61,63–65,67–69) (Table 1). Study quality
(GRADE) was low in eight studies58,59,61,63–66,68 and mod-
erate in the other four60,62,67,69, with an overall high risk
of bias. A summary of baseline characteristics, including
numbers of centres, country of origin, dates, patient
numbers, breast cancer pathology and adjuvant medi-
cal treatments in comparative adjuvant and neoadjuvant
radiotherapy groups, including non-comparative studies,
is provided in Table S1 (supporting information).
Clinical outcomes (Tables 2–5)
No study prospectively graded surgical complications
according to an accepted classification such as CDC (fat
necrosis, partial or total flap loss, infection and wound
complications). One study64 graded partial flap loss using
a novel flap necrosis classification system, adapted from
Kwok et al.70. Only 30 per cent of all surgical complica-
tions (30 of 99) reported across the 12 included studies
were defined a priori.
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Table 4 Surgical complications: delayed autologous breast reconstruction and neoadjuvant radiotherapy including non-comparative
studies (neoadjuvant radiotherapy only)
No. of patients Follow-up (months)
Total no. of
complications
No. of reoperations
for complications
Reference GRADE ROBINS-I
Neoadjuvant
RT
No
neoadjuvant
RT
Neoadjuvant
RT
No
neoadjuvant
RT
Neoadjuvant
RT
No
neoadjuvant
RT
Neoadjuvant
RT
No
neoadjuvant
RT
Modarressi
et al.64
Low Serious 60 45 1 1 20 9 n.a. n.a.
Mull et al.65 Low Serious 142 312 1 1 26 45 26 45
O’Connell
et al.58
Low Serious 38 80 50⋅3* 48⋅7* 12 20 3 8
Peeters
et al.66
Low Serious 77 109 ≥12 ≥12 n.a. n.a. n.a. n.a.
Baumann
et al.69
Moderate Moderate 189 n.a. 11† n.a. 88 n.a. 69 n.a.
Billig
et al.62
Moderate Moderate 67 n.a. 24 n.a. 37 n.a. 1 n.a.
Levine
et al.67
Moderate Moderate 50 n.a. 22⋅7† n.a. n.a. n.a. 3 n.a.
Temple
et al.68
Low Serious 100 n.a. ≥12 n.a. 41 n.a. 18 n.a.
Values are *median and †mean. GRADE, Grading of Recommendation, Assessment, Development, and Evaluation (tool for grading the quality of evidence);
ROBINS-I, Risk Of Bias In Non-randomised Studies – of Interventions (tool for assessing risk of bias); RT, radiotherapy; n.a., not applicable/available.
Table 5 Clavien–Dindo classification of surgical complications: delayed autologous breast reconstruction and neoadjuvant
radiotherapy including non-comparative studies (neoadjuvant radiotherapy only)
Neoadjuvant RT versus no neoadjuvant RT
Clavien-Dindo complication grade†
Reference
Total
flap loss
Partial
flap loss* Fat necrosis*
Wound dehiscence
and delayed
wound healing* II IIIa IIIb
Modarressi et al.64 2 versus 1 12 versus 2 n.a. n.a. n.a. n.a. n.a.
Mull et al.65 5 versus 15 7 versus 5‡ n.a. n.a. n.a. n.a. 26 versus 45
O’Connell et al.58 0 versus 0 0 versus 0 2 versus 2 7 versus 9 2 versus 3 0 versus 3 3 versus 5
Peeters et al.66 n.a. n.a. 29 versus 36 n.a. n.a. n.a. n.a.
Baumann et al.69 5 versus n.a. 14 versus n.a. 15 versus n.a. 22 versus n.a. 4 versus n.a. n.a. 69 versus n.a.
Billig et al.62 0 versus n.a. n.a. 7 versus n.a. 11 versus n.a. 4 versus n.a. n.a. 1 versus n.a.
Levine et al.67 n.a. 1 versus n.a. n.a. n.a. n.a. n.a. n.a.
Temple et al.68 2 versus n.a. 7 versus n.a. 16 versus n.a. n.a. n.a. n.a. 18 versus n.a.
*Complication grades were not always defined or classified. †Grade II, complications requiring pharmacological treatment with drugs other than those
allowed for grade I complications (drugs other than antiemetics, antipyretics, analgesics, diuretics and electrolytes); grade IIIa, complications requiring
surgical intervention not under general anaesthesia; grade IIIb, complications requiring surgical intervention under general anaesthesia. RT, radiotherapy;
n.a. not applicable/available. ‡P < 0⋅050.
Adjuvant post-mastectomy radiotherapy
Meta-analyses comparing PMRT (350 patients; mean
follow-up 27⋅1 (range 12⋅0–54⋅0) months) and no
radiotherapy (326 patients; mean follow-up 25⋅2
(12⋅0–48⋅7) months) showed no interstudy differences
in rates of: overall complications (233 patients; odds
ratio (OR) 1⋅52 (95 per cent c.i. 0⋅84 to 2⋅75), Z = 1⋅40,
P = 0⋅160) (Fig. 2a); CDC grade III surgical complications
(233 patients; OR 2⋅35 (0⋅63 to 8⋅81), Z = 1⋅27, P = 0⋅200)
(Fig. 2b); CDC grade II (293 patients; OR 0⋅94 (0⋅32 to
2⋅76), Z = 0⋅11, P = 0⋅910) (Fig. 2c); or fat necrosis (418
patients; OR 1⋅83 (0⋅67 to 5⋅00), Z = 1⋅18, P = 0⋅240)
(Fig. 2d). There were no differences in rates of infection
(293 patients; OR 0⋅94 (0⋅32 to 2⋅76), Z = 0⋅11, P = 0⋅910)
(Fig. S1a, supporting information) or wound complications
(293 patients; OR 1⋅16 (0⋅56 to 2⋅39), Z = 0⋅40, P = 0⋅690)
(Fig. S1b, supporting information). There were no total
flap losses.
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Fig. 2 Forest plots comparing adjuvant radiotherapy with no radiotherapy
Cooke et al.60
Reference
a  Overall complications
RT No RT Odds ratioWeight (%) Odds ratio
O’Connell et al.58
20 of 64
11 of 28
31 of 92
16 of 61
20 of 80
36 of 141
57·9
42·1
100·0
1·28 (0·59, 2·78)
1·94 (0·78, 4·83)
1·52 (0·84, 2·75)
0·01 0·1
Favours RT Favours no RT
1 10 100
Total
Heterogeneity: τ2= 0·00; χ2= 0·47, 1 d.f., P = 0·49; I2= 0%
Test for overall effect: Z = 1·40, P = 0·16
Cooke et al.60
Reference
b  CDC grade III complications
RT No RT Odds ratioWeight (%) Odds ratio
O’Connell et al.58
6 of 64
4 of 28
10 of 92
1 of 61
8 of 80
9 of 141
31·6
68·4
100·0
6·21 (0·72, 53·15)
1·50 (0·41, 5·43)
2·35 (0·63, 8·81)
0·01 0·1
Favours RT Favours no RT
1 10 100
Total
Heterogeneity: τ2= 0·23; χ2= 1·29, 1 d.f., P = 0·26; I2= 22%
Test for overall effect: Z = 1·27, P = 0·20
Cooke et al.60
Reference
c  CDC grade II complications
RT No RT Odds ratioWeight (%) Odds ratio
O’Connell et al.58
2 of 64
3 of 28
10 of 122
4 of 61
3 of 80
14 of 171
28·0
29·8
100.0
0·46 (0·08, 2·61)
3·08 (0·58, 16·24)
Rogers and Allen 61 5 of 30 7 of 30 42·1 0·66 (0·18, 2·36)
0·94 (0·32, 2·76)
0·01 0·1
Favours RT Favours no RT
1 10 100
Total
Heterogeneity: τ2= 0·29; χ2= 2·92, 2 d.f., P = 0·23; I2= 31%
Test for overall effect: Z = 0·11, P = 0·91
Cooke et al.60
Reference
d  Fat necrosis
RT No RT Odds ratioWeight (%) Odds ratio
O’Connell et al.58
2 of 64
1 of 28
16 of 138
1 of 61
2 of 80
39 of 280
15·7
15·5
100·0
1·94 (0·17, 21·91)
1·44 (0·13, 16·57)
Peeters et al.66 6 of 16 36 of 109 57·7 1·22 (0·41, 3·61)
Rogers and Allen61 7 of 30 0 of 30 11·2 19·47 (1·06, 358·38)
1·83 (0·67, 5·00)
0·01 0·1
Favours RT Favours no RT
1 10 100
Total
Heterogeneity: τ2= 0·15; χ2= 3·40, 3 d.f., P = 0·33; I2= 12%
Test for overall effect: Z = 1·18, P = 0·24
a Overall complications, b Clavien–Dindo classification (CDC) grade III complications, c CDC grade II complications, d fat necrosis. A Mantel–Haenszel
random-effects model was used for meta-analysis. Odds ratios are shown with 95 per cent confidence intervals. RT, radiotherapy.
Neoadjuvant radiotherapy
Comparisons between neoadjuvant radiotherapy (723
patients; mean follow-up 16⋅8 (range 1⋅0–50⋅3) months)
and no radiotherapy (546 patients; mean follow-up 15⋅7
(1⋅0–48⋅7) months) showed no differences in overall
complications (677 patients; OR 1⋅45 (95 per cent c.i.
0⋅97 to 2⋅18), Z = 1⋅82, P = 0⋅070) (Fig. 3a) and CDC
grade III surgical complications (572 patients; OR
1⋅24 (0⋅76 to 2⋅04), Z = 0⋅85, P = 0⋅390) (Fig. 3b). One
comparative study58 reported similar CDC grade II
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Fig. 3 Forest plot comparing neoadjuvant radiotherapy with no radiotherapy
Modarressi et al.64
Reference
a  Overall complications
Neoadjuvant RT No RT Odds ratioWeight (%) Odds ratio
Mull et al.65
20 of 60
26 of 142
58 of 240
9 of 45
45 of 312
74 of 437
19·8
57·8
100·0
2·00 (0·81, 4·95)
1·33 (0·78, 2·26)
O’Connell et al.58 12 of 38 20 of 80 22·4 1·38 (0·59, 3·24)
1·45 (0·97, 2·18)
0·01 0·1
Favours neoadjuvant RT Favours no RT
1 10 100
Total
Heterogeneity: τ2= 0·00; χ2= 0·60, 2 d.f., P = 0·74; I2= 0%
Test for overall effect: Z = 1·82, P = 0·07
Mull et al.65
Reference
b  CDC grade III complications
Neoadjuvant RT No RT Odds ratioWeight (%) Odds ratio
O’Connell et al.58
26 of 142
3 of 38
29 of 180
45 of 312
8 of 80
53 of 392
87·3
12·7
100·0
1·33 (0·78, 2·26)
0·77 (0·19, 3·09)
1·24 (0·76, 2·04)
0·01 0·1
Favours neoadjuvant RT Favours no RT
1 10 100
Total
Heterogeneity: τ2= 0·00; χ2= 0·52, 1 d.f., P = 0·47; I2= 0%
Test for overall effect: Z = 0·85, P = 0·39
O’Connell et al.58
Reference
c  Fat necrosis
Neoadjuvant RT No RT Odds ratioWeight (%) Odds ratio
Peeters et al.66
2 of 38
29 of 77
31 of 115
2 of 80
36 of 109
38 of 189
8·5
91·5
100·0
2·17 (0·29, 16·00)
1·23 (0·67, 2·25)
1·29 (0·72, 2·30)
0·01 0·1
Favours neoadjuvant RT Favours no RT
1 10 100
Total
Heterogeneity: τ2= 0·00; χ2= 0·29, 1 d.f., P = 0·59; I2= 0%
Test for overall effect: Z = 0·85, P = 0·40
a Overall complications, b Clavien–Dindo classification (CDC) grade III complications, c fat necrosis. A Mantel–Haenszel random-effects model was used
for meta-analysis. Odds ratios are shown with 95 per cent confidence intervals. RT, radiotherapy.
complications between neoadjuvant and no radiotherapy
(118 patients; OR 1⋅43 (0⋅23 to 8⋅91), Z = 0⋅38, P = 0⋅700).
There were no differences in rates of fat necrosis (304
patients; OR 1⋅29 (0⋅72 to 2⋅30), Z = 0⋅85, P = 0⋅400)
(Fig. 3c). Rates of partial flap loss were higher for neoad-
juvant radiotherapy than for no radiotherapy (559
patients; OR 3⋅85 (1⋅51 to 9⋅76), Z = 2⋅83, P = 0⋅005)
(Fig. S2a, supporting information), with no differ-
ences in rates of total flap loss (559 patients; OR 0⋅81
(0⋅31 to 2⋅09), Z = 0⋅44, P = 0⋅660) (Fig. S2b, supporting
information).
Combined adjuvant and neoadjuvant radiotherapy
Meta-analyses of pooled PMRT and neoadjuvant radio-
therapy compared with pooled no radiotherapy groups
(mean follow-up 18⋅3 (range 1⋅0–48⋅7) months) were
performed as a potential hypothesis-generating exercise.
This showed significantly higher overall complications
in the combined radiotherapy groups compared with
no radiotherapy (830 patients; OR 1⋅46 (95 per cent c.i.
1⋅04 to 2⋅07), Z = 2⋅16, P = 0⋅030) (Fig. 4a). There were
no interstudy differences in: CDC grade III complica-
tions (725 patients; OR 1⋅38 (0⋅83 to 2⋅32), Z = 1⋅24,
P = 0⋅220) (Fig. 4b); CDC grade II complications (331
patients; OR 0⋅89 (0⋅37 to 2⋅10), Z = 0⋅28, P = 0⋅780)
(Fig. S3a, supporting information); rates of fat necro-
sis (533 patients; OR 1⋅59 (0⋅96 to 2⋅64), Z = 1⋅79,
P = 0⋅070) (Fig. 4c); or emergency reoperations for com-
plications (725 patients; OR 1⋅38 (0⋅83 to 2⋅32), Z = 1⋅24,
P = 0⋅220) (Fig. S3b, supporting information). Rates
of partial flap loss were also higher in the combined
versus no radiotherapy groups (684 patients; OR 2⋅59
(1⋅27 to 5⋅28), Z = 2⋅63, P = 0⋅009) (Fig. S3c, supporting
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Fig. 4 Forest plot comparing combined adjuvant and neoadjuvant radiotherapy with no radiotherapy
Modarressi et al.64
Reference
a  Overall complications
RT No RT Odds ratioWeight (%) Odds ratio
Mull et al.65
20 of 60
26 of 142
89 of 332
9 of 45
45 of 312
90 of 498
14·5
42·5
100·0
2·00 (0·81, 4·95)
Cooke et al.60 20 of 64 16 of 61 19·7 1·28 (0·59, 2·78)
1·33 (0·78, 2·26)
O’Connell et al.58 23 of 66 20 of 80 23·3 1·60 (0·78, 3·28)
1·46 (1·04, 2·07)
0·01 0·1
Favours RT Favours no RT
1 10 100
Total
Heterogeneity: τ2= 0·00; χ2= 0·76, 3 d.f., P = 0·86; I2= 0%
Test for overall effect: Z = 2·16, P = 0·03
Mull et al.65
Reference
b  CDC grade III complications
RT No RT Odds ratioWeight (%) Odds ratio
O’Connell et al.58
26 of 142
7 of 66
39 of 272
45 of 312
8 of 80
54 of 453
72·8
21·5
100·0
1·33 (0·78, 2·26)
Cooke et al.60 6 of 64 1 of 61 5·6 6·21 (0·72, 53·15)
1·07 (0·37, 3·12)
1·38 (0·83, 2·32)
0·01 0·1
Favours RT Favours no RT
1 10 100
Total
Heterogeneity: τ2= 0·02; χ2= 2·15, 2 d.f., P = 0·34; I2= 7%
Test for overall effect: Z = 1·24, P = 0·22
O’Connell et al.58
Reference
c  Fat necrosis
RT No RT Odds ratioWeight (%) Odds ratio
Peeters et al.66
3 of 66
35 of 93
47 of 253
2 of 80
36 of 109
39 of 280
7·3
87·0
100·0
1·86 (0·30, 11·46)
Cooke et al.60 2 of 64 1 of 61 4·2 1·94 (0·17, 21·91)
1·22 (0·69, 2·18)
Rogers and Allen61 7 of 30 0 of 30 1·6 19·47 (1·06, 358·38)
1·59 (0·96, 2·64)
0·01 0·1
Favours RT Favours no RT
1 10 100
Total
Heterogeneity: χ2= 3·68, 3 d.f., P = 0·30; I2= 18%
Test for overall effect: Z = 1·79, P = 0·07
a Overall complications, b Clavien–Dindo classification (CDC) grade III complications, c fat necrosis. A Mantel–Haenszel random-effects model was used
for meta-analysis. Odds ratios are shown with 95 per cent confidence intervals. RT, radiotherapy.
information), with no differences in rates of total flap
loss (559 patients; OR 0⋅81 (0⋅31 to 2⋅09), Z = 0⋅44,
P = 0⋅660) (Fig. S3d, supporting information), infec-
tion (331 patients; OR 0⋅89 (0⋅37 to 2⋅10), Z = 0⋅28,
P = 0⋅780) (Fig. S3e, supporting information) or wound
complications (dehiscence/delayed wound healing) (331
patients; OR 1⋅29 (0⋅68 to 2⋅47), Z = 0⋅78, P = 0⋅430)
(Fig. S3f , supporting 1information).
Assessment of heterogeneity and meta-analyses
Clinical outcomes within studies of PMRT versus no
radiotherapy were homogeneous (I2 values below 50 per
cent). All remaining meta-analyses of outcomes were
similar (neoadjuvant radiotherapy versus no radiotherapy,
pooled PMRT and neoadjuvant radiotherapy versus no
radiotherapy).
Quality of life
There was limited reporting of patient-reported QOL;
outcomes were detailed in only two prospective studies60,62
and one retrospective study58, with small patient numbers
and short follow-ups for the PMRT groups58,60,62. A priori
hypothesis-driven selection of QOL domains was absent
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from methods58,60,62, with no reporting of missing data or
how this problem was tackled34.
Three studies58,60,62 used the BREAST-Q and one60
used the breast cancer-specific questionnaire (EORTC
QLQ-BR23)42. One small study58 reported significantly
better ‘satisfaction with breast’ (P = 0⋅008) after a median
follow-up of 27⋅5 months for PMRT compared with
48⋅7 months for no radiotherapy (Table S2, supporting
information). The moderate-quality comparative prospec-
tive study60 found a significant adverse impact of PMRT
on breast symptoms at 1 year (P < 0⋅001) compared with
no radiotherapy (Table S2, supporting information).
The third study62 evaluated serial QOL outcomes, con-
cluding a significant impact of PMRT on QOL domains
(BREAST-Q) at 1 and 2 years, despite the absence of a
control group (no radiotherapy). Moreover, clinical signif-
icance was defined as P = 0⋅05, which may not account for
multiple variables (Table S2, supporting information)43,62.
Highly significant abdominal adverse effects in a small
patient group (108 patients) may be unrelated to PMRT,
but rather an indication of donor site morbidity. Interest-
ingly, when evaluating the impact of neoadjuvant radio-
therapy in a small non-comparative study62, significant
time-related improvements in most QOL domains were
observed, except lower physical well-being relating to the
abdomen at 1 year (Table S3, supporting information).
Cosmetic outcomes
Three studies58,61,63 evaluated PMRT and the effects on
aesthetic outcomes (187 patients). There was no stan-
dardized evaluation of cosmetic outcomes, precluding
meta-analyses. Studies lacked robust methodology.
Discussion
The mixture of underpowered observational studies
included in this review were, in large part, lacking con-
temporaneous data to reflect current practice. Most were
retrospective single-centre cohorts, demonstrating poor
levels of clinical evidence (levels 3 and 4) with insufficient
follow-up11.
A previous study24 of over 40 000 women undergoing
BRR in 134 studies found that only 20 per cent reported
a priori surgical complications, as well as inconsistent
interstudy definitions24. The present review found sim-
ilar interstudy discrepancies, without uniform adoption
of the CDC26. The present authors graded all reported
surgical complications using the CDC. All surgical inter-
ventions were graded as CDC IIIa or IIIb, and surgi-
cal reoperations were differentiated according to whether
they were for complications or cosmetic revisions. Some
complications were not amenable to retrospective grading
in three studies64,66,67. In one66, it was not possible to deter-
mine whether fat necrosis required surgical revision for
each radiotherapy group (adjuvant or neoadjuvant), com-
pared with no radiotherapy. A second64 omitted individual
abdominal complications relative to timings of radiother-
apy, and the third67 omitted overall numbers of complica-
tions. Reviewed studies also failed to define postoperative
wound infections according to Centers for Disease Control
and Prevention criteria71.
The IDEAL (Idea, Development, Exploration, Assess-
ment, Long-term study) Collaboration describes key
methodological criteria for robust prospective cohort
studies72: studies should be powered on the effect size
of primary outcomes evaluating interventions of interest.
The Mastectomy and Breast Reconstruction Outcomes
Collaborative (MROC) is a multicentre prospective cohort
study that provides IDEAL level 2b evidence for clinical
safety and satisfactory QOL outcomes in the evaluation
of surgical complications in immediate autologous recon-
structions with PMRT versus no radiotherapy (delayed
BRR) in 11 US centres17,60. The MROC cohort data were
excluded from this systematic review based on its reporting
of group-related summative data for all types of autologous
reconstruction, as opposed to individual abdominal donor
sites.
The MROC has reported all surgical complications at
2 years and demonstrated that PMRT (versus no radiother-
apy) was significantly associated with a greater risk of devel-
oping any complication (OR 1⋅50 (95 per cent c.i. 1⋅20
to 1⋅86); P < 0⋅001), reoperative complications (OR 1⋅52
(1⋅17 to 1⋅97); P < 0⋅002) and wound infection (OR 2⋅77
(1⋅78 to 4⋅31); P < 0⋅001)16. Autologous BRR was done
more commonly in irradiated than non-irradiated patients
(38 versus 25 per cent respectively; P < 0⋅001), with simi-
larly low rates (1–2⋅4 per cent) of reconstruction failure at
2 years17.
Eligible studies in the present systematic review were sig-
nificantly underpowered in comparison with the MROC
study, which evaluated irradiated autologous BRR at 1 year
(236 patients) and 2 years (199), and non-irradiated pro-
cedures at 1 year (1625) and 2 years (332). The MROC
data showed no differences between radiotherapy and no
radiotherapy groups in the rates of total complications
(25⋅6 versus 28⋅3 per cent respectively), major compli-
cations (17⋅6 versus 22⋅9 per cent) or flap failure (1⋅0
versus 2⋅4 per cent) at 2 years after immediate autologous
reconstruction17. Studies in the present review showed
significantly lower rates of major complications after
radiotherapy compared with the MROC results, suggesting
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suboptimal overall reporting of surgical complications in
the reviewed studies24.
The retrospective grading of surgical complications in
the two moderate-quality studies reported showed a rate
of major complications (CDC grade IIIb) of 9 per cent
(6 of 64) at 1 year, and 4⋅6 per cent (5 of 108) at 2 years60,62.
These rates are also likely to reflect under-reporting com-
pared with the MROC rates of 14⋅8 per cent (35 of 236)
at 1 year and 17⋅6 per cent (35 of 199) at 2 years17. Despite
its strengths, the MROC cohort is based on the review of
complications from electronic patient records, potentially
also underestimating true complication rates17.
One way to measure what matters to patients is to use
patient-reported outcome measures (PROMs) to assess the
effects of disease or treatment on symptoms, function-
ing and health-related QOL34. In this systematic review,
PROMs were poorly reported and underpowered for over-
all small effect sizes of individual QOL domains43. Pre-
liminary conclusions regarding statistical significance were
not substantiated by adequate patient numbers, lack of
a comparator group or prospectively defined time points
for questionnaire collection58. Standardized and objective
evaluations of cosmetic outcome have also remained elu-
sive with emerging adoption of newer technologies such
as the Vectra® XT58. Robust study designs evaluating
these innovations should be accompanied by surgery- and
disease-specific questionnaires34.
Clear recommendations for the optimal timing of radio-
therapy in relation to autologous BRR will remain elu-
sive until information from high-quality systematic reviews
forms part of shared preoperative decision-making73.
Adequately powered prospective studies and ongoing
audits, to allow comparisons of postoperative radiotherapy
with neoadjuvant radiotherapy, are warranted. Current evi-
dence for irradiating autologous abdominal flaps remains
weak, involving only two moderate-quality studies of the
12 included in this report. Future cohort studies should be
designed and powered to take advantage of newly evolv-
ing study designs, such as multiple-cohort RCTs or trials
within cohorts74. These designs permit collection of big
data within registry or cohort platforms, and allow mul-
tiple synchronous randomized trials to be conducted in a
cost-effective manner74.
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ABSTRACT
Objectives: Effective communication is critical to the safe delivery of care but is characterized by outdated tech-
nologies. Mobile technology has the potential to transform communication and teamwork but the evidence is
currently uncertain. The objective of this systematic review was to summarize the quality and breadth of evi-
dence for the impact of mobile technologies on communication and teamwork in hospitals.
Materials and Methods: Electronic databases (MEDLINE, PsycINFO, EMBASE, CINAHL Plus, HMIC, Cochrane
Library, and National Institute of Health Research Health Technology Assessment) were searched for English
language publications reporting communication- or teamwork-related outcomes from mobile technologies in
the hospital setting between 2007 and 2017.
Results: We identified 38 publications originating from 30 studies. Only 11% were of high quality and none met
best practice guidelines for mobile-technology-based trials. The studies reported a heterogenous range of quan-
titative, qualitative, and mixed-methods outcomes. There is a lack of high-quality evidence, but nonetheless mo-
bile technology can lead to improvements in workflow, strengthen the quality and efficiency of communication,
and enhance accessibility and interteam relationships.
Discussion: This review describes the potential benefits that mobile technology can deliver and that mobile
technology is ubiquitous among healthcare professionals. Crucially, it highlights the paucity of high-quality evi-
dence for its effectiveness and identifies common barriers to widespread uptake. Limitations include the limited
number of participants and a wide variability in methods and reported outcomes.
Conclusion: Evidence suggests that mobile technology has the potential to significantly improve communica-
tion and teamwork in hospital provided key organizational, technological, and security challenges are tackled
and better evidence delivered.
Key words: medical informatics, communication, hospitals, smartphone
INTRODUCTION
Effective communication between healthcare professionals within hos-
pitals is critical to the safe delivery of care but is frequently character-
ized by a reliance on outdated technologies. The delivery of high-
quality care inherently relies on effective communication and the
inaccurate, incomplete, or delayed transfer of information can result
in avoidable errors and patient harm.1–4 Failures in communication
occur twice as often as those due to inadequate skill or knowledge5
and contribute to more than half of all patient safety events.3,6
Interprofessional teamwork within hospitals is complex and
around the world typically relies on a mix of technologies and
VC The Author(s) 2019. Published by Oxford University Press on behalf of the American Medical Informatics Association.
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approaches including 1-way pagers, fixed telephones, face-to-face
conversations, and newer technologies such as e-mail and
smartphone messaging. Numerous problems have been highlighted
with traditional pagers such as the fragmentation and burden of
communication,7,8 interruptive communication behaviors,9–11 and
limitations with 1-way data transfer and the supply of supporting
contextual information,12,13 all of which may contribute to harmful
failures of care for patients.14–16 These failings not only harm
patients, but also lead to significant financial costs for healthcare
providers.17
Outside of healthcare, there has been a technological revolution
in handheld communication devices spawning new ways to effec-
tively and reliably communicate, collaborate, and share informa-
tion. The requirements for immediacy and accuracy of
communication within healthcare, together with the potentially
harmful consequences of communication failure, mean that emer-
gent communication technologies must be studied robustly. Any
change to clinical practice as a result of the deployment of new tech-
nology must be based on evidence and not on transient technology
trends or individual preference. Despite this, hospital communica-
tion systems receive much less attention than other areas of health-
care innovation, and there is little robust empirical evidence on
which to assess the relative advantages and disadvantages of new
technologies.18 There is a careful trade-off to be made between new
technologies that lead to increased complexity and cognitive over-
load and those that deliver meaningful improvements in communi-
cation, teamwork, and patent safety.19 The aim of this review was
therefore to evaluate the current quality and breadth of evidence for
the impact of mobile technologies on communication and teamwork
within hospitals.
MATERIALS AND METHODS
This review was conducted in accordance with best practice princi-
ples as outlined in the PRISMA Statement.20 The review protocol
was prospectively registered with the PROSPERO Database as per
best practice guidelines (CRD42017064128).21
Search strategy and study selection
In consultation with expert medical librarians at Imperial College
London, MEDLINE, PsycINFO, EMBASE, CINAHL Plus, HMIC,
the Cochrane Library, and National Institute of Health Research
Health Technology Assessment Database were searched for relevant
literature published in English online or in print between January 1,
2007, and January 1, 2017. The search strategy encompassed 3
broad categories: mobile technology teamwork and communication,
and the hospital setting. The search terms and strategy employed for
each respective database are summarized in Supplementary Appen-
dix Table 1 and prespecified inclusion and exclusion criteria in Sup-
plementary Appendix Table 2. This review focuses on the impact of
mobile technology on communication and teamwork within real-life
hospital settings. For the purposes of this review, mobile technology
was defined as hand-held devices (mobiles, smartphones, tablets, or
bespoke mobile devices) that facilitate 2-way communication or
data transfer and which directly impact patient care. All studies
evaluating the impact of mobile technologies were included, even if
the intervention studied did not form part of the study protocol (eg,
questionnaire studies reporting the impact of mobile technology at
work in general). There were otherwise no restrictions on study de-
sign, intervention, or sample size, and both qualitative and quantita-
tive studies were included.
Two reviewers (GM, AK) independently reviewed all titles and
abstracts for eligibility against the specified inclusion and exclusion
criteria with only those papers considered relevant advanced to full
text review. Cohen’s kappa agreement was calculated for each stage
of screening and review with disagreements resolved through con-
sensus. The PRISMA Diagram for study inclusion is outlined in
Figure 1.
Data extraction and quality assessment
For each study, relevant data on study design, population, interven-
tion, comparators, outcomes, and setting were extracted. A second
independent investigator reviewed this data for quality and accuracy
before analysis. A quality and risk-of-bias assessment was performed
for all studies according to the appropriate National Institutes of
Health Quality Assessment Tool22 with findings confirmed by con-
sensus. A further quality assessment of each interventional study
was performed by assessing compliance to the mobile health
(mHealth) evidence reporting and assessment (mERA) checklist.23
The mERA checklist was compiled by the World Health Organiza-
tion mHealth Technical Evidence Review Group and identifies a
minimum set of information that is needed to define the content,
context, and technical features of an mHealth intervention and stan-
dardize the quality of evidence reporting, essentially a CONSORT24
or PRISMA20 statement for mobile technology–based interventions.
Data synthesis and analysis
The data for each study were summarized and are presented in Ta-
ble 1 together with the quality assessment outcome. Studies deemed
to be of poor quality are typically excluded for the purposes of anal-
ysis; however, as they formed a large number of the identified stud-
ies in this instance, they were retained. For the purposes of the
analysis, studies were grouped into 6 categories: quantitative inter-
ventional studies, qualitative interventional studies, mixed-methods
interventional studies, quantitative noninterventional studies,
qualitative noninterventional studies, and mixed-methods noninter-
ventional studies.
RESULTS
A total of 8 072 studies were initially identified, and following re-
moval of duplicates a total of 5 683 eligible papers remained for
screening and review. From this, we identified 38 publications from
30 unique studies as outlined in Figure 1. Included studies originated
from a broad range of countries: 15 from Canada; 4 each from the
United States and United Kingdom; 2 each from Singapore, Saudi
Arabia and New Zealand; and a single paper arising from each of
Germany, Turkey, India, Australia, Israel, Malaysia, Taiwan, Swe-
den, and South Korea. Inter-rater agreement for inclusion and exclu-
sion of papers was “very good” throughout, with a Cohen’s kappa
of 0.842-0.980 reported at each stage. Of note, 9 publications
reported data related to the same study investigating the introduc-
tion of smartphones and web-based messaging across a small num-
ber teams within a single institution.35,36,38,43,45,46,58,61,62 Table 1
summarizes the recorded data for each study. Quality assessments
for all studies are summarized together with mERA Checklist com-
pliance for the 22 interventional studies in Table 2.
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Table 1. Included studies with data for each by study design, comparator group, setting, intervention, findings, compliance with the mERA
checklist, and quality assessment
Study Study Design Setting and Intervention
Key Findings (communication/
teamwork)
Quality
Assessment22
mERA
Assessment23
Interventional Studies—Quantitative Outcomes
Daruwalla et al
201425
Prospective observa-
tional cohort study
Orthopaedic surgical team
(25 participants)—Singa-
pore
MyDoc—HIPAA-compliant
mobile application with
messaging, case discussion,
patient details and photo
sharing functionality
- 23 of 25 (92%) agreed it should
replace current communication
methods
- 23 of 25 (92%) agreed they
could communicate easily using
the application
- 22 of 25 (88%) agreed that the
potential for telerounding via
the application may have
advantages (eg, out-of-hours)
Poor 6/16
Duhm et al 201626 Controlled prospec-
tive crossover study
University Hospital
(14 participants)—
Germany
iPad with mobile eHR
- Application led to improve-
ments in discussing clinical evi-
dence with colleagues and
streamlined clinical workflows
Fair 6/16
Gulacti et al 201627 Retrospective obser-
vational cohort
study
Tertiary hospital emergency
department (628 consulta-
tions)—Turkey
WhatsApp Messenger
- Message content: 510 images,
517 text messages, 59 videos,
10 voice messages across 519
patients
- Median arrival time 3.94 min
and response time 2.83 min
- As a result of messaging 59.9%
led to discharge of patient with-
out a face-to-face specialty con-
sultation and 71.6% out-of-
hours consultations
Fair 5/16
Khanna et al
201528
Pre/postobservational
cohort study
Tertiary orthopaedic depart-
ment (8 junior doctors, 25
consecutive patients pre/
post intervention)—India
Issued smartphone with
WhatsApp messenger
- 100% felt WhatsApp improved
the efficiency of handover and
patient care
- Use of WhatsApp led to signifi-
cant improvement in quality of
information transfer and recall
Poor 7/16
Lane et al 201229 Pre/postobservational
cohort study
University hospital (40 par-
ticipants)—United States
VigiVU—integrated mobile
situational awareness appli-
cation with monitoring,
text and voice communica-
tion and access to eHR
functionality
- Use of the application increased
speed of communication com-
pared with pagers (latency 18 s
vs 22 s)
Poor 11/16
Motulsky et al
201730
Prospective cross-
sectional mixed-
methods study
University hospital (124 par-
ticipants)—Canada
FLOW—in-house mobile ap-
plication allowing free-text
communication of 200
characters within eHR
accessed through personal
smartphones
- Number of “flows” created
mean 26 per day, 8 per patient
per day
- Majority prefer to access infor-
mation and communicate
through a smartphone
- Majority think application
improves handover and patient
care
Fair 6/16
Ng et al 200731 Prospective observa-
tional cohort study
Neurosurgical team in Uni-
versity hospital (12 partici-
pants)—Singapore
Issued smartphone with mul-
timedia messaging and pic-
ture capability
- Senior doctor perspectives: fre-
quently used, improved confi-
dence and decision making,
improved interteam communi-
cation, and reduced need for
call-back
- Junior doctor perspective: fre-
quently used, facilitated in-
creased involvement of senior
decision making from home
Poor 3/16
(continued)
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Table 1. continued
Study Study Design Setting and Intervention
Key Findings (communication/
teamwork)
Quality
Assessment22
mERA
Assessment23
Patel et al 201632 Pre/postobservational
cohort study
4x clinical teams in large Uni-
versity hospital (229 multi-
professional participant’s
preintervention, 210 partic-
ipants’ postintervention)—
United States
Cureatr—HIPAA compliant
smartphone application
with encrypted messaging
and other applications
accessed through personal
and issued devices
- 708 456 messages across
130 073 patient threads
- Junior doctors and nurses the
largest senders: 5 (range, 2-12)
and 6 (range, 2-13) per day
- Messages sent by doctors
shorter (28 vs 41; P < .001)
- >50% of messages sent read in
<1 min
- All staff found the application
to cause significantly less dis-
ruption to workflows than pag-
ers, with more responsive
physicians and better transfer
of information
Fair 10/16
Power et al 201433 Prospective observa-
tional cohort study
Pharmacy team in hospital
setting (90 participants)—
Canada
Issued iPhone with multiple
generic functionalities
- Principle use as a communica-
tion device
- 98% found it useful, 87% im-
proved performance, 68% im-
proved efficiency,
- Positive impact: accessibility,
rapid communication, easier
management of email and
calendar
- Negative comments: small
screen size, connectivity
Fair 5/16
Przybylo et al
201434
Controlled prospec-
tive cluster-ran-
domized study
5 general medicine teams at a
University hospital (26 con-
trol and 49 intervention
participants)—United
States
Medigram—HIPAA compli-
ant group messaging appli-
cation accessed through
institutional or personal
smartphones
- Ineffective aspects of pagers:
time wasted for responses,
1-way nature of communica-
tion, needing to find a
computer/phone
- Effective features of pagers:
reliability, ease of use,
responsiveness, brevity
- At baseline majority (90.5%)
already use text messaging
- Compared with paging smart-
phones significantly more
effective, allow clearer more ef-
ficient communication, and in-
tegrate better into workflow
- Satisfaction with smartphone
higher. 85% would recommend
its use
Good 10/16
Smith et al 201235 Prospective observa-
tional cohort study
4 medical teams in 2 large
hospitals (34 participants—
analysis of 13 717 e-
mails)—Canada
Issued team and individual
Blackberry smartphones
with messaging/email func-
tionality
- 7 784 structured and 5 933 un-
structured messages
- Median response time 2.3 min,
50% did not get a response
- 28.1% of emails requested an
inappropriate response given
content
Poor 3/16
Vaisman and Wu
201736
Retrospective obser-
vational cohort
study
8 clinical teams across 2 large
academic hospitals (21 doc-
tor participants over 18
months)—Canada
Institutional smartphones
with secure voice calls, mes-
saging and e-mail function-
ality
- 187 049 interruptions identified
- Peak of interruptions at 11 am
to 12 pm and 2-3 pm
- Average daily interruptions
42.3-51.4 per day per team
- Crisis mode experienced 2.3 per
day per team with a mean du-
ration of 35.1 min
Fair 4/16
(continued)
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Table 1. continued
Study Study Design Setting and Intervention
Key Findings (communication/
teamwork)
Quality
Assessment22
mERA
Assessment23
Wani et al 201337 Prospective observa-
tional cohort study
Plastic surgery department in
academic hospital (116
communication events)—
Saudi Arabia
Institutional smartphone
with WhatsApp
- Overall positive response to the
efficacy of using WhatsApp as
a means of communication
- Led to elimination of redundant
steps in vertical reporting
within teams
Poor 6/16
Wu et al 201538 Prospective observa-
tional cohort study
5 general medicine teams in 2
large academic hospitals
(60 969 messages, 165 mul-
tiprofessional partici-
pants)—Canada
Clinical Message—bespoke
application with secure
messaging and handover
tools accessed through in-
stitutional smartphone
- On average, 14.8 messages per
day per team with median re-
sponse time 2.3 min
- 76.5% requested a text reply,
7.7% a call back, and 15.7%
no response
- Majority of staff felt system im-
proved care and speed of work,
accountability, timeliness of
communication, and interpro-
fessional relationships
- Not seen as effective for com-
municating complex issues
- Doctors felt frequently inter-
rupted with low-value informa-
tion, nurses conversely perceived
a lack of desired response
Fair 6/16
Interventional Studies—Qualitative Outcomes
Farrell 201639 Retrospective cross-
sectional interview
study
Gynaecology ward (20 par-
ticipants)—Australia
iPhone with relevant generic
medical applications (eg,
MIMS drug information,
MedCalc, Medscape)
- Overall positive impact on
interprofessional interactions
and communication
- Primary use for interprofes-
sional communication
- Negative aspects: screen size,
battery life, connectivity unpro-
fessional to use at bedside
Poor 6/16
Lo et al 201240 Retrospective cross-
sectional question-
naire study
General internal medicine
teams (31 participants) in
teaching hospital—Canada
Individual and team Black-
berry smartphones with
web-paging/email
functionality
- Positive impact of smartphones:
value in delivery of nonurgent
information, aid in triage and
prioritization, improvement in
efficiency of communication
and access to clinical staff, im-
proved timeliness of replies
compared with pagers
- Negative impact of smart-
phones: conflict between nurses
and doctors about correct com-
munication method and subjec-
tive decision on urgency/
priority, accessibility leads to
increase in unnecessary com-
munication, residents find in-
creased calls disruptive
Fair 4/16
Interventional Studies—Mixed Methods Outcomes
Johnston et al
201541
Prospective mixed-
methods cohort
study
Acute general surgery team in
a teaching hospital (40 par-
ticipants, 1140 hours of
clinical communication
with 1495 communication
events)—United Kingdom
WhatsApp messenger
- Median number of communica-
tion events within team 65.5
per week.
- Message content: 39.3% com-
munication events, 35.6% in-
formation giving, 60.5%
administration
- Juniors like the ability to send
messages rather than voice
calls, seniors like additional su-
pervision; universal agreement
that it led to the removal of
communication barriers
Fair 8/16
(continued)
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Table 1. continued
Study Study Design Setting and Intervention
Key Findings (communication/
teamwork)
Quality
Assessment22
mERA
Assessment23
O’Connor et al
200942
Prospective mixed-
methods cohort
study
Intensive Care Unit in com-
munity hospital (106 multi-
professional participants)—
Canada
Institutional Blackberry with
messaging/e-mail function-
ality
- Staff sent a mean 5.2 messages
and received 8.9 per day
- Positive perceptions—usability,
impact on communication,
team relationships and patient
care, fast and reliable, im-
proved doctor response times,
improved coordination and job
satisfaction
- Negative experiences reported:
impact on quality of communi-
cation, reduced face-to-face
communication, and inappro-
priate use of devices for per-
sonal reasons
- 87% wanted to continue using
the devices
Good 8/16
Quan et al 201343 Pre-/post observa-
tional cohort study
Four general internal medi-
cine teams in academic hos-
pital (17 multiprofessional
participants—5 doctors,
8 nurses, 2 pharmacists,
2 social workers)—Canada
Institutional Blackberry with
email/messaging
functionality
- Increase is number of messages
710 vs 2 196
- 233% increase in interruptions
to clinical tasks
- Increased interruptions due to
elimination of traditional bar-
riers (eg, waiting for phone),
ease of access and impersonal
nature of communication
- Increased messaging from
nurses due to push for account-
ability and reassurance, doctors
saw this as nurses absolving
themselves of responsibility
- Nurses found to often exagger-
ate severity or urgency of issues
to illicit a response, particularly
at the end of a shift
Poor 5/16
Webb et al 201644 Pre-/Post observa-
tional cohort study
2 academic hospitals and a
satellite community hospi-
tal (104 multiprofessional
iPhone users with 49 web
console users)—Canada
Vocera Collaboration Suite—
smartphone enabled appli-
cation with call alerting,
chat, voice calls
- Significant reduction in re-
sponse times (5.5 min vs 3 min;
P ¼ .027)
- 85% of staff used mobile for
day-to-day communication
- 35% of staff used mobile for
communication with patients
- 81% of doctors positive about
system
- Positive aspects of system: re-
duction in interruptions, ability
to answer in own time, ability
to send additional information,
receipt confirmation, conve-
nience
- Negative aspects of system: bat-
tery life, having to enter pass-
word every time, balance
between interruptions and
missing messages when on do
not disturb
Fair 6/16
(continued)
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Table 1. continued
Study Study Design Setting and Intervention
Key Findings (communication/
teamwork)
Quality
Assessment22
mERA
Assessment23
Wu et al 201145 Prospective observa-
tional cohort study
General medicine teams in
multiple academic hospitals
(16 months data collec-
tion)—Canada
Institutional Blackberry with
email/messaging
functionality
- Analysis of 13 717calls and
12 936 emails
- Efficiency: smartphones lead to
faster response times and in-
creased accessibility, and in-
crease multidisciplinary
communication
- Interruptions: smartphones lead
to increase in interruptions
through overall increase in
number of calls/messages
- Interprofessional relationships:
nurses think smartphones re-
duce face-to-face interactions
which are valued; conversely,
doctors felt there were no nega-
tive implications for team
working
- Professionalism: using phones
during clinical activities seen to
be unprofessional with negative
perceptions from patients
Fair 5/16
Wu et al 201346 Prospective observa-
tional cohort study
General medicine teams in
multiple academic hospitals
(16 months data
collection)—Canada
Institutional Blackberry with
email/messaging
functionality
- Impact on senders: frustrations
with pagers (lack of response,
wait for call back, no ability to
identify caller, often need to re-
page, lack of acknowledgement
of receipt); benefits of smart-
phones (quicker resolution, no
need to wait by phone, can
page and continue to work, ac-
knowledgement of receipt and
ability to convey urgency)
- Impact on receiver: ability to
defer, smartphones facilitate
triage and prioritization and
make it easier to reply; pagers
hugely disruptive due to need
to find phone, smartphones dis-
ruptive due to increased mes-
sage/call load; direct voice calls
very disruptive
Fair 5/16
Noninterventional Studies—Quantitative Outcomes
Avidan et al 201747 Cross-sectional obser-
vational study
Operating theaters (7 207
min of observation across
52 surgical procedures)—
Israel
No intervention—impact of
mobile phones on
interruptions
- 100% of procedures interrupted
by phone calls
- Median 3 calls/procedure (inter-
quartile range, 2-5 calls)
- 0% of incoming calls related to
patient undergoing the proce-
dure
- 14.7% of calls led to a stoppage
of care (mean duration 43.6 s)
Fair
Ganasegeran et al
201748
Cross-sectional ques-
tionnaire study
General/Emergency Medicine
(307 multiprofessional par-
ticipants)—Malaysia
No specific intervention—
benefits of WhatsApp
- 68.4% perceived WhatsApp to
be useful adjunct to clinical
practice
- 5.6 hours/day on WhatsApp
during clinical practice
- Common reasons for use: clini-
cal questions, information
transfer, instruction giving, pa-
tient administration
Fair
(continued)
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Table 1. continued
Study Study Design Setting and Intervention
Key Findings (communication/
teamwork)
Quality
Assessment22
mERA
Assessment23
- Those clinicians who have been
using WhatsApp for longer and
more frequently report greater
perceived benefit from its use
Jamal et al 201649 Cross-sectional ques-
tionnaire study
17 specialties across 2 large
academic teaching hospitals
(101 doctor participants)—
Saudi Arabia
No specific intervention—
prevalence and perceptions
of mobile phone use
- 99% of staff mobile phone
users
- Work-related use: 65.3% text
applications and 64.4% voice
calls
- 98% agree integrating smart-
phones with hospital systems is
a good idea, and 89% say
mobiles useful for staff commu-
nication
- 79% support replacing existing
pagers with hospital-provided
mobiles
- Key issues highlighted: short
battery life, distractions caused
by mobiles, confidentially and
security
Fair
Martin et al 201650 Cross-sectional ques-
tionnaire study
Hospital doctors (206 doctor
participants)—United King-
dom
No specific intervention—
prevalence and perceptions
of mobile phone use
- 92% use their personal mobile
for work and switchboard
holds personal numbers for
64%
- 77% discuss patient matters
and 12% have sent a photo
with PID
- 32% contacted on a weekly ba-
sis, 21% on a daily basis when
not at work
- 73% feel pagers should be
replaced with mobiles
Poor
Menzies at al
201251
Cross-sectional ques-
tionnaire study
Hospital doctors (850
doctor participants)—
New Zealand
No specific intervention—
prevalence and perceptions
of mobile phone use
- 51% of participants use smart-
phones for work
- 26% stored patient data, of
which 31% were not password
protected
- Principal uses: emails/communi-
cation, informatics, sharing
images
- Issues with mobiles: cost, lack
of institutional integration, bat-
tery life, screen size, user inter-
face, dependency, lack of
support, security concerns
Poor
Mobasheri et al
201552
Cross-sectional ques-
tionnaire study
Large academic hospital (718
participants—249 doctors
and 469 nurses)—United
Kingdom
No specific intervention—
prevalence and perceptions
of mobile phone use
- 98.9% of doctors and 95.1% of
nurses own a smartphone
- 92.6% of doctors and 53.2% of
nurses use a mobile for daily
clinical practice
- 93.8% of doctors and 28.5% of
nurses communicate at work
with smartphones, and 50.2%
use a smartphone in place of is-
sue pager
- 27.5% of doctors and 3.6% of
nurses have PID on their
phones
- 71.6% want a secure messaging
platform for identifiable data
Fair
(continued)
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Table 1. continued
Study Study Design Setting and Intervention
Key Findings (communication/
teamwork)
Quality
Assessment22
mERA
Assessment23
O’Connor et al
201453
Cross-sectional ques-
tionnaire study
Junior doctors in national
training network (108 par-
ticipants)—Canada
No specific intervention—
prevalence and perceptions
of smartphone use
- 94.4% own a smartphone
(67% iPhone, 27% Android)
- 83.3% use their smartphone for
work-related calls, 87.2% for
text messaging, 41.2% for
emails, and 52.9% for pictures
Fair
Prochaska et al
201554
Cross-sectional ques-
tionnaire study
Two academic hospitals (132
doctor participants)—
United States
No specific intervention—
prevalence and perceptions
of mobile phone use
- 71.7% prefer text messaging to
pagers/landlines, with 79.8%
using it as their preferred
method of communication
- 82.5% though existing pagers
better for security, but despite
this 70.9% have received iden-
tifiable data on their mobile
Poor
Wyber et al 201355 Cross-sectional ques-
tionnaire study
Large academic hospital (208
doctors)—New Zealand
No specific intervention—
prevalence and perceptions
of mobile phone use
- 95.7% carried mobile phones at
work
- Content of messages: clinical
management (61%), logistics
(55%), social arrangements
(42%), results (34%)
- Rationale for using mobiles at
work: more convenient, less in-
trusive, less reliable, more effi-
cient, less intimidating
- Barriers: cost, ambiguity of
communication, reliability, pa-
tient confidentiality, impolite/
unsocial, slowness, unsure of
others use
Fair
Noninterventional Studies—Qualitative Outcomes
Hsiao and Chen
201256
Cross-sectional ques-
tionnaire study
Hospital-based nursing staff
(219 participants)—Taiwan
No specific intervention—
benefits of mNIS
- mNIS systems promote infor-
mation identification, integra-
tion and interpretation
- mNIS has a significant positive
impact on message exchanges
between healthcare professio-
nals, facilitates communication
with patients and improves
overall performance and qual-
ity
Good
Scholl and Groth
201257
Cross-sectional ethno-
graphic study
Department of surgery in aca-
demic hospital (25 partici-
pants, 360 h of data
collection)—Sweden
No specific intervention—
ethnographic study of mo-
bile phone use
- Advantages of mobiles over
pagers: ease of contact, displays
who is calling, no need to find
phone for call back, reduced
delays in answering
- Disadvantages of mobiles: prob-
lematic contexts (busy environ-
ments, large number of devices,
lack of usage policy), nonpro-
fessional image in using in front
of patients, interruption of
work/life balance with inter-
ruptions and ease of contact
when not at work
- Design for ripple effect: im-
prove awareness that mobiles
may impact those not directly
involved in the communication
(eg, nurses in operating theater)
Good
(continued)
Journal of the American Medical Informatics Association, 2019, Vol. 0, No. 0 9
D
ow
nloaded from
 https://academ
ic.oup.com
/jam
ia/advance-article-abstract/doi/10.1093/jam
ia/ocy175/5301725 by D
upre Library Serials D
ept user on 26 January 2019
Table 1. continued
Study Study Design Setting and Intervention
Key Findings (communication/
teamwork)
Quality
Assessment22
mERA
Assessment23
Wu et al 201458 Cross-sectional ethno-
graphic study
General medicine wards in 5
hospitals with text-based
mobile messaging systems
(108 interviews, 260 h of
observation)—Canada
No specific intervention—
ethnographic study of text-
based mobile messaging
systems
- Decontextualization and deper-
sonalization of communication
highlighted
- Mobile-based systems lead to
increasing communication
workload and asynchronous
communication
- Depersonalization of communi-
cation is a barrier to effective
interprofessional teamwork
through reduction in nonverbal
Fair
Noninterventional Studies—Mixed Methods Outcomes
Moon and Chang
201459
Cross-sectional ques-
tionnaire study
Academic hospital (122 mul-
tiprofessional partici-
pants)—South Korea
No specific intervention—
prevalence and perceptions
of mobile phone use
- 56.5% use hospital-issued
smartphones
- 51.4% receive regular work-re-
lated calls, 37.5% messages
- Attitude toward smartphones
influenced by cost, quality, ease
of use, support, and security
Fair
Moore and Jaye-
wardene 201460
Cross-sectional ques-
tionnaire study
161 hospital organizations
(416 participants—82
nurses, 334 doctors)—
United Kingdom
No specific intervention—
prevalence and perceptions
of mobile phone use
- 81% of doctors and 58% of
nurses use their smartphones
for work
- Perceptions of smartphones:
easy to use, improve safety,
useful, save time
- Smartphones improve commu-
nication, access to information,
efficiency, and decision making
- Minority perform a risk assess-
ment before using a phone (eg,
for storing using identifiable
data)
Poor
Tran et al 201461 Cross-sectional
mixed-methods
study
General medicine teams in 4
academic hospitals—
Canada
No specific intervention—
mixed-methods study of
mobile phone use
- 59% of respondents carry per-
sonal smartphones and use
them as their primary method
of communication
- Acknowledgment of risk to se-
curity and confidentiality of in-
formation, but respondents
favor efficiency and mobility
over security
- Minority of users observed using
personal smartphones at work
Poor
Wu et al 201362 Cross-sectional ethno-
graphic study
General medicine teams in 5
academic hospitals—
Canada
No specific intervention—
mixed-methods study of
mobile phone use
- Pagers are frustrating, slower
and deliver less context to the
message than smartphones;
lack of response to pagers the
major frustration
- Smartphones make it easier to
receive and respond to calls,
and coordinate teams, but still
highly disruptive; direct calls to
phones are very disruptive Im-
pact on privacy and security ac-
knowledged
– The use of hospital issued smart-
phones influences the adoption
of informal communication (eg,
adding 911 to bleeps). Informal
communication methods can
cause confusion
Fair
eHR: electronic health record; MIMS: Monthly Index of Medical Specialties; mNIS: mobile nursing information system.
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Interventional studies
Description of studies
Twenty-two interventional studies—those with a specific technology
deployed for the purpose of evaluation—were identified. Of these
14 reported quantitative outcomes,25–38 2 were qualitative out-
comes39,40 and a further 6 were mixed-methods outcomes.41,43–46
Overall, the interventional study designs adopted were heteroge-
neous, with only 1 study involving any form of randomization,34
and a further single study employing a crossover study design26; all
other studies otherwise took the form of uncontrolled cohort stud-
ies. The populations studied were varied, but importantly were of
limited size, with the mean number of participants being only 63
(range, 8-210). Seventeen discrete interventions were available for
comparison; 8 bespoke mobile applications,25,26,29,30,32,34,38,44
4 WhatsApp messenger (WhatsApp Inc, Menlo Park, CA) serv-
ices,27,28,37,41 3 generic smartphones,31,33,39 and the remaining 2
interventions involved smartphones with a specific messaging or
email communication functionality that were reported across multi-
ple studies.35,36,40,43,45,46 The 14 studies reporting quantitative
results utilized a range of methodologies with all but 229,36 using
questionnaires, and 7 using content analysis of mobile phone
data.27,30,32,35–38 Two studies used direct observational data, with
one assessing the time taken to complete handover28 and the other
the speed and latency of communication.29 Two further studies
reported qualitative outcomes, with one using semistructured inter-
views and focus groups39 and the other using an exploratory case
study approach.40 Six studies adopted a mixed-methods approach,
with all including content analysis of messages sent or received
Figure 1. PRISMA Diagram of study identification, screening, and inclusion.
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during the study period, 4 including additional structured inter-
views,41,43,45,46 2 including questionnaires,42,44 and 2 including
more direct observation.45,46 Overall, the quality of studies as
judged through compliance with the mERA Checklist23 was poor,
with a mean score of 6.1 of 16 (range, 3-11), and no study was fully
compliant. The studies assessed a variety of mobile interventions
with a range of cross-cutting themes being evident: improvements in
workflow, efficiency, and the quality of communication; improve-
ments in accessibility and interteam relationships; and the near uni-
versal acceptance that mobile devices should replace current
methods of communication despite some key limitations being iden-
tified.
Workflow, efficiency and quality of communication
Broadly speaking, the introduction of mobile devices led to improve-
ments in workflow, efficiency, and the quality of communication. A
number of papers reported significant streamlining of clinical work-
flows and improvements in the quality of clinical discussion,26,34
improvements in handover and patient care,30 faster response
times,33,45 and the elimination of redundant steps in vertical com-
munication within teams.37 Significant improvements in the effec-
tiveness of communication with greater efficiency and integration
into existing workflows34 and improvements in the quality of infor-
mation transfer and recall28 were also demonstrated. A further study
reported that smartphones created additional value by facilitating
the easy delivery of nonurgent information while also supporting the
triage, prioritization, and timeliness of communication.40 Some
studies looked to quantify these improvements in efficiency and
timeliness with a mean response time of 2-3 minutes with mobile
devices,27,38,41 and 1 study reported that >50% of email messages
sent by smartphone were read in <1 minute.32 Meanwhile, the use
of mobile applications led to significantly less disruption to clinical
workflows,32 improvements in the speed of communication,29 and
significant reductions in response times, from 5.5 to 3 minutes.44
Accessibility and interteam relationships
In addition to improved efficiency and quality of communication
the use of mobile devices also had a positive impact on accessibility,
interprofessional interactions, and the involvement of senior deci-
sion makers in clinical care.31,32,39 Many of the positive impacts of
better communication on team relationships were highlighted in the
previous section; however, improved accessibility and ease of com-
munication can also be highly interruptive. One study identified an
average of 42-51 interruptions per day and 35 minutes a day where
the level of interruptions reached a potentially dangerous level.36
Other studies identified that doctors frequently felt that they were
regularly interrupted with low-value and unnecessary information38
and that they were often overwhelmed by the volume of interrup-
tions caused by their mobile device.45 A further study identified that
the introduction of mobile devices led to a large increase in the num-
ber of messages sent and a subsequent 233% increase in interrup-
tions.43 This increased communication burden may account for the
50% of messages that do not get a response.35 Increases in the com-
munication burden may also lead to the depersonalization of the
clinical team. Nurses reported feeling that mobiles negatively impact
interprofessional relationships via a reduction in the face-to-face
interactions that they value in helping to build relationships; con-
versely, doctors felt this was a positive change.45 One study reported
that doctors felt the frequent interruptions they received were often
inappropriate given the content and context,38 and another found
interprofessional conflict due to the different subjective assessment
of the urgency and priority of messages.40 A further study reported
that increased messaging by nurses to seek accountability and reas-
surance was perceived as an attempt to absolve themselves of re-
sponsibility by doctors who felt that nurses often exaggerated the
severity or urgency of a issues to illicit a response.43
Limitations and professionals’ views of mobile technology
In addition to the many positive influences reported, there were also
some negative consequences of mobile devices identified. The physi-
cal limitations of mobile devices was commonly highlighted as a
weakness, with small screen size, poor battery life, the requirement
to enter a password on a regular basis, and unreliable connectivity
all identified as limiting their effectiveness.33,39,44 In addition to
their practical limitations, mobile devices were also reported to be
regarded as less effective than face-to-face or direct communication
for complex patient issues,38 potentially giving an unprofessional
appearance if used at the bedside39 and often used inappropriately
for personal non–work-related reasons.42 Despite these negative
reports, there was universal agreement that the use of mobile devices
acted to remove barriers to effective communication. In one study,
87% of participants wanted to continue using their devices at the
end of the study period,42 while in another the majority of users
stated that they would prefer to access information and communi-
cate through a smartphone.30 A total of 85% of participants recom-
mended the widespread use of mobiles,34 and 92% agreed that
mobile applications should replace traditional pagers and there is
significant potential for the greater integration of mobiles in the hos-
pital setting.25
Noninterventional studies
Description of studies
Sixteen noninterventional studies were identified. Of these 9
reported quantitative outcomes,47–55 3 reported qualitative out-
comes,56–58 and a further 4 reported mixed-methods outcomes.59–62
All 16 studies adopted a cross-sectional study design, with 11
questionnaire-based studies,48–56,59,60 3 ethnographic study
designs,57,58,62 and 1 purely observational study.47 The final study
used a mixed-methods approach combining direct observation,
interviews, and questionnaire data.61 This group of noninterven-
tional studies sampled a larger population with a mean number of
participants of 220 (range, 25-718).
Fifteen of the studies looked to evaluate the prevalence, percep-
tion, or use of mobile technology on communication in hospitals,
with a further study specifically characterizing the impact of mobile
phones on interruptions in the operating theater.47 Key findings
from these studies were consistent; namely, the ubiquitous use of
mobile technology by healthcare professionals, the predominance of
personal devices being used for work-related activity, the clear bene-
fits that mobile-based technologies bring despite well-articulated
negative consequences, the potential risks to patient confidentiality
and security, and the broad support for the formal adoption of mo-
bile technologies by healthcare institutions.
Prevalence of mobile technology in hospitals
Mobile technologies are used on a daily basis by the vast majority of
healthcare professionals. Doctors use their personal devices at work
more frequently than other healthcare professionals do, with up to
95% reporting regular daily use and sharing of their personal num-
ber with other members of staff50,52,55 compared with only around
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50% of nurses.52,60 The messaging and email functionality of mo-
bile devices was consistently highlighted as the principal reason for
their use. One study reported that around 65% of staff use text
applications,49 and another found that up to 88% use messaging or
e-mails,50 and a further study found that 87% of staff use text mes-
saging and a further 41% emails53 while at work. Indeed, 72% of
staff prefer text messaging to traditional pagers, 80% cite it as their
preferred method of communication,54 and 68% believe that What-
sApp is a useful adjunct to clinical practice.48 There were a number
of advantages to be gained with the use of mobile communication
devices, such as the ease of contact, ability to see who is calling, and
reduced delays in answering.57 Another study highlighted the pro-
motion of better information identification, integration, and inter-
pretation and the positive impact of this on overall performance and
quality.56 Further studies found mobile devices to be more conve-
nient, less intrusive, more efficient, and less intimidating than tradi-
tional methods of communication,55 while also helping deliver
better context to messages and facilitating the easy coordination of
teams62 and enhancing access to information and improving deci-
sion-making.60
Negative impact of mobile technology
In addition to the benefits that mobile devices may bring, there were
also a number of negative consequences identified. Studies described
issues with mobile devices including the cost, lack of institutional in-
tegration and support, poor battery life, reliability, and small screen
size.49,51,55 The use of mobile phones was also seen as promoting a
nonprofessional image and appearing rude or impersonal when used
in front of patients.55,57 One study described how the use of mobile
devices depersonalizes and decontextualizes communication and
introduces informal work-arounds compared with direct methods of
communication such as face-to-face interactions or voice calls.58 It
was also observed that mobile devices can lead to unwanted ripple
effects such as disturbing nurses in the operating theater, or by in-
creasing the unwanted contact of doctors when not at work.57 In-
deed, one-third of doctors are contacted on a weekly basis, and over
1 in 5 on a daily basis when not at work.50
Patient confidentiality and data security
Importantly, a number of studies identified the potential risk to se-
curity and confidentiality of patient information with the use of per-
sonal devices.49,51,54,55,59,61 Despite these security concerns, staff
favor efficiency and mobility over security,61 with only a minority
performing any form of security risk assessment60 and one-third of
devices not password protected.51 Crucially, 71% of staff have re-
ceived54 and a further 28% regularly store confidential patient in-
formation on their personal device.52 Despite the potential negative
consequences of mobile devices, the vast majority of studies found
that clinical staff advocate their use and strongly support their wider
deployment. One study reported that the overwhelming majority of
clinical staff think mobile devices and secure messaging platforms
should be integrated with current hospital systems and that existing
pagers should be replaced with hospital-issued mobile
phones.49,50,52
DISCUSSION
Delivering high-quality, safe healthcare is a complex endeavor re-
quiring the careful and precise coordination of numerous professio-
nals in the care of a single patient. This review has found that
overall there is a lack of high-quality evidence evaluating the impact
of mobile technologies on communication and teamwork in hospital
settings. Only 11% of studies were deemed to be of high quality, no
study complied with best practice guidelines for the conduct and
reporting of trials involving mobile technology, and all examined
small populations in restricted environments that do not truly repre-
sent complex real-world settings. Importantly, no studies sought to
examine the impact on meaningful patient outcomes. Despite the
relative lack of evidence, this review supports the assertion that mo-
bile technology has the potential to significantly improve communi-
cation and teamwork within hospitals provided that concerns over
the evolution of negative communication behaviors, technological
flaws, and security and privacy concerns are adequately addressed
and that greater evidence for safety and efficacy is delivered.
Mobile technology is ubiquitous across the world. This review
has shown that these technologies are valued by healthcare staff for
being more convenient and are preferred to existing modes of com-
munication such as traditional pagers. They may act to improve and
streamline clinical workflows and boost the efficiency and quality of
communication. Mobile technology may also act to increase the ac-
cessibility and responsiveness of staff, improve interprofessional
teamwork and relationships, and enhance access to information and
better decision making. The review has also highlighted that that the
negative aspects of mobile technology must be carefully considered.
Clear physical and technological limitations have been identified in-
cluding poor battery life, small screen size, unreliable connectivity,
and the lack of consistent integration with other hospital systems.
Making communication easier may result in a large increase in the
communication burden that could stem from the elimination of tra-
ditional communication barriers such as the need to wait for a
phone, the impersonal nature of message-based communication, and
flattening of hierarchal team structures. This increased communica-
tion burden can lead to potentially harmful disruptions to care, cog-
nitive overload, and conflict. It is crucial to align the content and
purpose of a message against the process and mode of communica-
tion to mitigate against these risks.
One barrier to the adoption of mobile technology is the lack of
high-quality evidence that supports the new investment hospitals
need to make. It is difficult to draw clear conclusions due to method-
ological inadequacies including the lack of prospective randomiza-
tion or assessment of matched comparator groups, the limited
number of participants and truncated study lengths, and an inability
to effectively pool results from multiple studies due to the substan-
tial variability in methodologies and outcomes used. The majority of
studies were based in single centers and the populations evaluated
were small. Twenty-six of the studies included some form of
questionnaire-based data collection yet only 630,42,49,52,56,59 dis-
cussed validity testing of the questionnaires used. While some of
these methodological flaws may be put down to the inherent diffi-
culty of assessing such interventions in complex hospital settings,
few studies clearly set out to try and overcome these challenges in a
meaningful way. Of the 22 interventional studies reviewed, only
226,34 had any form or randomization or prospective assessment of
matched comparator groups, and in the remainder only
528,29,32,43,44 made reference to preintervention baseline data against
which the mobile intervention was compared.
Despite the pervasive use of mobile technology outside of work,
there are a number of diverse organizational, individual, and techno-
logical factors that are likely to impact the adoption of new commu-
nication technologies. The failure to adopt new technologies may be
caused by a failure to plan for the complexity and cost, not gaining
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buy-in and engagement from end users or failing to appreciate that
new technology changes the work, the nature of work, and who
does that work.63 Additional technical, financial, legal, social, and
ethical factors have also been identified that prevent the widespread
uptake of new technologies.64,65 In addition to these structural fac-
tors, it has also been suggested that the extent to which mobile devi-
ces deliver value is unclear and there is a need address explicit
questions about how mobile technology will deliver real benefit.66
However, it has been estimated that the use of mobile technology in
healthcare has the potential to significantly improve productivity
and reduce costs.67 There is a need to promote the positives of a
“mobile-first” culture within healthcare organizations and provide
the required leadership and resource to deliver it while being cogni-
zant of the potential risks. This focus must come hand-in-hand with
a need to target future research on understanding the broader socio-
technical aspects of new mobile technology, and how it comple-
ments and enables new pathways and processes of care to improve
outcomes for patients and the working life of staff.
Concerns of privacy and security were highlighted in this review,
particularly when personal mobile devices are used for the transmis-
sion of patient identifiable data. In both the United States68 and Eu-
rope69 the need to comply with stringent legislation has undoubtedly
limited the deployment of smartphone-based messaging, and the use
of SMS messaging for in-hospital communication has been discour-
aged by the Joint Commission due to security concerns.70 Improving
the awareness and training of staff with regard security and privacy
hand-in-hand with developing security compliant technology has the
potential to greatly accelerate the uptake of new mobile technologies.
Many of the negative aspects of mobile devices relate to the technol-
ogy itself including poor battery life, small screen size, and lack of
connectivity. To address these concerns, there is a need to design and
develop technology specifically for the healthcare context and adapt
work practices to alleviate some of these technological limitations. As
devices become increasingly complex and data heavy, the importance
of the underlying supporting infrastructure that is needed to securely
and reliability store, process, and transmit huge volumes of clinical
and communication data becomes increasingly important.71
CONCLUSION
Healthcare professionals use innovative mobile technology on a daily
basis outside of work, yet have to cope with outdated and inadequate
technology to coordinate and deliver care at work. Mobile technology
can deliver very real benefits, but there is a lack of high-quality evi-
dence, and the poor experience of institutional technology results in
the development of a potentially harmful patchwork of informal
workarounds and ad hoc technology adoptions. An evidence-based
approach to the development, deployment and evaluation of new mo-
bile communication devices is therefore required. To secure the
“right” technology it is important to recognize and understand both
the advantages and disadvantages of any particular technology and
how it is used in real-world settings. Mobile technology has the poten-
tial to transform communication and teamwork in hospitals and de-
liver very real benefits provided a pragmatic and evidence-based
approach is taken to its design, deployment and evaluation.
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Abstract
Background: Mastectomy in the context of breast malignancy can have a profoundly negative impact on a
woman’s self-image, impairing personal, sexual and social relationships. The deep inferior epigastric perforator
(DIEP) flap and implants are the two commonest reconstructive modalities that can potentially overcome this
psychological trauma. The comparative data on clinical outcomes and costs of the two modalities is limited. We
aim to synthesise the current evidence on DIEP versus implants to establish which is the superior technique for
breast reconstruction, in terms of clinical outcomes and cost-effectiveness.
Methods: A comprehensive search will be undertaken of EMBASE, MEDLINE, Google Scholar, CENTRAL and Science
citation index databases (1994 up to August 2017) to identify studies relevant for the review. Primary human
studies evaluating clinical outcomes and cost of DIEP and implant-based reconstruction in context of breast
malignancy will be included. Primary outcomes will be patient satisfaction and cosmetic outcome from patient-
reported outcome measures (scores from validated tools, e.g. BREAST-Q tool), complications and cost-analysis. The
secondary outcomes will be duration of surgery, number of surgical revisions, length of stay, availability of
procedures and total number of clinic visits.
Discussion: This will be the first systematic review and meta-analysis in available literature comparing the clinical
outcomes and cost-effectiveness of DIEP and implants for breast reconstruction. This review is expected to guide
worldwide clinical practice for breast reconstruction.
Systematic review registration: PROSPERO CRD42017072557.
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Background
Breast cancer is the commonest malignancy in women
and a major cause of cancer-related mortality [1]. While
mastectomy is the primary treatment modality for these
patients, it can have a profoundly negative impact on
their lives, impairing personal, sexual and social relation-
ships. Fifty percent of women post-mastectomy suffer
from negative self-image with negative changes in their
sexuality [2, 3]. The demand for reconstructive proce-
dures has risen, not only as a consequence of advancing
cancer treatment but also because of the demonstrated
functional, psychological and social benefits for patients,
overcoming the psychological trauma associated with
mastectomy [4–9]. The rates of post-mastectomy breast
reconstruction doubled from 13 to 26% between 1998
and 2007 [10].
A number of reconstructive techniques exist for breast
reconstruction. The two most frequently employed tech-
niques include the autologous deep inferior epigastric
perforator (DIEP) flap and implant-based reconstruction
[11]. The choice of treatment is determined by combin-
ation of patient factors (individual preference, age, body
image) and surgeon factors (team experience, availability
of resources) [8, 9]. Despite this, many plastic surgery
units worldwide regard autologous flap reconstruction
as the superior technique as it follows the paradigm of
replacing ‘like with like’ [10]. Indeed, there is growing
evidence to support increased aesthetic patient satisfac-
tion with autologous flap reconstruction compared to
implants, as well as increased suppleness and resiliency,
especially in irradiated recipient beds [11–19].
On first glance, implant-based reconstruction is a
simpler technique compared to free flap reconstruction,
requires less training and time and can be performed by
many more surgeons [15]. However, implant-based
reconstruction has complications. These include migra-
tion, implant rupture, infection, exposure/extrusion and
patient dissatisfaction with edge visibility and implant
animation [20]. Capsular contracture can result in pain,
asymmetry, increased palpability and requirement of im-
plant removal [21]. The placement of the implant itself
can lead to reduced or absent sensation at the nipple in
1 in 7 women [20]. Allergan’s 10-year cumulative risk
study found that 24.6% of patients who underwent implant-
based reconstruction developed capsular contracture neces-
sitating implant removal and/or replacement [22].
Conversely, DIEP flap is often now considered the
gold-standard autologous flap reconstructive technique.
This is because it results in less abdominal donor site
morbidity compared to the traditional transverse rectus
abdominus myocutaneous (TRAM) flap, by preserving
the continuity of the rectum abdominis muscles [23].
Compared to implant-based reconstruction, some
authors have argued that DIEP flap reconstruction is
more cost-effective and results in fewer complications
[11, 24]. Modern healthcare aims to provide cost-
effective treatment, and thus, discussion on reconstruct-
ive modalities warrants scrutiny on cost associated with
autologous and implant-based reconstruction. While
some North American and European centres have
published cost-effectiveness analysis on DIEP versus im-
plants, the data is sparse and there is a relative scarcity
of inclusion of data from public and free universal
healthcare system settings [11].
Thus, an extensive search will be undertaken in the
MEDLINE (Ovid SP), EMBASE (OvidSP), Google
Scholar, Cochrane Central Register of Controlled Trials
and Scientific Citation Index databases to identify
primary studies on DIEP (intervention) and implant-
based reconstruction (comparator) in context of patients
with breast malignancy. Data extracted will be used to
evaluate which technique is superior in terms of clinical
outcomes and cost and thus inform worldwide clinical
practice.
Methods
Objective
This systematic review is intended to evaluate the
current evidence on the clinical outcomes and cost of
deep inferior epigastric perforator (DIEP) flap versus im-
plants for breast reconstruction post cancer-related
mastectomy, to determine which technique is more
cost-effective and clinically superior.
General methods
This protocol has been registered with the National
Institute of Health Research (NIHR) Prospective Register
of Systematic Reviews PROSPERO CRD42017072557. We
have adhered to and completed the Preferred Report-
ing Items for Systematic Review and Meta-Analysis
Protocols (PRISMA-P) 2015 statement [25] (please see
Additional file 1, PRISMA-P checklist). If no randomised
controlled trials (RCT) are available, the review will be re-
ported according to the Meta-Analysis of Observational
Studies in Epidemiology (MOOSE) guidelines [26].
Search strategies
We will conduct a comprehensive search of the
MEDLINE (OVID SP), EMBASE (OVID SP), Google
Scholar, CENTRAL and Science citation index databases
from 1994 up to August 2017 to identify studies relevant
to the review. A combination of Medical Subject
Headings (MeSH) terms and free text will be used,
combined with Boolean logical operators to construct
the search strategy. Explode function will be used to
capture narrower terms. No language or study design
restrictions will be applied. The reference list of all
included articles will also be screened for relevance. A
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sample search strategy, for EMBASE (OVID SP), is
shown below and a similar strategy will be adapted for
the other databases:
– (1) exp Breast Neoplasms/ OR ((breast adj6 cancer*)
or (breast adj6 neoplasm*) or (breast adj6
carcinoma*) or (breast adj6 tumour*) or (breast adj6
tumor*) or (breast* adj4 reconstruct*))
– (2) exp deep inferior epigastric perforator flap/ OR
DIEP flap* OR DIEAP flap* OR ((Deep and inferior
and epigastric and perforator) adj2 flap*) OR Deep
and inferior and epigastric and perforator and flap*)
– (3) exp breast implant/ OR breast adj3 implant* OR
exp silicone prosthesis/
– [(1) AND (2)] OR [(1) AND (3)]; publication date:
January 1994–August 2017
Identification and selection of studies
Studies extracted following database searching will be
populated into an Endnote X7 library (Clarivate
Analytics, USA). The screening will be carried out in
two stages using pre-specified screening criteria by
two independent reviewers. Inter-rater reliability will
be calculated using Cohen’s kappa score.
Stage 1: Title and abstract screening will be carried out
by two researchers acting independently. Any
discrepancies will be resolved by consensus. If any
doubt remains, the article would usually proceed to
full-text review.
Stage 2: The full-text versions of the studies included in
Stage 1 will be downloaded and screened for eligibility
by two researchers independently. Discrepancies will
again be resolved by consensus. If this is not possible, a
third author will be consulted.
Study design
All primary human studies evaluating clinical outcomes
and cost of DIEP and implant-based reconstruction in
context of breast malignancy will be included. The
intervention is the DIEP flap and the comparator is
implant-based reconstruction. The inclusion and exclu-
sion criteria are highlighted below.
Inclusion criteria
a Studies involving adult patients between 18 and
90 years old.
b Unilateral DIEP flap or implant-based breast
reconstruction due to breast cancer (bilateral
reconstruction is usually after bilateral prophylactic
mastectomy).
c Clinical studies (randomised controlled trials,
prospective and retrospectives cohort studies, case
series).
Exclusion criteria
a) Review articles, case reports, simulation studies,
clinical studies in non-human subjects, patients with
segmental or partial mastectomy, technical
descriptions of operative repair with no outcome
measures, breast reconstruction not related to
cancer, other autologous flap techniques.
b) Duplicates will be excluded and studies will be
screened for bias. The Cochrane’s risk of bias tool
will be used for randomised controlled trials [27].
Bias will be assessed and judged as being high, low
or unclear for individual elements from five domains
(selection, performance, attrition, reporting and
other) [27]. For non-randomised comparative
studies, ROBINS-I (Risk Of Bias In Non-randomised
Studies—of Interventions) by Cochrane will be used
[28]. ROBINS-I covers seven distinct domains from
which bias may be introduced, with ‘signalling
questions’ that facilitate judgements about the risk of
bias. The judgements within each domain will be
carried forward for an overall risk of bias judgement
across bias domains [28]. Studies affected by bias will
be excluded.
Outcomes
The primary outcomes will be:
1. Patient satisfaction and cosmetic outcome from
patient-reported outcome measures (PROMs, scores
from validated tools, e.g. BREAST-Q tool)
2. Complications (arterial thrombosis, fat necrosis,
venous congestion, infection, partial/full flap loss,
donor site complications, haematoma/seroma,
return to theatre, capsular contracture, scarring,
implant deflation/rupture/displacement)
3. Cost-analysis
The secondary outcomes will be:
1. Duration of surgery
2. Number of surgical revisions
3. Length of stay
4. Availability of procedures
5. Total number of clinic visits
If the data is appropriate for quantitative synthesis,
then risk ratio with 95% confidence interval (CI) will be
used to determine dichotomous outcomes (complica-
tions). Continuous outcomes (cost, PROMs [BREAST-Q],
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secondary outcomes excluding availability of procedures)
will be determined by weighted or standardised mean
differences with 95% CI. Subgroup analysis may be per-
formed for patients with different breast cancer types and
for breast implant materials, dependent on sufficient data
sets. Where possible, we will utilise results from an
intention to treat analysis.
Data extraction, collection and management
Data, from the full-text articles, will be extracted by two
independent authors using a standardised extraction
form. Any discrepancy will be resolved by consensus or
with referral to a third author. If any data is missing or
further information is required, the primary authors of
the manuscript will be contacted directly. The following
data will be extracted:
 first author
 year of publication
 study design
 study setting
 study population
 participant demographics (sex, mean age, BMI,
comorbidity)
 complications (arterial thrombosis, venous
congestion, infection, fat necrosis, partial/full flap
loss, haematoma/seroma, donor site complications,
return to theatre, capsular contracture, scarring,
implant, deflation/rupture/displacement)
 measures of patient satisfaction (PROMs e.g.
BREAST-Q)
 economic data
An assessment of heterogeneity will be performed
using Review Manager 5.3 provided by The Cochrane
Collaboration [29]; if the studies are relatively
homogenous in terms of methodology and outcomes,
meta-analyses of the data will be performed. If there is
high heterogeneity, a narrative synthesis will be per-
formed instead, without meta-analysis.
Statistical heterogeneity will be quantified by the I2 stat-
istic [30]. If the I2 statistic is high, indicating high hetero-
geneity, a random effects model will be employed. The
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) approach [31] will be utilised to
assess the methodological quality of the studies. Cochrane
has produced GRADE tables that identify the basis for
judgements about evidence quality. An overall GRADE
score (from 4 to 0) is calculated based on quality of overall
evidence. The tables specify why points may be added or
deducted to obtain the final score [31]. Sensitivity analysis
maybe performed based on the quality of the studies, with
analyses repeated after removal of poor quality studies to
evaluate any change in the overall effect estimate.
Discussion
The aim of this review is to evaluate the clinical out-
comes and cost of DIEP flap versus implants for breast
reconstruction in context of breast malignancy. Despite
many centres ascribing DIEP flap as the gold-standard
reconstructive modality, data on clinical outcomes and
cost-effectiveness is limited. Therefore, it is important to
determine which of the two techniques is clinically
superior and more cost-effective as this will guide
clinical management. To our knowledge, this is the first
systematic review to compare the clinical outcomes and
cost of DIEP versus implants.
Dissemination
Based on the results of this systematic review, independ-
ent recommendations will be made to plastic surgeons,
researchers, policy makers and plastic surgery societies.
The results will be disseminated at international meet-
ings in the fields of Plastic, Reconstructive and Aesthetic
Surgery and published in a high-impact peer-reviewed
journal.
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Abstract
Background—Serious games have demonstrated efficacy in improving participation in surgical 
training activities, but studies have not yet demonstrated the effect of serious gaming on 
performance. This study investigated whether competitive training affects laparoscopic surgical 
performance.
Methods—Twenty novices were recruited, and 18 (2 drop-outs) were randomized into control or 
competitive (CT) groups to perform 10 virtual reality (VR) laparoscopic cholecystectomies (LC). 
Competitiveness of each participant was assessed. The CT group was informed they were 
competing to outperform one another for a prize; performance ranking was shown prior to each 
session. The control group did not compete. Performance was assessed on time, movements, and 
instrument path length. Quality of performance was assessed with a global rating score (GRS).
Results—There were no significant intergroup differences in baseline skill or measured 
competitiveness. Time and GRS, at final LC, were not significantly different between groups; 
however, the CT group was significantly more dexterous than control and had significantly lower 
variance in number of movements and instrument path length at the final LC (p=0.019). 
Contentiousness was inversely related to time in the CT group.
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Conclusion—This was the first randomized controlled trial to investigate if competitive training 
can enhance performance in laparoscopic surgery. Competitive training may lead to improved 
dexterity in laparoscopic surgery but yields otherwise similar performance to standard training in 
novices. Competition may have different effects on novices versus experienced surgeons, and 
subsequent research should investigate competitive training in experienced surgeons as well.
Keywords
Surgical education; Virtual reality simulation; Student education; Competitive training; Minimally 
invasive
Introduction
Surgical training programs are working to adapt their curricula to improve the efficiency of 
surgical education by augmenting didactic training and intraoperative education with 
simulation to remain in compliance with Accreditation Council for Graduate Medical 
Education (ACGME) requirements.1 Many questions remain, however, about how best to 
implement simulation into curricula to maximize the efficiency of training.
While prior comparisons to aviation have yielded a fair amount of knowledge regarding the 
utility of simulation,2 other high performance industries, such as sports, may also provide 
valuable insight into potential training strategies to elicit superior performance. Some 
pedagogical techniques identified in sports have already been investigated in surgery, 
including warm-up,3 mental practice,4 and deliberate practice.5,6 Competition has been 
found to lead to improved performance in sports including golf, weight lifting, and 
basketball.7-9 Gamification, the use of game mechanics such as competition, has been 
successfully utilized to improve motivation to participate in surgical simulation training and 
to teach and assess clinical decision making10,11; however, no studies have investigated the 
effects of competition on technical skills performance in a randomized, controlled manner.
We hypothesized that competition would lead to improved performance in trainees. This 
study investigated the effects of competition on performance during successive virtual 
reality (VR) laparoscopic cholecystectomy (LC) cases.
Methods
Participant Selection
Due to the educational nature of the study, this protocol was exempted from further ethics 
review. Informed consent was obtained from all participants, and participants were informed 
that their participation, or lack thereof, would in no way impact their medical training or 
medical care they might receive. Medical students from London hospitals with an interest in 
surgery were invited to participate in the study. Based on power analysis and cost 
constraints, twenty (n=20) medical students were recruited. All trainees had limited surgical 
experience (performed 0 but observed > 1 LCs in the operating room). All participants were 
offered a certificate of completion in a basic laparoscopic skills course if they completed all 
sessions of the study. At recruitment, participants were randomized into one of two equal 
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groups – Competitive Training (CT) group or Control group – using a random number 
generator (STATA, College Station, TX) (Figure 1).
Baseline Assessment
Each participant underwent a validated baseline skills assessment on the LapMentor VR 
(Simbionix; Cleveland, OH) laparoscopic simulator on Basic Skills tasks 5 and 6. For Basic 
Skills task 5, time to completion was assessed. For Basic Skills task 6, time to completion 
and number of movements was recorded as these metrics have been shown to be construct 
valid.12
Participants were also asked to complete the Revised Competitiveness Index, a 
psychometric questionnaire designed to assess individuals’ trait of competitiveness along 
two domains – enjoyment of competition and contentiousness (desire to outperform 
others).13 Each domain is tested on its own subscale within the Revised Competitiveness 
Index and can be considered as an individual factor that makes up a person’s trait of 
competitiveness.
Didactic and Proficiency Training
Participants underwent a modified laparoscopic skills training program based on a 
previously validated curriculum.12 Participants were trained to proficiency in basic skills 
and were given video instruction on performing a full procedure LC on the simulator.
Competitive Training Group Sessions
Participants in the CT group underwent 10 training sessions comprising a total of 10 VR 
LCs. Participants in the CT group were told to perform each procedure as safely and 
efficiently as possible but were also informed that the top performer after 10 sessions would 
be awarded a gift card for a flight simulator experience (valued at approximately $150). 
Each session, participants completed a VR LC on the LapMentor simulator, and their 
performance was assessed in real time by a trained observer using a previously validated 
rating scale of surgical technical skill [Objective Structured Assessment of Technical Skills 
Global Rating Scale (OSATS GRS)].14,15 They were then given immediate post-procedure 
feedback on their performance by being shown time to complete the VR LC, number of 
movements, total path length (cm) of instrument tips, and OSATS GRS. At the conclusion 
of each session, participants were shown a leader board demonstrating their performance 
and rank compared to others in the CT group (Figure 2).
Ranking was based on a formula (Formula 1) that weighted quality of performance (OSATS 
GRS) greater than time or dexterity (as measured by number of movements and path length) 
based on the recommendations of surgical educators at Imperial College London. Similar to 
golf, a lower score was considered to have a higher rank.
Formula 1
Before and after each VR LC, participants were asked to complete a short form State Trait 
Anxiety Inventory (STAI), a validated tool to assess state anxiety.16 After each VR LC, 
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participants were also asked to complete the NASA Task Load Index (TLX), a validated, 
subjective multidimensional assessment tool that allows participants to rate perceived 
workload.17 TLX was utilized to assess for any increased workload that participants may 
experience from competition. Participants in the CT group were asked to not disclose their 
status in the study to prevent a potential effect on motivation in the control group.
Control Group Training Sessions
The control group similarly underwent 10 training sessions comprising a total of 10 VR 
LCs, but no mention of a prize was made. They were only instructed to perform each 
procedure as safely and efficiently as possible. Their performance was also assessed using 
the same metrics as the CT group by the same trained observer. The control group was given 
immediate post-procedure feedback on their performance by being shown time to complete 
the VR LC, number of movements, total path length (cm) of instrument tips, and OSATS 
GRS. Participants in the control group were not ranked against one another and were not 
shown the performance of other participants.
Control group participants were also asked to complete a short form State Trait Anxiety 
Inventory before and after each VR LC. After each VR LC, participants were asked to 
complete the NASA TLX.
Participants in both groups were not allowed to practice laparoscopic skills outside of the 
scheduled study sessions. Participants were allowed no more than two sessions per day with 
each trial separated by one hour to prevent fatigue. Scheduling of sessions was controlled to 
allow for accurate comparison of performance amongst the CT group based on session 
number.
Statistical Analysis
Statistical analysis was performed using STATA Intercooled 12 (College Station, TX). 
Shapiro-Wilk test showed the nature of the data to be nonparametric. Mann-Whitney U-test 
was employed to compare intergroup baseline laparoscopic performance and VR training 
session performance. Wilcoxon signed-rank test was utilized for intra-group comparison. 
Data are reported as median (interquartile range). Levene’s test was utilized to compare the 
consistency in performance of the CT group versus the control group. Multivariate 
regression was used to assess the effect of competitiveness and contentiousness on surgical 
performance. Nonlinear regression was utilized to assess the learning curve of 
participants.18
In addition to live ratings, videos of VR LCs from both groups were assessed by an 
independent, blinded rater using the OSATS GRS. Intraclass correlation coefficient (ICC) 
was calculated to assess inter-rater reliability of the OSATS GRS. A p <0.05 was be 
considered statistically significant.
Sample size was based on detecting at least a 25% difference in time and dexterity with 
alpha of 0.05 and beta of 0.8 as based on preliminary data collected prior to the study.
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Results
Subjects
Eighteen of the twenty recruited participants completed the study. Two participants dropped 
out during proficiency training and cited scheduling conflicts for their inability to complete 
the study. All participants were right handed. Two of the participants in the control group 
and three in the CT group were female.
Baseline Assessment of Laparoscopic Skill
There were no significant differences in baseline laparoscopic skill between control and the 
CT groups (Table 1).
Competitiveness Index
Analyzing the results of the Revised Competitiveness Index, there was no significant 
difference in enjoyment of competition between groups (Control: 27.44 ± 2.51, CT: 27.11 ± 
3.78; p=0.3). However, the CT group (16.89 ± 5.39) was significantly more contentious than 
the Control group (13 ± 2.59; p<0.001).
Virtual Reality LC Performance
Both the control and CT groups improved over the course of 10 LCs in time, movements, 
path length, and OSATS GRS (Table 2). The intraclass correlation coefficient for OSATS 
GRS was ICC=0.858.
At the first LC, the CT group was significantly faster, made fewer movements, and had 
lower path length than the control group. There was no significant difference between 
groups in quality of surgical performance as assessed by the OSATS GRS at first LC (Table 
2). By the tenth and final LC, there were no significant differences between groups in time 
to complete the procedure or OSATS GRS score. With regards to dexterity, the CT group 
made significantly fewer movements and had lower path length than the control group 
(Table 2).
The CT group had significantly lower variance in number of movements and instrument 
path length than the control group at the tenth and final LC (p=0.019).
Virtual Reality LC Learning Curves
After 5 cases, the control group plateaued at an average procedure completion time of 345.8 
seconds (p<0.001), total number of movements of 308 (p<0.001), and path length of 482 
cm. (p<0.001). The control group plateaued at an average OSATS GRS of 20 after 5 cases 
(p<0.001) (Figure 3A-D).
The CT group plateaued at 365.1 seconds (p<0.001) after 8 cases, total movements of 288 
(p<0.001) after 9 cases, and path length of 427.4 cm (p<0.001). The CT group on average 
plateaued at an OSATS GRS of 21 after 5 cases (p<0.001) (Figure 3A-D). There were no 
significant differences in the plateau levels of the two groups for any of the metrics.
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Virtual Reality LC Performance and Psychometrics
The CT group reported higher mean state anxiety after completing a VR LC compared to 
state anxiety just prior to performing a VR LC while the control group reported no 
difference in state anxiety either before or after VR LC performance (Table 2). For both 
groups, state anxiety as assessed after VR LC had a negative effect on quality of surgical 
performance (Table 3).
There was no significant difference in perceived workload between groups after each VR 
LC. There was no effect of perceived workload on either group for any of the performance 
metrics.
For both groups, there was no effect of competitiveness or contentiousness on quality of 
performance. For the CT group, contentiousness was inversely related to time to complete a 
VR LC (β=−4.56 ± 2.23, R2=0.57, p=0.044) and number of movements (β=−5.6 ± 2.41, 
R2=0.65, p=0.023). There was no relationship between contentiousness and time or 
movements for the control group.
Discussion
Trainees engaging in competitive training developed greater dexterity when performing VR 
LC. Although the time taken to complete the procedure and quality of surgical performance 
were similar between trainees in CT and those in standard training, the decreased 
movements and instrument path length suggest that the CT group was able to complete a VR 
LC with greater efficiency. Furthermore, the CT group was more consistent in movements 
made and instrument path length as suggested by the decreased variance of these metrics in 
the CT group at the final LC (Figure 3B-C).
Gamification in surgical education has predominantly been rooted in the utilization of 
serious games.10 Serious games are interactive, scored computer games that are fun, 
engaging, yet challenging with the goal of improving skills or knowledge applicable to real 
world scenarios. While many games investigated in the literature have focused on teaching 
decision-making skills or cognitive knowledge, surgical skills competitions are often held at 
various society meetings and within institutions as a fun exercise in skills practice. To our 
knowledge, this was the first randomized controlled trial investigating the effect of 
competitive training on the acquisition of surgical skill.
As the assignment of participants to CT versus control training was random, we did not 
intend to have more contentious people in the CT group. However, the CT group in this 
study reported being more contentious than the control group, and a regression model of the 
performance data suggests that contentiousness in the CT group relates to faster and more 
dexterous performance. While we interpret these findings with caution, one potential 
explanation is that contentious participants, when placed in a competitive environment, have 
improved performance in dexterity that may have been driven by their desire to outperform 
others.
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Competition is not the only tool that may exist to promote improved performance in novice 
surgeons. Delivery of surgical care requires a coordinated team effort involving surgeons, 
nurses, technicians and other ancillary staff; and cooperation in the team setting may be the 
more appropriate means of improving performance as suggested in both the surgical and 
sports science literature.9,19 However, a study in sports science suggests that in situations 
where individuals are involved in a structured, fair competition and are able to gauge the 
progress of opponents, competition can lead to higher levels of individual motor 
performance.20 Acquisition of skill in the simulation center tends to occur in the individual 
setting, and a structured competition may promote improved performance in domains such 
as dexterity as suggested in this study. These skills may then be translated to the team 
environment to provide the best care for patients. Being able to anonymously gauge the 
progress of other trainees in a program may have provided a target for which the participants 
in the CT group could strive to outperform, thus leading to improved dexterity versus the 
control group.
Analysis of the state anxiety in participants found that high state anxiety after completion of 
VR LC negatively affected quality of surgical performance as assessed by the OSATS GRS. 
Due to the design of the study, we are not able to conclude whether increased anxiety during 
the VR LC resulted in a decreased OSATS GRS score or if the increased anxiety was a 
result of technical errors that were reflected in a decreased OSATS GRS score. Previous 
research suggests either explanation may be plausible as the literature has reported technical 
errors to be a source of stress for surgeons but also that some individuals may be less 
capable of skilled surgical performance under pressure.21,22 While there was no difference 
in state anxiety before or after a VR LC for the control group, the CT group reported 
significantly higher state anxiety after completing a VR LC. The participants were not 
surveyed on why they may have felt more anxious; however, competition may have 
heightened levels of anxiety as the CT group awaited the results of their ranking. While it is 
certainly not ideal to stress trainees to the point of negatively impacting performance, 
surgeon stress is present and measurable in an operation.23 Competition in the simulation 
environment may provide a safe avenue through which to expose trainees to stress that may 
be present in a real operative setting.
The results of this study are not without limitations. Although participants received their 
OSATS GRS scores, they did not receive feedback on specific steps to improve quality of 
surgical performance. Previous work has demonstrated that specific feedback is necessary to 
improve performance quality; thus, quality of performance may have been limited in this 
study.5 To control elements such as complexity of the case, the competition was limited to 
VR in this initial study. As the ultimate goal of simulation training is to improve 
performance in the operating room, individuals who participate in CT should undergo 
evaluation in a live operative case. Since this study was conducted with medical students, no 
attempt was made to assess the participants in a live operating room. However, future work 
with residents should assess the effect of CT in a real clinical setting. Steps should be taken 
to ensure that competition remains confined to the simulation environment, as patient care 
and safety should not be treated as a game.
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Implementation of competitive training for programs with pre-existing simulation programs 
can be low cost. We utilized an in-house programmed webpage; however, a similar study 
could be conducted by manually placing values into a spreadsheet and sorting values to 
calculate rank. Future work should survey participants on motivation prior to each session to 
determine whether participants subjectively report being motivated by competition, and 
studies can investigate a tailored approach to learning that compares competitive and non-
competitive training based on the motivational preferences of the trainees. Such work may 
help elucidate whether competition motivates trainees to varying levels depending on 
individual motives.
Conclusion
Surgical skills competitions have been held at surgical meetings and at institutional levels, 
but competition as a novel training strategy had not previously been investigated. The results 
of this study suggest that competition in surgical education for medical students may lead to 
improved dexterity in laparoscopic cholecystectomy but has otherwise equivalent effects as 
standard, repetition-based training on time and quality of performance. Additional research 
is needed to determine if similar effects are seen in residents who receive feedback on their 
performance.
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Figure 1. 
Flow chart of study protocol with recruited subjects and drop-outs
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Figure 2. 
Leader board demonstrating participant performance and rank compared to others in the CT 
group.
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Figure 3. 
(A-D) Virtual Reality learning curves and performance box-and-whisker plots of control and 
CT groups for time to complete procedure (A), total number of movements (B), total path 
length (cm) (C), and OSATS GRS (D).
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Table 1
Pre-test baseline skills assessment of control and CT groups. Values as median (interquartile range).
Control CT p-value
Task 5
Time (sec) 132.7 (122-142) 134 (123-146) 0.70
Control CT p-value
Task 6
Time (sec) 164.3 (132-177) 170.5 (139-198) 0.31
Movements 208 (169-253) 264 (229-307) 0.10
Path Length (cm) 510 (405-631) 668.5 (525-726) 0.30
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Table 2
Comparison of first and final VR LC time, movements, path length, and quality of surgical performance. 
Comparison of pre- and post-LC mean State Trait Anxiety Index between groups. Values as median 
(interquartile range).
Control CT p-value
Time (sec)
First LC 871 (797-898) 598 (529-708) 0.01
Final LC 390 (305-405) 319 (208-357) 0.40
p-value 0.008 0.008
Movements
First LC 816 (684-952) 643 (529-756) 0.04
Final LC 327 (301-373) 253 (230-258) 0.02
p-value 0.008 0.008
Path Length (cm)
First LC 1397 (1053-1617) 920.7 (810-1057) 0.04
Final LC 518 (509-633) 376.7 (343-404) 0.02
p-value 0.008 0.008
OSATS GRS
First LC 16 (15-17) 16 (16-18) 0.47
Final LC 20 (18-21) 21 (21-22) 0.16
p-value 0.013 0.008
STAI
Pre-LC 8 (7-11) 11 (10-12) <0.001
Post-LC 9 (7-11) 12 (10-14) <0.001
p-value 0.118 <0.001
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Table 3
Multiple linear regression model for VR LC quality of performance and state anxiety. State anxiety after VR 
LC had a negative effect on quality of surgical performance.
Control Group State Anxiety
Variable Coefficient SE 95% CI R2 p-value
Intercept 20.66 0.92
Pre-STAI 0.11 0.09 −0.08 to 0.29 0.13 0.253
Post-STAI −0.33 0.09 −0.51 to −0.14 0.13 0.001
CT Group State Anxiety
Variable Coefficient SE 95% CI R2 p-value
Intercept 20.61 1.45
Pre-STAI 0.16 0.12 −0.08 to 0.39 0.1 0.19
Post-STAI −0.24 0.08 −0.4 to −0.09 0.1 0.003
J Surg Educ. Author manuscript; available in PMC 2016 November 01.
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Abstract
Various comorbidities represent risk factors for severe coronavirus disease 2019
(COVID‐19). The impact of smoking on COVID‐19 severity has been previously re-
ported in several meta‐analyses limited by small sample sizes and poor methodology.
We aimed to rigorously and definitively quantify the effects of smoking on COVID‐19
severity. MEDLINE, Embase, CENTRAL, and Web of Science were searched between
1 December 2019 and 2 June 2020. Studies reporting smoking status of hospitalized
patients with different severities of disease and/or at least one clinical endpoint of
interest (disease progression, intensive care unit admission, need for mechanical
ventilation, and mortality) were included. Data were pooled using a random‐effects
model. This study was registered on PROSPERO: CRD42020180920. We analyzed 47
eligible studies reporting on 32 849 hospitalized COVID‐19 patients, with 8417
(25.6%) reporting a smoking history, comprising 1501 current smokers, 5676 former
smokers, and 1240 unspecified smokers. Current smokers had an increased risk of
severe COVID‐19 (risk ratios [RR]: 1.80; 95% confidence interval [CI]: 1.14‐2.85;
P = .012), and severe or critical COVID‐19 (RR: 1.98; CI: 1.16‐3.38; P = .012). Patients
with a smoking history had a significantly increased risk of severe COVID‐19 (RR:
1.31; CI: 1.12‐1.54; P = .001), severe or critical COVID‐19 (RR: 1.35; CI: 1.19‐1.53;
P < .0001), in‐hospital mortality (RR: 1.26; CI: 1.20‐1.32; P < .0001), disease progres-
sion (RR: 2.18; CI: 1.06‐4.49; P = .035), and need for mechanical ventilation (RR: 1.20;
CI: 1.01‐1.42; P = .043). Patients with any smoking history are vulnerable to severe
COVID‐19 and worse in‐hospital outcomes. In the absence of current targeted
therapies, preventative, and supportive strategies to reduce morbidity and mortality
in current and former smokers are crucial.
K E YWORD S
coronavirus, epidemiology, pandemics, pathogenesis, respiratory tract, virus classification,
zoonoses
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1 | INTRODUCTION
As of 28 July 2020, severe acute respiratory syndrome coronavirus 2
(SARS‐CoV‐2) has infected 16 341 920 patients, with 650 805 deaths
across 188 countries.1,2 Risk factors for poor outcome in patients with
coronavirus disease 2019 (COVID‐19) include older age, male sex, hy-
pertension, diabetes, cardiovascular disease, and respiratory disease.3‐5
Remarkably, current peer‐reviewed data surrounding the effect of
smoking tobacco on the clinical severity of COVID‐19 has thus far been
controversial, and there is an urgent need for definitive answers.6
An early systematic review without meta‐analysis concluded that
smoking is most likely associated with negative progression and out-
comes in COVID‐19,7 however, a preliminary meta‐analysis showed
that active smoking is not significantly associated with increased risk of
severe disease.8 Four subsequent meta‐analyses have shown an in-
creased risk of severe COVID‐19 associated with smoking.9‐12 A sum-
mary of the six previously published systematic reviews7‐12 alongside
assessment of their methodological quality using A Measurement Tool
to Assess systematic Reviews 213 (AMSTAR 2) is provided in the
Appendix (Appendix pp2‐3). The articles ranged from critically poor to
moderate quality, indicating that significant methodological flaws in
critical domains exist with all six currently published reviews assessing
the impact of smoking on COVID‐19 severity. It is therefore likely that
the true effect of smoking on COVID‐19 severity reported in these
analyses is clouded by considerable bias.
Furthermore, as a result of several nonpeer reviewed preprint ar-
ticles falsely equating the prevalence of smoking in COVID‐19 study
populations with population estimates for smoking prevalence, there has
been widespread attention paid to recent mass media reports that
smoking may exert a protective effect against COVID‐19 infection.14
This led to the World Health Organization releasing a statement on
11 May urging caution with regards to these claims, and emphasizing the
lack of evidence confirming a link between smoking or nicotine in the
prevention or treatment of COVID‐19.15 Consequently, there remains a
distinct lack of clarity and high‐quality evidence regarding the relation-
ship between smoking and the severity of COVID‐19. Therefore, to
address this important clinical question, this systematic review and meta‐
analysis aimed to evaluate the effect of smoking status, including current
smoking and a history of smoking, on the clinical severity of COVID‐19.
2 | METHODS
2.1 | Search strategy and selection criteria
This systematic review and meta‐analysis adhered to PRISMA
guidelines16 and was AMSTAR 2 compliant (Appendix pp8‐12).13 Two
authors independently searched MEDLINE, Embase, CENTRAL, and
Web of Science for studies published between 1 December 2019 and
2 June 2020. The search strategy is provided in the Appendix (p13).
No language restrictions were applied. COVID‐19 resource centers
of The Lancet, The Lancet Respiratory Medicine, The New England Journal
of Medicine, and The BMJ were also hand searched up to 5 July 2020.
Reference lists of included studies and previous systematic reviews
were additionally screened for their relevance.
To capture all available relevant evidence, randomized, and ob-
servational studies reporting the smoking status of hospitalized patients
presenting with different severities of disease and/or at least one clinical
endpoint of interest were deemed eligible for inclusion. Smoking history
included current and former tobacco smokers or e‐cigarette users.
Disease severity, including severe or critical cases, was defined a priori
and based on the COVID‐19 diagnostic criteria issued by the Chinese
National Health Commission (Appendix p13).17 Other acceptable cri-
teria included the Infectious Diseases Society of America/American
Thoracic Society (IDSA/ATS) criteria for severe community‐acquired
pneumonia.18 Clinical endpoints of disease progression, intensive care
unit (ICU) admission, mechanical ventilation requirement, and/or mor-
tality were used as surrogate markers for in‐hospital severity. We ex-
cluded studies on other coronaviruses or if there was insufficient
information to distinguish disease severity based on smoking status.
Case series involving less than 20 patients, review articles, editorials,
conference abstracts, and nonclinical studies were also excluded. Pre-
prints were not assessed for eligibility due to their preliminary nature.
Two authors (WNC, AS) independently screened the titles and
abstracts of retrieved studies, with full‐texts of all potentially eligible
papers subsequently assessed for inclusion. Any discrepancy was
resolved by consensus discussion with the senior author (AK).
2.2 | Data analysis
Data from studies that fulfilled our inclusion criteria were extracted
independently by three authors (WNC, AS, and RKR). Main data‐
points included: study details (author, journal, date, country, study
design, study period, and funding), total numbers of patients, and
their clinical outcomes by smoking status.
Two authors (AS and AD) independently assessed the quality of
included studies using the Newcastle‐Ottawa Scale modified for case
series, cohort studies, and cross‐sectional studies.19 Scores were then
classified by the Agency for Healthcare Research and Quality stan-
dards as good, fair, or poor. Any discrepancies in quality assessment
were resolved by a third author (WNC).
As per our prespecified analysis plan, random‐effects meta‐
analyses of pooled raw data were employed using the DerSimonian
and Laird method for each outcome with sufficient data to account
for anticipated differences across countries and study design over
time. Current smokers were compared to former and never‐smokers,
and patients with a smoking history were compared to never‐
smokers. Where available, adjusted effect estimates were combined
and in the absence of adjustment for confounders, raw effect esti-
mates were combined. The results are presented in forest plots as
risk ratios (RR) and corresponding 95% confidence intervals (CI) for
each outcome. I2 estimates of heterogeneity, representing the
variability across studies, are classified as low (<30%), moderate
(30%‐60%), or high (>60%). Sensitivity analyses included only good‐
quality studies and, for severity outcomes, studies using the
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COVID‐19‐specific criteria for grading severity. Subgroup analyses were
completed by country. Funnel plots were used to check for publication
bias and tested for asymmetry using Harbord's test,20 with studies with
no events in either exposed or unexposed arms excluded from this
analysis. P values <.05 were considered significant.
Data were analyzed using Stata (version 15). The study protocol was
prospectively registered with PROSPERO, number CRD42020180920.21
2.3 | Role of the funding source
This study received no funding. All authors had full access to all of the
data and took responsibility for the decision to submit for publication.
3 | RESULTS
The search identified 1038 papers, of which 339 were duplicates. After
screening the titles and abstracts of the remaining 699 papers, 350 full‐
texts were reviewed. Overall, 35 studies met the inclusion criteria, with a
further 12 identified from the references of included studies or by the
reviewer team (Figure 1). The 47 included studies4,22‐67 represented a
total of 32 849 hospitalized COVID‐19 patients: 8417 (25.6%) with any
reported smoking history, comprising 1501 current smokers, 5676 for-
mer smokers, and 1240 unspecified smokers; 22 420 (68.3%) never‐
smokers; and a further 2012 (6.1%) patients who did not currently
smoke, though it was unclear whether they were former or never‐
smokers (Table 1).
There were 25 multicentre studies (three prospective31,49,66
and 22 retrospective)4,22,25‐27,29,32‐34,38,39,41‐44,47,51,52,54,60,61,63
and 22 single‐centre studies (two prospective,36,55 two with
prospective and retrospective components,45,56 and 18 retro-
spective23,24,28,30,35,37,40,46,48,50,53,57‐59,62,64,65,67). The majority
of studies investigated a Chinese population (32/47, 68%), with
the United States contributing 10 studies. Overall, study quality
was good in 22 studies, fair in six and poor in 19 (Appendix p17).
Of 38 studies disclosing funding status, 28 received funding.
Three studies32,56,64 reported smoking index or pack‐years by
outcome of interest. Six studies23,25,39,49,54,61 reported outcomes for
tobacco smokers, including one25 that had pooled outcomes with those
of e‐cigarette users. The remaining studies did not specify the substance
of smoking.
Disease severity was graded according to the Chinese COVID‐19‐
specific criteria in 14 studies,24,28,32,35,38,46,48,53,55,57,63‐66 the IDSA/ATS
criteria in three studies34,45,59 and a locally devised criteria in one study
(Appendix p13).54 Two studies52,62 did not specify the criteria utilized.
Current smokers, whose outcomes were evaluated in 27 studies, had
an overall prevalence of 6.2% (specifically, China: 8.7%, United States:
4.6%). They had a significantly increased risk of presenting with severe
disease (RR: 1.80; 95% CI: 1.14‐2.85; P = .012; I2 = 76%; Figure 2A), as
well as severe or critical disease (RR: 1.98; 95% CI: 1.16‐3.38; P= .012;
I2 = 87%; Figure 2B), compared to former or never‐smokers. Effects were
F IGURE 1 Flow diagram of selection of included studies
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TABLE 1 Characteristics of included studies
Setting Study design
Number of
centers
Study
period
Number of patients,
current smokers vs
former/never‐smokers
Number of patients,
any smoking history vs
never‐smokers
Study
quality
Azar et al22 United States Cohort 24 Jan‐Apr 10 vs 216 73 vs 153 Fair
Bhargava et al23 United States Cohort 1 Mar‐Apr 11 vs 186 ⋯ Good
Bi et al24 China Cohort 1 Jan‐Mar 8 vs 105 ⋯ Good
Brenner et al25 International Cohort 1+ ‐Apr 11 vs 150 ⋯ Poor
Buckner et al26 United States Case series 3 Mar‐May ⋯ 22 vs 64 Poor
CDC COVID‐19
Response Team27
United States Cohort 1+ Feb‐Mar 27 vs 1467 105 vs 1389 Poor
Chen et al28 China Case series 1 Jan‐Mar ⋯ 15 vs 130 Poor
Chen et al29 China Cohort 575 ‐Jan ⋯ 111 vs 1479 Good
Chen et al30 China Case series 1 Jan‐Feb 12 vs 262 ⋯ Poor
Docherty et al31 UK Cohort‡ 208 Feb‐May 852 vs 13 332 5216 vs 8968 Good
Feng et al32 China Cohort 3 Jan‐Mar ⋯ 44 vs 410 Good
Goyal et al33 United States Case series 2 Mar‐Apr 20 vs 373 98 vs 295 Poor
Guan et al34 China Cohort 552 Dec‐Jan 137 vs 948 158 vs 927 Poor
Hu et al35 China Case series 1 Jan‐Mar ⋯ 38 vs 285 Good
Huang et al36 China Case series‡ 1 Dec‐Jan 3 vs 38 ⋯ Poor
Huang et al37 China Cohort 1 Jan‐Mar 56 vs 288 ⋯ Good
Huang et al38 China Case series 8 Jan‐Feb ⋯ 16 vs 186 Good
Hur et al39 United States Cohort 10 Mar‐Apr 16 vs 470 163 vs 323 Good
Inciardi et al40 Italy Cohort 1 Mar‐Mar ⋯ 17 vs 82 Poor
Ji et al41 China Cohort 2 Jan‐Mar ⋯ 19 vs 189 Good
Kalligeros et al42 United States Cohort 3 Feb‐Apr 12 vs 91 48 vs 55 Good
Klang et al43 United States Cohort 5 Mar‐May ⋯ 793 vs 2613 Good
Kuderer et al44 Internationala Cohort 1+ Mar‐May 25 vs 406 226 vs 205 Fair
Li et al45 China Cohort† 1 Jan‐Mar 41 vs 503 92 vs 452 Good
Li et al46 China Case series 1 Jan‐Feb ⋯ 7 vs 18 Poor
Liu et al47 China Cohort 3 Dec‐Jan ⋯ 5 vs 73 Good
Petrilli et al49 United States Cohort‡ 4 Mar‐May 141 vs 2145 702 vs 1584 Good
Qin et al48 China Cohort 1 Jan‐Feb ⋯ 7 vs 445 Poor
Rastrelli et al50 Italy Case series 1 ⋯ 1 vs 30 12 vs 19 Poor
Shi et al51 China Cohort 2 Jan‐Mar ⋯ 16 vs 290 Good
Shi et al52 China Cohort 1+ ‐Feb ⋯ 40 vs 434 Good
Sun et al53 China Cohort 1 Feb‐Mar ⋯ 12 vs 45 Good
Toussie et al54 United States Cohort 1+ Mar‐Mar ⋯ 29 vs 94 Fair
Wan et al55 China Case series‡ 1 Jan‐Feb 9 vs 126 ⋯ Poor
Wang et al56 China Cohort† 1 ⋯ 41 vs 503 92 vs 452 Poor
Wang et al57 China Cohort 1 Jan‐Feb 16 vs 109 16 vs 109 Poor
Yang et al58 China Cohort 1 Dec‐Feb ⋯ 2 vs 50 Poor
Yao et al59 China Cohort 1 Jan‐Mar 4 vs 104 ⋯ Good
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consistent when only analyzing studies using the COVID‐19‐specific
criteria (Appendix p22). On sensitivity analysis, including only good‐
quality studies resulted in these effects becoming nonsignificant. There
were no significant effects on in‐hospital outcomes, including disease
progression (RR: 1.54; 95% CI: 0.52‐4.58; P = .439; I2 = 81%; Appendix
p19), ICU admission (RR: 0.72; 95% CI: 0.42‐1.24; P= .237; I2 = 40%;
Appendix p20), mechanical ventilation requirement (RR: 1.13; 95% CI:
0.75‐1.72; P= .561; I2 = 32%; Appendix p21) or mortality (RR: 1.46; 95%
CI: 0.83‐2.60; P= .192; I2 = 81%; Figure 2C). There were no differences in
outcomes by country of origin (Appendix p23). A meta‐analysis was not
performed for critical disease alone as only one study reported this
outcome.
The overall prevalence of a smoking history, including current,
former, and/or unspecified smokers, was 26.9% (specifically, China:
10.3%, United States: 23.6%). Their outcomes were investigated in
35 studies. Compared to never‐smokers, a history of smoking sig-
nificantly increased the risk of presenting with severe disease (RR:
1.31; 95% CI: 1.12‐1.54; P = .001; I2 = 12%; Figure 3A), as well as
severe or critical disease (RR: 1.35; 95% CI: 1.19‐1.53; P < .0001;
I2 = 19%; Figure 3B). However, only the effect on severe or critical
disease remained significant when limiting the analysis to only stu-
dies using the COVID‐19‐specific criteria for grading severity
(Appendix p29). The effect on critical disease alone was not statistically
significant (RR: 1.44; 95% CI: 0.95‐2.17; P = .085; I2 = 0%; Appendix
p25). However, a smoking history significantly increased mortality risk
(RR: 1.26; 95% CI: 1.20‐1.32; P < .0001; I2 = 0%; Figure 3C) in addition
to other in‐hospital outcomes, such as disease progression (RR: 2.18;
95% CI: 1.06‐4.49; P = .035; I2 = 69%; Appendix p26) and mechanical
ventilation requirement (RR: 1.20; 95% CI: 1.01‐1.42; P = .043; I2 = 0%;
Appendix p28). There was no statistically significant difference in ICU
admission (RR: 1.12; 95% CI: 0.96‐1.31; P = .157; I2 = 0%; Appendix
p27). Sensitivity analyses excluding lower‐quality studies supported the
primary analyses for all outcomes of interest (Appendix p29). Only the
mortality analysis facilitated comparison by country, in which sig-
nificant detrimental effects were observed in publications from China,
United States, and the UK, but not Italy, which contributed one study
only for this outcome (Appendix p29).
Overall, there was a moderate‐to‐high degree of heterogeneity
between studies evaluating the effects of current smoking and a low
degree of heterogeneity between studies investigating a history of
smoking. The potential for publication bias was only detected in the
comparison of disease progression in patients with a smoking history
(Appendix p26), though heterogeneity was high for this outcome.
4 | DISCUSSION
To our knowledge, this is the largest meta‐analysis amongst peer‐
reviewed literature assessing the effect of smoking tobacco on the se-
verity of COVID‐19. Principally, the present analysis found that current
smokers have an increased risk of presenting to hospital with severe
COVID‐19 and are approximately twice as likely to experience severe
or critical COVID‐19 as former or never‐smokers. While this risk be-
came nonsignificant following sensitivity analysis of good‐quality studies
only, there were only two studies for each outcome and none graded
disease severity by COVID‐19‐specific criteria, thus precluding mean-
ingful interpretation. Overall, there was a high degree of heterogeneity
amongst studies evaluating current smoking, even when analyzing good‐
quality studies only. For patients with a smoking history, there is an
increased risk of presentation to hospital with severe, as well as severe
or critical, COVID‐19 and subsequent increased risk of in‐hospital
mortality. Additionally, these patients were more likely to experience
disease progression and require mechanical ventilation. That all out-
comes remained significant on inclusion of only good‐quality studies
suggests these analyses represent true effects. A high level of hetero-
geneity was only observed in assessing the effect of smoking history on
disease progression, which is likely secondary to substantial inter‐study
variation in defining progression. This outcome also displayed potential
for publication bias, however, none was found in other analyses,
indicating the low impact of publication bias on our results.
TABLE 1 (Continued)
Setting Study design
Number of
centers
Study
period
Number of patients,
current smokers vs
former/never‐smokers
Number of patients,
any smoking history vs
never‐smokers
Study
quality
Yu et al60 China Cohort 24 Jan‐Mar 13 vs 408 ⋯ Good
Yu et al61 China Cross‐sectional 2 Jan‐Feb ⋯ 5 vs 65 Good
Yu et al62 China Cohort 1 Jan‐Mar ⋯ 16 vs 76 Poor
Yu et al63 China Cohort 1+ Dec‐Feb ⋯ 26 vs 265 Fair
Zhang et al64 China Case series 1 Jan‐Feb 2 vs 138 9 vs 131 Poor
Zhang et al65 China Cohort 1 Jan‐Feb 6 vs 114 ⋯ Fair
Zheng et al66 China Cohort‡ 3 Jan‐Feb 8 vs 58 ⋯ Fair
Zheng et al67 China Case series 1 Jan‐Feb 8 vs 65 8 vs 65 Poor
Zhou et al4 China Cohort 2 Dec‐Jan 11 vs 180 ⋯ Good
Note: All studies are retrospective except: †ambispective (includes prospective and retrospective components) and ‡prospective.
aContains data from the United States, Canada, and Spain.
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F IGURE 2 A, Forest plot showing the effect of current smoking on severe COVID‐19. B, Forest plot showing the effect of current smoking
on severe or critical COVID‐19. C, Forest plot showing the effect of current smoking on mortality. COVID‐19, coronavirus disease 2019
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F IGURE 3 A, Forest plot showing the effect of a
smoking history on severe COVID‐19. B, Forest
plot showing the effect of a smoking history on
severe or critical COVID‐19. C, Forest plot showing
the effect of a smoking history on mortality.
COVID‐19, coronavirus disease 2019
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Our finding that current smoking is associated with increased dis-
ease severity in COVID‐19 patients validates previous findings from
several smaller meta‐analyses in a much larger patient population,
achieved through a more rigorous, prospectively registered methodol-
ogy.9‐12,21 The finding that patients with a smoking history are at in-
creased risk of more severe disease, and increased mortality, also
confirms previous findings of a smaller meta‐analysis.11 The association of
both current smoking and smoking history with greater severity of
COVID‐19 is biologically plausible for a wealth of reasons. Smoking to-
bacco is the primary cause of preventable disease, disability, and death in
the United States, and is responsible for over 8 million deaths worldwide
per year.68 Smoking is a major risk factor for adverse respiratory and
cardiovascular outcomes, in addition to a wide range of malignant
and nonmalignant disease.68 In addition, smoking increases severity and
mortality of both bacterial and viral infections through the induction of
mechanical and structural changes in the respiratory tract and alteration
of cell‐ and humoral‐mediated immune responses.69,70 In the context of
respiratory viruses, smoking has been reported to cause increased hos-
pital and ICU admissions with influenza infection, greater severity with
respiratory syncytial virus bronchiolitis and increased mortality with viral
pneumonia.71‐73
With regard to coronaviruses, in particular, smoking is associated
with increased susceptibility and mortality in MERS‐CoV infection, po-
tentially due to upregulation of dipeptidyl peptidase‐IV, the host receptor
for MERS‐CoV, in smokers.74,75 The angiotensin‐converting enzyme‐2
(ACE‐2), previously shown to be the host receptor for SARS‐CoV, has
also been proven to be the host receptor for SARS‐CoV‐2, facilitating
initial intracellular entry via interactions with viral spike glycoproteins.76
Subsequent studies have confirmed that ACE‐2 expression is upregu-
lated in human lung tissue samples taken from both current and past
smokers, likely mediated by the α‐7 subtype of the nicotinic acetylcholine
receptor.77‐81 In a series of elegant in vitro experiments, Smith et al80
report a consistent correlation between smoking history and increased
ACE‐2 expression that was dose‐dependent, detectable in both bulk and
single‐cell analyses, and remained significant after multivariate linear
regression controlling for age, sex, race, and body mass index. It is,
therefore, plausible that smokers are exposed to higher SARS‐CoV‐2
loads as a result of increased expression of ACE‐2, which may provide a
mechanistic explanation for the increased risk of severe disease and
mortality associated with smoking in COVID‐19 patients that we report.
Moreover, the inhibition of SARS‐CoV‐2 progression in vitro by human
recombinant soluble ACE‐2, a neutralizing agent, holds therapeutic po-
tential and is currently in phase II clinical trials (ClinicalTrials.gov Iden-
tifier: NCT04335136).82 However, to complicate matters, previous
studies also report that postentry viral‐mediated downregulation of
ACE‐2 played a major role in the pathogenesis of SARS‐CoV‐associated
acute lung injury.83,84 Smoking itself has been postulated as having
varying, organ‐specific effects on ACE‐2 levels, with specific cigarette
components, such as nicotine, potentially exerting a different effect to
whole smoke.80 Therefore, further studies characterizing the complex
relationship of smoking and ACE‐2 in COVID‐19 are warranted.
That smoking history is associated with a significantly increased risk
of in‐hospital mortality in COVID‐19 patients, whilst current smoking is
not, is a surprising finding. Reductions in morbidity and all‐cause mor-
tality following smoking cessation are well characterized and thus for-
mer smokers would be expected to have better baseline health status
and improved outcomes.68 A systematic review assessing prevalence of
current smokers who were hospitalized for COVID‐19 reported a
pooled prevalence of 6.5% and propose that in view of the lower than
expected prevalence of current smokers compared to population esti-
mates, current smoking is not a predisposing factor for hospitalization
and smoking and/or nicotine may exert a protective effect against se-
vere COVID‐19.85 The idea that smoking and/or nicotine may be pro-
tective against COVID‐19 is echoed by several preprint studies that
gained widespread media attention.14 Although these hypotheses may
explain the nonsignificant association of current smoking and increased
mortality that we report, since the majority of included studies did not
statistically adjust the effect of smoking for baseline covariates, it is not
appropriate to compare the prevalence of smoking in hospitalized
COVID‐19 patients with overall population estimates, as the two po-
pulations are inherently different with regards to demographic factors.
We believe there are far more credible reasons for the nonsignificant
association between current smoking and mortality that we report and
the low prevalence of smoking among patients with COVID‐19 in
published studies.
Predominantly, in the context of a global pandemic, accurately re-
cording smoking history is likely to be of low priority for frontline
clinicians whose principal focus is stabilizing severely and critically ill
patients. Therefore, patients may have been too acutely unwell to an-
swer questions or clinicians may not enquired directly about smoking
status, leading to misclassification of smokers as nonsmokers. Similarly,
collateral history collected from family members or referring clinicians is
likely to be less accurate than ascertainment of patient‐reported
smoking status. Additionally, in an example of reverse causality, hospi-
talized patients are more likely to have quit smoking on admission,
resulting in additional potential misclassification of current smokers as
former or nonsmokers. Given the well‐known scarcity of ICU resources
such as ventilators, it is also possible that social desirability bias may
have contributed to patients not reporting current smoking for fear of
being denied access to such interventions, further exacerbating mis-
classification bias.14,86 Finally, given the association of smoking with
lower socioeconomic status,87 it is possible that current smokers are
exhibiting worse health‐seeking behaviors and either self‐treating or
deteriorating in the community. Thus, they would not be accounted for
in the reported studies which assessed hospitalized patients, leading to
survivorship bias and lower event rates for in‐hospital mortality. Due to
these factors, the summary estimate for in‐hospital mortality we report
has likely been biased towards a null result for current smokers. Simi-
larly, the twofold increase in risk of severe or critical disease for current
smokers is likely an underestimate of the effect size.
With no targeted therapies against COVID‐19 currently available,
as a scientific community, we must focus on prevention, particularly
for those at risk of severe or critical disease. Frontline clinicians must
conscientiously record accurate smoking histories in all confirmed
COVID‐19 patients, both for triage of vulnerable patients and to
support future research efforts. During the current pandemic,
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independent surveys have reported increased smoking frequency in
current smokers and high rates of relapse in former smokers,88‐90
which is unsurprising given the stress, isolation, and other adverse
psychosocial repercussions of life during a global pandemic.91,92 Con-
sidering our finding that current smoking and smoking history are
associated with increased COVID‐19 severity, urgent public health
measures emphasizing smoking cessation advice, support and phar-
macotherapy must be provided to reduce overall disease burden, de-
spite a currently altered social landscape. Good‐quality studies have
proven the benefits of mobile phone‐based interventions,93 high-
lighting that even during periods of social distancing and self‐isolation,
remote methods of smoking cessation may be feasible and efficacious.
Furthermore, as countries begin easing lockdown restrictions, it is
imperative that governments and policymakers protect vulnerable
populations, such as current and former smokers, through adequate
shielding measures and appropriate legislation.
The present analysis has several limitations, principally the use of
aggregate data for our meta‐analysis, which precludes adjustment for
certain covariates reported to be predictive of disease severity, such
as age, gender, and comorbidities,3‐5 and prevents examination of
heterogeneity and subgroup analysis at the patient level. The use of
individual patient data may have addressed this, however, considering
the urgency of our research question and direct applicability to patient
care, the considerable time burden associated with conducting an in-
dividual patient data meta‐analysis was deemed inappropriate. Also,
with most studies reporting on Chinese populations, we cannot ex-
clude the possibility of ethnic differences in smoking and susceptibility
to severe COVID‐19 caused by smoking, which may have confounded
our analysis. However, this reflects the current landscape of peer‐
reviewed literature, which at the present time consists mainly of data
from China. We were also unable to assess the effect of e‐cigarettes
on COVID‐19 as no studies collected separate data on their usage,
which would have been informative considering rises in popularity of
these products. Finally, as discussed, the high likelihood of mis-
classification bias concerning current smoking status across included
studies suggests that our analysis potentially underestimates the im-
pact of current smoking on both disease severity and mortality,
creating an even more compelling argument for urgent public health
measures to support smoking cessation during the present time.
In conclusion, in the largest meta‐analysis available amongst peer‐
reviewed literature, we report that both current smoking and a smoking
history significantly increased COVID‐19 severity, whilst smoking history
also significantly increased mortality risk. Due to problems with potential
misclassification of current smokers among included studies, the analysis
likely underestimates the likelihood of severity in this patient population.
As the COVID‐19 pandemic continues to burden societies worldwide, our
analysis suggests that smoking represents one of the most immediately
modifiable risk factors to reduce the substantial morbidity associated
with the disease. In light of this finding, governments, policymakers, and
other key stakeholders must ensure that appropriate measures are taken
to support and maintain smoking cessation to protect vulnerable popu-
lations and reduce the strain placed on healthcare systems working at full
capacity during this global crisis.
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The applications of machine learning in
plastic and reconstructive surgery: protocol
of a systematic review
Angelos Mantelakis1,2*† and Ankur Khajuria3,4†
Abstract
Background: Machine learning, a subset of artificial intelligence, is a set of models and methods that can
automatically detect patterns in vast amounts of data, extract information and use it to perform various kinds of
decision-making under uncertain conditions. This can assist surgeons in clinical decision-making by identifying
patient cohorts that will benefit from surgery prior to treatment. The aim of this review is to evaluate the
applications of machine learning in plastic and reconstructive surgery.
Methods: A literature review will be undertaken of EMBASE, MEDLINE and CENTRAL (1990 up to September 2019)
to identify studies relevant for the review. Studies in which machine learning has been employed in the clinical
setting of plastic surgery will be included. Primary outcomes will be the evaluation of the accuracy of machine
learning models in predicting a clinical diagnosis and post-surgical outcomes. Secondary outcomes will include a
cost analysis of those models. This protocol has been prepared using the Preferred Items for Systematic Review and
Meta-Analysis Protocols (PRISMA-P) guidelines.
Discussion: This will be the first systematic review in available literature that summarises the published work on
the applications of machine learning in plastic surgery. Our findings will provide the basis of future research in
developing artificial intelligence interventions in the specialty.
Systematic review registration: PROSPERO CRD42019140924
Keywords: Artificial intelligence, Machine learning, Deep learning, Plastic surgery, Big data
Background
In the era of big data, the plethora of efforts towards
gathering and analysing patient data in large scale is
rapidly increasing [1]. Amongst others, these efforts try
to improve the diagnosis of diseases and the prediction
of post-treatment outcomes using large amounts of data
from past cases. The analysis of this vast amount of
information, however, is beyond the capabilities of
traditional statistical methods previously used in aca-
demic medicine [2].
Machine learning, a subset of artificial intelligence, is
the set of models and methods that can automatically
detect patterns in vast amounts of data, extract informa-
tion and use it to perform various kinds of decision-
making under uncertain conditions [3]. These models
have the potential of two principally distinct functions:
supervised and unsupervised learning (termed “deep
learning”). Supervised learning involves the creation and
optimisation of statistical models which aim to predict
an outcome using information from past cases [2, 4]. In
contrast, unsupervised learning aims to identify patterns
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in previously seemingly random data and generate novel
associations [2, 4, 5].
Healthcare professionals have been quick to adopt
these emerging technologies to improve patient out-
comes [5]. Examples include machine learning models
created to identify clinical diagnoses, which perform to
the level of expert clinicians in identifying acute cerebral
ischaemia, malignant skin lesions and lung cancer sub-
types [6–8]. In the field of surgery, this technology has
demonstrated a unique potential in predictive post-
operative success and complication rate in procedures
such as traumatic brain injury, cervical spine fusion and
glioma removal, amongst others [9–11].
This technology has the potential to provide clinically
relevant information across many areas of plastic sur-
gery. In burn surgery, machine learning has been used to
predict whether complete wound healing will require
more or less than 14 days with an accuracy rate of 86%
[12]. In the field of microsurgery, authors have been able
to predict surgical site infections following free flap re-
construction in head and neck cancer with a sensitivity
of 81% and specificity of 61% through using artificial
intelligence neural networks [13]. Further, machine
learning has also been applied in aesthetic surgery re-
search, where using supervised learning, the authors
were able to extract potential beauty-determining facial
features to guide pre-operative planning [14].
The aim of this review is to systematically analyse the
available literature on the applications of deep learning
in plastic surgery. Data collected will be used to provide
an up-to-date overview of the potential utility of this
technology in the specialty and suggest future directions
of further research.
Methods
Aim
This systematic review is intended to evaluate the clin-
ical applications of machine learning models in the field
of plastic and reconstructive surgery and to determine
areas of future research on this technology.
Protocol and registration
This protocol is registered in the Prospective Register of On-
going Systematic Reviews (PROSPERO) CRD42019140924
and adheres to the Preferred Reporting Items for Systematic
Review guidelines and Meta-Analysis Protocols (PRISMA-P
2015) [15] [Additional File].
Search strategies
All studies published between 1990 and the date of the
search will be considered for review.
We will perform a comprehensive search of MEDLINE
(OVID SP), EMBASE (OVID SP), Science Citation
Index, ClinicalTrials.gov and CENTRAL. A combination
of free text and Medical Subject Headings (MeSH) terms
will be used. An example search strategy in MEDLINE is
the following:
1 (“deep learning” OR “artificial intelligence” OR “machine learning”
OR “decision trees” OR “random forests” OR SVM OR “support vector
machine”)
2 exp “NEURAL NETWORKS (COMPUTER)”/ OR exp “DEEP LEARNING”/
3 exp “ARTIFICIAL INTELLIGENCE”/
4 (1 OR 2 OR 3)
5 (microsurgery OR (surgery AND (plastic OR reconstructive OR
esthetic OR aesthetic OR burns OR hand OR craniofacial OR
“peripheral nerve”)))
6 exp “SURGERY, PLASTIC”/ OR exp “RECONSTRUCTIVE SURGICAL
PROCEDURES”/
7 (5 OR 6)
8 (4 AND 7)
Identification and selection of studies
Following database searching, studies will be populated
into Endnote X7 library (Clarivate Analytics, USA).
There will be two stages of screening, carried by two
independent reviewers using pre-specified criteria. The
search results, including abstracts, full-text articles and
record of reviewer’s decisions, including reasons for ex-
clusion, will be recorded.
1. Stage 1: Title and abstract review. This will be
carried out by the two independent researchers by
adhering to the set eligibility criteria. Any
discrepancies will be resolved through a consult by
a third reviewer.
2. Stage 2: Studies included will undergo full-text
review by the same independent reviewers. Any
discrepancies will be resolved through a consult to
a third reviewer.
Eligibility criteria
Types of studies
Any primary studies (including case reports), which
assess the prediction rate of deep learning models in
diagnosis of disease or post-operative outcomes in plas-
tic surgery, either on its own or compared to other tech-
niques, will be included. There will be no geographical
restriction. Our exclusion criteria include studies utilis-
ing machine learning without clinical data, non-English
language articles and review articles.
Types of study participants
We will include clinical data from adult participants
(> 18 years old) with conditions requiring plastic or
reconstructive surgery. Data from animal studies will
be excluded.
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Types of interventions
The studies considered will present artificial intelligence
models utilising deep learning as an intervention with the
aim to provide a diagnosis of a clinical presentation, or a
clinical prognosis of a plastic surgery intervention. The
intervention may be used by itself or in combination with
other methods. Since this technology is new, there is no
single best deep learning model, and because of the
versatility of conditions treated in plastic surgery, it is
expected that various different models will be identified in
our review.
Outcomes
Primary outcomes
The primary outcomes will be the evaluation of deep
learning models on two distinct functions. The first
function is the accuracy of providing a clinical diagnosis.
Studies must have a defined clinical condition for which
the model is designed to identify. The accuracy of
performing this task (either on its own or in assistance
with a clinician) will be collected.
The second primary outcome will be the accuracy of
prediction of post-operative outcomes and complications
of plastic surgery interventions. In order to qualify,
studies will need to have created a model to predict a
particular clinical outcome (for example, probability of
post-operative wound infection), with data collected pro-
spectively or retrospectively.
In both settings, the model’s accuracy will be assessed
by the reported specificity, sensitivity, positive predictive
value and negative predictive value of performing the
named task.
Secondary outcomes
The secondary outcomes will include cost analysis of the
deep learning models. Further, outcomes of studies that
have utilised deep learning models as a treatment for a
clinical condition (for example, neuroprosthesis) will
also be collected.
Data extraction, collection and management
After the study selection is completed, the two reviewers
will independently extract data using a standardised data
extraction form. Any disagreements and differences will
be resolved by discussion with a third reviewer.
The following data will be extracted:
1. Study characteristics (authors, year of publication,
study design)
2. Patient demographics (number of participants, sex,
mean age)
3. Indication of application of the software model
(prediction of a diagnosis or treatment outcome)
4. Software characteristics
5. Outcomes (specificity, sensitivity, positive predictive
value and negative predictive value of forming a
diagnosis; predicting rates of overall survival,
treatment success, post-operative function, aesthetic
outcome, complications and recurrence)
6. Complications or adverse events reported
Risk of bias
The risk of bias in the selected randomised controlled
trials will be evaluated by the two independent reviewers
through utilising the Cochrane Collaboration Risk of
Bias tool [16]. The methodological quality will be
assessed based on appropriate participant selection and
randomisation, blinding of participants and reviewers,
attrition, selective reporting and others. An overall
grading of low, medium or high risk of bias will then be
allocated. For non-randomised trials, the ROBINS-I
(Risk of Bias in Non-randomised Studies-of Interven-
tions) will be utilised [17]. For quantitative studies in
which the ROBINS-I is not applicable, risk of bias
assessment will be undertaken using the Quality Assess-
ment Tool for Quantitative studies [18]. Case reports
will be included as part of screening for all available evi-
dence; however, they are inherently at high risk of bias
and this will be considered during the assessment of the
quality of overall evidence.
The risk of bias in the performance of deep learning
models will be evaluated using the QUADAS-2 (Quality
Assessment for Diagnostic Accuracy Studies) tool [19].
This will examine the process of patient selection and
the conduction and interpretation of the index test and
reference standard. An overall risk of bias will be subse-
quently allocated (high, low, or unclear).
Data analysis
The two independent reviewers will explore the
heterogeneity between the studies using the Review
Manager 5.3 provided by the Cochrane Collaboration (1).
Potential sources of heterogeneity include the deep learning
software, its intention (diagnosis or treatment), the
treatment indication and population. A narrative review
will be carried out structured around the intervention and
outcome of interest. A quantitative analysis (meta-analysis)
will be performed if sufficient homogeneous studies in
terms of design and outcomes measures are identified.
Statistical heterogeneity will be assessed using the I2
statistic [20]. A random-effects model will be employed
for heterogenous cohorts (I2 > 50%). The quality of overall
evidence will be assessed using The Grading of Recom-
mendations Assessment, Development and Evaluation
(GRADE) approach [21]. Sensitivity analysis will be
attempted based on the study quality. This may be
repeated after removal of poor-quality studies that
may affect the overall effect estimate.
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Discussion
Due to the incredible potential of machine learning to
process vast amounts of patient information and provide
clinically relevant predictions, it is important for plastic
surgeons to be informed with the up-to-date applica-
tions of this technology in the specialty. The aim of our
review is to systematically evaluate the current evidence
of this technology in the clinical setting and to discuss
the future prospects of machine learning in guiding
patient management. To the authors’ knowledge, this is
the first systematic review to evaluate the applications of
artificial intelligence in plastic surgery.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13643-020-01304-x.
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